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This work develops microfluidic technologies to advance the state-of-the-art in 
living cell-based assays.  Current cell-based assay platforms are limited in their 
capabilities, particularly with respect to spatial and temporal control of external signaling 
factors, sample usage, and throughput.  The emergence of highly quantitative, data-driven 
systems approaches to studying biology have added further challenges to develop assay 
technologies with greater throughput, content, and physiological relevance.  The primary 
objectives of this research are to (i) develop a method to reliably fabricate 3-D flow 
networks and (ii) apply 3-D flow networks to the development and testing of microfluidic 
chamber arrays to query cellular response to soluble-matrix signal combinations and 
gradient signaling fields.  An equally important objective is for the chamber arrays to be 
scaled efficiently for higher-throughput applications, which is another reason for 3-D 
flow networks. 
Two prototype chamber arrays are designed, modeled, fabricated, and 
characterized.  Furthermore, tests are performed wherein cells are introduced into the 
chambers and microenvironments are presented to elicit complex responses.  Specifically, 
soluble-matrix signaling combinations and soluble signal gradients are presented.  The 
study of complex biological processes necessitates improved assay techniques to control 
the microenvironment and increase throughput.  Quantitative morphological, migrational, 
and fluorescence readouts, along with qualitative observations, suggest that the chamber 
arrays elicit responses; however further experiments are required to confirm specific 
phenotypes.  The experiments provide initial proof-of-concept that the developed arrays 
can one day serve as effective and versatile screening platforms. 
Understanding the integration of extracellular signals on complex cellular 
behaviors has significance in the study of embryonic development, tissue repair and 
 xv
regeneration, and pathological conditions such as cancer.  The microfluidic chamber 
arrays developed in this work could form the basis for enhanced assay platforms to 
perform massively parallel interrogation of complex signaling events upon living cells.  
This could lead to the rapid identification of synergistic and antagonistic signaling 
mechanisms that regulate complex behaviors.  In addition, the same technology could be 
used to rapidly screen potential therapeutic compounds and identify suitable candidates to 












Challenges in Cell-Based Assays 
 Assaying the response of living cells to chemical and biomolecular stimuli is an 
essential activity in the life sciences and the pharmaceutical industry.  Living cell-based 
assays are in vitro models consisting of (i) the cell(s) of interest and (ii) the environment 
(a.k.a. microenvironment) that surrounds the cells.  Cell-based assays are performed in a 
variety of platforms, such as flasks, well plates, and microfluidic systems.  The platform 
determines the manner in which the microenvironment can be manipulated, which in turn 
determines how well the assay mimics in vivo conditions while simultaneously providing 
a well-controlled environment.  Because of the differences between in vitro and in vivo 
conditions, cells in assays tend to present a different phenotype from what they would in 
the tissue context; therefore, cellular behavior in such in vitro assays is often a poor 
predictor of behavior in vivo.1  This limits the insightfulness of basic research and imparts 
a substantial economic cost to pharmaceutical development.2,3  As a result, a major goal 
in the development of assay platforms is to provide new capabilities that improve the 
quality and control of the microenvironment.  Ideally, such platforms would enable cell-
based assays that emulate physiological, pathological or otherwise perturbed conditions, 
which elicit responses that are faithful representations of their in vivo counterparts. 
There are also other important goals in assay development.  Considerable efforts 
are being placed to increase parallelization (throughput),1 increase data types (content),4 
and lower costs in cell-based assays.  A key motivator in such efforts is the emergence of 
a more quantitative, data-driven systems approach to biological studies.5,6  The systems 
approach poses a dramatic challenge to advance experimental and computational assay 
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tools.7  Such tools will require massive experimental parallelization, automated data 
analysis, and the ability to convert complex questions from the systems viewpoint into 
functional experimental systems that closely reflect the relevant physiology and disease 
state.8,9   
The need for high-throughput, high-content, and high-relevance screening tools is 
not only useful at the basic science level, but also an imperative in the pharmaceutical 
and biotechnology industries.  In the development of new medicines, the rate-limiting 
step has shifted from target/early lead identification to cell-based assays.  High-content 
screening platforms, usually in the form of well-plates with sophisticated image 
processing software, are regularly being used for live-cell imaging and data acquisition.  
Assay platforms that create microenvironments with greater predictive ability could 
reduce the risk in selecting candidate drugs and dramatically improve the drug 
development process, where costs increase exponentially into later stages of animal and 
human testing.1 
Research Objectives 
 This work utilizes microfluidic technologies to address the challenges of cell-
based assays.  The microfluidic approach holds great potential for dramatically reduced 
sample usage and the creation of complex, previously unattainable microenvironments.10  
However, the networking of flow paths to address large-scale chamber arrays in 
microfluidic systems is difficult, as it ultimately requires multi-layer designs.  
Furthermore, if individual chamber addressing is required, inter-layer 3-D flow routing is 
necessary.  This is especially the case for chambers arrayed in a 2-D grid, which is the 
hallmark of high-throughput experimental platforms. 
The objectives of this research are to develop microfluidic chamber arrays that 
exhibit unique microenvironmental capabilities.  These systems are designed to be 
scalable to larger, high-throughput arrays by the use of 3-D flow networks, which are 
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made possible by a novel fabrication process.  The final objective is to test each system 
as a viable assay platform by eliciting complex cellular responses.  Therefore, the 
technologies resulting from this work could be generalized for broader application.  
Overall, the key motivator of this work is the prospect of developing technologies that 
could dramatically improve the economics of cell-based assays and ultimately facilitate 
significant biological discoveries and more rapid drug discovery. 
Objective 1:  Develop a Reliable Method to Fabricate 3-D Flow Networks 
 The objective is to develop a process to fabricate 3-D flow networks with a yield 
that is acceptable for device design and testing.  Previously developed methods are first 
tested as possible fabrication processes.  Modifications are developed, involving focused 
pressures and alignment with partially cured PDMS, resulting in a modified compression-
molding process.  Yields are estimated, and a final process is adopted. 
Objective 2:  Design, Realize, and Test a Novel Chamber Array for Combinations of 
Matrix and Soluble Signals 
The objective is to develop a continuously perfused, non-cross-contaminating 
microfluidic chamber array for studying cellular responses to orthogonal combinations of 
immobilized and soluble signals.  This system is a prototype assay platform designed to 
exhibit the following novel combination of attributes:  (i) continuous perfusion, (ii) flow 
paths that forbid cross-chamber contamination, and (iii) chamber shielding from direct 
perfusion to minimize shear-induced cell behavior.  In addition, the system is designed to 
provide experimentalist with considerable versatility through four modes of operation.  
To confirm proper operation of the array, responses of rat-derived lung cells are observed 
under four pair-wise combinations of soluble and immobilized signaling molecules.   
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Objective 3:  Design, Realize, and Test a Novel Chamber Array That Generates 
Soluble Signal Gradients 
 The objective is to develop a novel microfluidic chamber array to establish and 
modulate soluble gradients for chemotaxis studies.  The system is a prototype assay 
platform designed to exhibit the following novel combination of microenvironmental 
features:  (i) fully stable signal gradients, (ii) a shear-free microenvironment, (iii) gradient 
profiles approaching basal concentrations of zero, (iv) gradients switchable on-off 
without changing input flows, (v) gradient profiles whose curvature can be changed.  In 
addition, the array is designed to exhibit robustness in the form of similar gradients in all 
chambers, a network architecture enabling efficient scale-out of the chamber array, and a 
fabrication process requiring only one alignment step.  These features are enabled by a 3-
D flow network.  To test the platform, the migrational and morphological responses of 
human breast cancer cells to a serum gradient are measured.  The intent is to highlight the 
utility of many features of the platform and show statistically significant differences 








This chapter discusses cell signaling, combinatorial signaling fields, and two 
examples of cellular responses.  Also, traditional and microfluidic in vitro cell-based 
screening tools are reviewed. 
The focus of this research is on developing cell-based assay platforms that can 
present novel microenvironments in scalable chamber arrays.  To validate that the 
platforms are effective assays, specific cellular responses must be elicited within them.  
The two representative responses that are elicited are epithelial-to-mesenchymal 
transition (EMT) and directed cell migration (chemotaxis).  Therefore, this chapter 
briefly describes extracellular signaling and the microenvironment, and it discusses EMT 
in response to soluble and immobilized signal combinations and chemotaxis as a result of 
a soluble signal gradient.  EMT and chemotaxis are complex phenomena, and greater 
understanding of these processes could lead to breakthroughs in medical treatment, 
particularly for cancer.   
Signaling and the Microenvironment 
 In multicellular organisms, cells must communicate with each other in order to 
coordinate their behavior.  By coordinating their behavior, cells work together to assure 
the well-being of the organism as a whole.  Cells communicate with each other via 
extracellular signaling molecules (external signals), which are produced by cells and 
transported by various means to target cells.  At the target cell, transmembrane receptor 
proteins bind to the external signal, which activates intracellular signaling pathways at 
various locations in the cell’s interior.  Propagation of the signal may be complex, 
involving many different types of intracellular signaling molecules working in series and 
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in parallel.11  As a whole, signaling pathways can initiate, sustain or alter specific cell 
responses, such as growth, differentiation, apoptosis and migration. 
 External signals exist in both soluble and immobilized forms.  In soluble form, 
external signals are dissolved in the fluid medium surrounding cells.  Some examples of 
soluble external signals are growth factors, cytokines, and dissolved gases, such as 
epidermal growth factor (EGF, a regulator of cell growth, differentiation, and 
proliferation), interleukin-8 (IL-8, a molecule that attracts white blood cells), and nitric 
oxide (NO, a regulator of smooth muscle contraction), respectively.  Immobilized 
external signals are comprised of molecules of the extracellular matrix (ECM) or proteins 
anchored to cell membranes.  Examples of ECM molecules are proteoglycans, collagen, 
laminin, and fibronectin.11 
 The local environment surrounding each cell, or microenvironment, presents cells 
with a diverse array of external signals.  The microenvironment consists of the fluid, 
ECM, and cells that are near to (or in direct contact with) the cell.  Scores of external 
signals have been identified, and to a typical cell, each external signal can vary in space 
and time.  In addition, external signals can exert their effect on cells either alone or in 
combination with other types of signals.  An example of this is in embryonic 
development, where multiple signaling proteins dynamically segregate or overlap to form 
the body plan12 and organs.13   
Combinations of Multiple Signaling Fields 
 Understanding cellular response to multiple simultaneously-applied external 
signals is essential to gaining new insight into cellular responses.  Current experimental 
platforms oftentimes do not fully recapitulate the microenvironment compared to in vivo 
conditions that are rich with chemical and physical signals.  When a cell is subjected to 
many different types of external signals at once, it is subjected to a specific signaling 
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combination.  External signaling combinations can exist as mixtures of soluble signals,11 
mixtures of soluble and immobilized signals14 or mixtures of signal gradients.15 
 External signal combinations can act as switches to initiate basic cellular 
functions.  Combinations of soluble and immobilized (ECM) external signals have been 
shown to facilitate and enhance cell growth, cell cycle regulation, and differentiation.14,16-
18  Such responses can come as a result of coupling between pathways emerging from 
growth factor receptors and integrins; for example, the pathways of epidermal growth 
factor (EGF) and platelet-derived growth factor (PDGF) receptors interact with the 
pathways of various integrins through Rho family GTPases, such as Cdc42, Rac, and 
Rho.  These proteins share a number of target effectors that organize cytoskeletal 
structures, such as lamellipodia and stress fiber formation.16 
 Interestingly, external signal combinations can produce synergistic effects in 
diverse processes, where the cellular response may be greater than the summed 
contributions of each individual signal.  Examples include ECM remodeling during 
inflammation19,20 and modulation of synaptic strength during learning and memory 
formation.21,22  Much more combinatorial experimentation of external signals will be 
required to understand the pathways that lead to additive, antagonistic or synergistic 
effects. 
Gradient Signaling Fields 
 Concentration gradients exist when the concentration field of an external signal is 
non-uniform.  Gradients of external signals act as directional cues for various cellular 
functions.  Gradients establish the direction that cells migrate;13,23 gradients also act as a 
graded field to assign different fates to stem cells at different concentrations within the 
field.12  These functions in turn affect larger biological processes, such as wound healing, 
immune response, and embryonic development.11  Combinations of external signal 
gradients have been shown to play important roles in organogenesis15,24 and neural 
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mapping (and axon guidance)25  For example, it has been shown that ephrin-A and 
ephrin-B form overlapping gradients that affect the guidance of retinal axons.  
Interestingly, they not only act as chemoattractants, but also act as chemorepellants, 
depending on the background concentration and receptor expression of nearby neurons.26 
 Also, gradient combinations affect the navigation of immune system cells.27,28  
Despite these observations, the study of signal gradients and their effect on cellular 
behavior is still a nascent field; many more discoveries will come about through more 
quantitative and controlled experimentation. 
Two Examples of Cellular Response 
This work attempts to elicit two types of cellular response; therefore, they are 
briefly described below.  The first is epithelial-to-mesenchymal transition (EMT) in 
response to a soluble-immobilized signal combination, and the second is cell migration 
(chemotaxis) in response to a soluble chemoattractant gradient.  A common link between 
EMT and chemotaxis is they are both observed in the context cancer metastasis, which is 
a complex, multi-step process.11  EMT and chemotaxis are active fields of research with 
the potential for high impact discoveries, which could be facilitated by new assay 
technologies. 
Epithelial-to-Mesenchymal Transition (EMT) 
 EMT is a major change in cellular phenotype, where a cell loses the morphology 
and gene expression pattern of a normal epithelial cell and instead takes the morphology 
and expression pattern of a typical mesenchymal cell.  Epithelial cells form sheets that 
line cavities and ducts, and they are tightly connected by E-cadherin transmembrane 
protein junctions.  In contrast, mesenchymal cells express N-cadherin, fibronectin, and 
vimentin (among other proteins) and display an elongated fibroblast-like morphology, as 
well as motility and invasiveness.29  EMT is critical and beneficial to processes like 
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wound healing in adults30 and morphogenesis in developing embryos,31 where cells must 
migrate to close the gaps in wounds or position themselves during the modeling of tissue, 
respectively.  Interestingly, it is highly suspected that metastatic cancer cells acquire their 
migrational and invasive characteristics not by genetic mutation, but instead by simply 
reactivating the EMT program that was pre-encoded for wound healing and 
developmental purposes.29 
E-cadherin expression plays a critical role in the induction of EMT.  E-cadherins 
expressed on the membranes of epithelial cells attach to each other, forming adherens 
junctions that provide mechanical tensile strength to hold the cells together in a sheet.  
Reduced expression of E-cadherin has been shown to cause changes associated with 
EMT, allowing cells to break away from the epithelial sheet and migrate.32  In contrast, 
the expression of N-cadherin that comes as a result of EMT does not promote cell-cell 
adhesion, but instead causes the cells to have a greater affinity toward stromal cells (e.g. 
fibroblasts).  Such behavior is implicated in the metastasis of cancer cells of epithelial 
origin, where the cells detach from the epithelial sheet and invade into the stroma.33 
Signal Combinations and EMT 
The causes of EMT are not well understood.  Although, there is evidence that 
EMT is caused by various combinations of extracellular signals from the stroma, which 
could be soluble, immobilized or a combination of both.34  In particular, transforming 
growth factor-β1 (TGF-β1) is highly-suspected as an extracellular signal for EMT.35  
Also, tumor necrosis factor-α (TNF-α), epidermal growth factor (EGF), hepatocyte 
growth factor (HGF), and insulin-like growth factor-1 (IGF) are possible causative 
signals, either acting alone or in combination. 
Significance and Challenges of EMT Studies 
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EMT-related genes or protein products could provide new targets for cancer 
therapy, which makes the study of EMT particularly significant.  The difficulty in 
understanding EMT (and possibly interfering with EMT in a rational way) is that it is 
likely caused by various combinations of signaling factors, each initiating EMT through 
different intracellular pathways.  In addition, EMT is a reversible process in which cancer 
cells are thought to follow a progression through (i) onset of EMT, (ii) invasion into the 
stroma, (iii) intravasation into the bloodstream, (iv) transport through circulation, (v) 
extravasation into the stroma at a different site, (vi) colonization of a new tumor, and (vii) 
reversion to an epithelial phenotype via MET (mesenchymal-to-epithelial transition).32 
Simulating such events in time and space is difficult to perform in vitro; however, such 
difficulty becomes motivation for the development of more sophisticated assay platforms, 
which can be used to determine the effects of specific, well-controlled signaling 
combinations on the induction and possible arrest (and reversal) of EMT. 
Cell Migration 
 Cell migration is a complex process in which cells integrate chemical and 
physical cues to determine how they will move.  Included in those cues are multi-
directional, overlapping, and time-varying external signaling fields.  Cell migration is 
essential to many biological processes.  For example, cell migration is required for 
animal development.  During gastrulation, cells must migrate to relative to each other to 
create a gut.36  To develop the nervous system, neural crest cells migrate over long 
distances (as long as meters) to construct and guide axons to their synaptic targets.37  
Also, cell migration is important in adult animals.  White blood cells, such as 
macrophages and neutrophils, must chemotax towards infection sites to destroy foreign 
invaders.38  Osteoclasts and osteoblasts migrate through bone to remodel and renew it.39  
Fibroblasts migrate to damaged connective tissue to repair it.40  As well, epithelial cells 
of the intestine migrate in a controlled manner toward the tip of the villi to replace lost 
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cells.41  From a pathological perspective, cancer cells must migrate to escape primary 
tumors and create new ones in other parts of the body (metastasis).  Understanding the 
signaling pathways that govern cancer cell migration may lead to new targets for 
therapy.42 
Basic Process of Cell Migration 
 Directed cell migration is induced by gradients of external signals.  Two types of 
migration are chemotaxis and haptotaxis:  chemotaxis, where a cell migrates up a 
concentration gradient of a soluble signal (a chemoattractant) and haptotaxis, where a cell 
migrates up a gradient of immobilized ECM proteins.  In any case, cell migration begins 
when the cell senses a non-uniform concentration field and polarizes itself in the 
direction of the gradient.  When a chemoattractant binds to its corresponding 
transmembrane receptor on the cell, the receptor becomes activated (by phosphorylation) 
and initiates a signaling pathway intracellularly. 
 Polarization occurs when a cell assumes an asymmetric morphology (when one 
can recognize a “front” and a “rear” to it).  Once a cell is polarized, migration proceeds 
via four distinct activities:  (i) extension (protrusion) of the cell membrane, (ii) formation 
of attachments between the substratum (i.e. ECM) and cell, (iii) contractile force and 
traction, and (iv) release of attachments.43 
Protrusions 
 Two types of membrane extension are lamellipodia (two-dimensional, sheet-like) 
and filopodia (one-dimensional, spike-like).11  Polymerization of the protein actin 
provides the protrusive force necessary to extend lamellipodia and filopodia outward 
from the leading edge of a migrating cell.   
Focal Adhesions  
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Cell-substratum attachments, called focal adhesions (FAs), are formed at the 
leading edge of lamellipodia and filopodia to anchor the cell to the substratum.  Focal 
adhesions are characterized by the clustering of integrins, which are cell membrane 
adhesion receptors that link ECM proteins on the cell’s exterior to the cytoskeleton in the 
cell’s interior.  Focal adhesions are also characterized by the co-localization of several 
proteins (e.g. focal adhesion kinase (FAK), talin, paxillin, and vinculin) to the FA site 
that are all implicated in FA formation.43 
Contraction  
Contractile forces are generated by myosin motor proteins.  The contractile force 
is countered by the traction force of FAs with the substratum.  The traction force is 
transmitted through anchor proteins, such as vinculin and talin, which provide the 
mechanical linkage between integrins and the actin filaments.  As a result, a net forward 
force is generated, causing cell movement.44 
Release 
Throughout the process of migration, actin filaments and FAs disassemble in the 
rear of the cell as they are constructed in the front;45 this process is known as 
“treadmilling.”  Thus, while a migrating cell moves relative to the substratum, actin 
filaments and FAs are fixed.  Calcium (Ca2+) facilitates the process.46 
 The migration speed of cells is shown to be dependent upon substratum ECM 
concentration, integrin expression levels, and integrin-ECM binding affinity.47  Various 
combinations that counter-balance the three factors will achieve a maximum migration 
speed.  Migration speeds vary depending upon cell type.  While a fibroblast migrates at 
roughly 1 μm/min, a neutrophil can migrate up to 20 μm/min.48  
Significance and Difficulty in Cell Migration Studies 
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 Our knowledge of the molecular aspects of cell migration is still in the early 
stages, and many studies yield conflicting conclusions,49-51 which indicates that more 
subtle and complex roles for migratory proteins may yet be discovered.  As well, despite 
many advances in our understanding of cell migration in general, many unanswered 
questions remain.  Many of these questions involve the temporal and spatial regulation of 
intracellular signaling molecules, as well as the morphological and migratory readouts, in 
response to more precisely-controlled external signaling conditions.44 
 Literature points to a number of knowledge gaps that present major challenges in 
our knowledge of cell migration:43,44,52,53  how cells establish and maintain a polarized 
state, how FAs form and disassemble, how cells recognize their targets, and how spatially 
and temporally segregated molecular interactions are integrated into a coherent migratory 
decision-making process.  One way to elucidate the interactions between different 
signaling pathways is to engage more than one pathway simultaneously.  The 
technologies developed in this research will enable the simultaneous generation of 
multiple, overlapping external signal gradients.  By doing so, different types of cell 
surface receptors will be activated, which then initiate different intracellular signaling 
pathways.   
 An interesting line of inquiry is to apply the external signal gradients from 
different directions.  Thus, not only will different signaling pathways be initiated, but also 
they could be initiated in different locations within the cell.  Such conditions will 
facilitate probing the cellular decision-making process when multiple chemoattractant 
gradients (and the induced signaling pathways) compete with each other.  Furthermore, 
by time-varying the gradients, temporal characteristics could be observed, such as the 
speed at which signaling molecules become activated or expressed, as well as how fast 
they spatially distribute themselves within the cell. 
 This combinatorial approach is likely to expand our knowledge of how 
migrational decisions are made, as well as how to identify or predict them from 
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movement, morphological, and biomolecular readouts.  Eventually, the systematic 
investigation of multiple signaling pathways may lead to the discovery of new integrating 
molecules (or complexes) or the discovery new functions of known molecules. 
In Vitro Screening Tools 
The general aspects of cell-based assay platforms are reviewed, beginning with 
traditional and microfluidic platforms, and then briefly discussing combinatorial 
signaling platforms and gradient platforms.  Specific aspects, as they relate to the devices 
of this work, are addressed in Chapters 4 and 5. 
Traditional Screening Platforms 
 Control of the in vitro microenvironment has been achieved using culture dishes 
and multi-well plates for over 100 years.  These tools have facilitated many spectacular 
discoveries; however, their use as cellular assay platforms is limited in a number of 
respects.  Principal among these limitations is the inability to quantitatively control 
spatial and temporal alterations in the cellular microenvironment using standard culture 
plates (or modifications thereof).54  This lack of spatio-temporal resolution stems from 
the difficulty in implementing structures and fluid patterns on the cellular scale using 
standard methods. 
 Over the past decade, high-throughput screening systems have been developed as 
DNA (or protein) microarrays, flow cytometry systems, chromatography and 
spectroscopy systems, and high-density well plates for ligand binding affinity screens.  
However, time course measurements of living cells in response to a stimuli or 
combinations thereof are still commonly performed in well plates.  Therefore, traditional 
cell-based assays continue to face substantial limitations in the form of high cost due to 
cell and sample usage, as well as technical difficulties like evaporation, which can cause 
well-to-well growth and phenotype variability. 
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Microfluidic Systems 
 Microfluidics has emerged with the potential to overcome many limitations of 
traditional methods.  Microfluidics is the science and technology of systems that flow and 
manipulate very small amounts of fluids using channels with dimensions of tens to 
hundreds of micrometers.55,56  Much of the inspiration for microfluidics is derived from 
the experience of the microelectronics industry.  The invention of the integrated circuit 
(IC) led to the large-scale automation of computations, fundamentally changing the way 
people live and work.  In turn, microfluidics researchers are investigating whether the 
automation of chemistry and biology will lead to equally fundamental impacts to science, 
industry, and society.  A major catalyst for microfluidics research came in the 1990s 
through Defense Advanced Research Projects Agency (DARPA) programs aimed at 
developing microfluidic systems to serve as detectors for chemical and biological 
weapons.  Since then, microfluidics has grown rapidly and established itself as a distinct 
research field. 
 Microfluidics takes advantage of physical phenomena that dominate as systems 
are scaled from the macro- to micro-scale.  One of these is low Reynolds number flow.  
The Reynolds number (Re) is a dimensionless parameter that compares the viscous and 
inertial effects in a fluid flow stream through the following relationship, 








where ρ is the fluid mass density, U0 is the flow speed, L0 is the characteristic length of 
the system, and η is the fluid viscosity.  In microfluidic systems, the characteristic length 
is dramatically reduced compared to that of macro-scale systems.  The dominance of 
viscous effects leads to two main results.  First, low Re flow is strictly laminar, which 
makes fluid flows predictable and stable.  Second, because of the absence of turbulent 
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flow, mixing occurs almost exclusively by Brownian diffusion.  This enables engineers to 
numerically simulate microfluidic systems to speed the device prototyping process. 
 Because of their small size, microfluidic systems have the potential for extremely 
low sample usage, which is essential for screening with rare compounds or small 
numbers of primary cells.  The size of microfluidic systems also enables them to better 
mimic the cellular microenvironment (compared to flasks and well plates), since the high 
surface-to-volume ratio is a better match for those of interstitial spaces and capillaries in 
the body.  
 Microfluidic systems have enabled some remarkable studies in the life sciences.  
For instance, parallel laminar flow streams loaded with different factors have been used 
to probe localized response and internal diffusion in a cell as it straddles the interface of 
the two streams loaded with different stimuli.57-59  Also, large-scale integration through 
an array of individually-addressable chambers, channels, and valves has demonstrated the 
potential for highly automated microfluidic devices.60  Many reviews discuss the 
considerable efforts of those who apply microfluidics to biology.10,54,56,61,62 
Tools for Combinations of Multiple, Overlapping Signaling Fields 
 The customary way to combine uniformly-distributed signaling fields is simply to 
include the signals of interest in a culture medium, which is then used to immerse cells in 
a culture well.  Recently, the focus upon systems biology and the need for higher-
throughput tools has led to arraying techniques (not microfluidic) to scan through 
multiple signaling conditions in parallel.   
 For example, Flaim et al.63 developed a technique to study the response of cells 
attached to different combinations of immobilized ECM proteins.  They deposited a 32-
spot array of different mixtures of five ECM proteins (fibronectin, laminin, collagen I, 
collagen III, and collagen IV) on the surface of an acrylamide gel and then seeded cells 
on each spot to observe each combination’s effect on differentiation.  Soen et al.64 
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developed a method to generate an array of spots on a glass slide that included not only 
ECM proteins, but also cell surface molecules (CAMs) and soluble external signals.  
They used the array to observe the effect of different signaling combinations on the 
differentiation of neural precursor cells. 
 Although array-based techniques offer the advantage of high throughput, a major 
limitation is that the external signals cannot be varied in time.  In addition, the spot-
making techniques immobilize signals to a surface.  For signals that naturally occur as 
soluble proteins, their immobilization to a surface may lead to a physiologically 
irrelevant condition. 
Tools for Gradient Signaling Fields 
 Traditional methods to generate gradients of signals are the Boyden chamber,65 
Dunn chamber,66 and under-agarose assay,67 which are all used for cell migration studies.  
The three methods are variants of a similar strategy:  a soluble signal is introduced to a 
source on one side of a chamber and allowed to diffuse to the other side of the chamber, 
establishing a gradient.  Cells seeded within the well or chamber then respond to the 
gradient. 
 The main disadvantage of the traditional methods is that the source of the signal is 
non-replenishing and the concentration sink on the other side of the diffusion bridge is 
not fixed at a constant concentration.  Thus, the gradient continually decays into a 
uniform concentration field, which leads to two problems for analysis.  First, since the 
gradient is decaying, it is difficult to know exactly which gradient (and background 
concentration) is affecting the cells.  Second, for slow-moving cells (e.g. fibroblasts), the 
gradient may decay to equilibrium before any appreciable observation can be made.48 
 To address these issues, the Whitesides group developed a groundbreaking 
microfluidic technique to produce stable gradients.68  In these systems, two input streams 
of different signal concentrations are fed into a branching array of channels that undergo 
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multiple generations of splitting and recombining the flows.  The resulting output is a set 
of several parallel laminar streams, each with a slightly different concentration.  
Brownian diffusion between the streams causes enough blending to produce a continuous 
concentration profile with a stable gradient.  Split-and-recombine systems have been used 
to study cell migration,69-72 study neural stem cell differentiation,73 and generate multiple 
concentration conditions for parallel cell culture systems.74,75  A significant limitation of 
the split-and-recombine technique is that fluid flow must pass directly over cells to 
establish gradients.  The resulting shear stress upon the cells has been shown to bias the 
direction of cell movement, so that cells begin to migrate in the direction of flow.76  In 
addition, flow-induced shear stress in microfluidic systems can induce Ca2+ fluxes within 
cells, indicating that typical microfluidic flow rates could activate unintended 
intracellular signaling pathways.77 
 With respect to multiple, overlapping gradients, the under-agarose method can be 
modified to include multiple source reservoirs.  Use of this modification has led to 
remarkable discoveries in signal integration and memory in leukocyte migration;27,28 still, 
the method suffers from lack of temporal control and an unstable, decaying gradient.  To 
produce quasi-stable overlapping gradients, a microfluidic multi-injector has been 
developed, where valves control the pulsatile release of signals into a stagnant chamber.78  
The drawback is that the chamber must be large enough to approximate an infinite 
reservoir; ultimately, the gradient and background concentration de-stabilize as the 
chamber fills with the molecules of interest, since it is not replenished with low 
concentration medium.  Also, because the system does not periodically replenish with 
fresh medium, cells in the chamber may become nutrient-deprived.  Two fully-stable 
opposing gradients have successfully been generated using the split-and-recombine 
technique.79  However, the gradients are limited to the direction perpendicular to flow, 
precluding multi-directional studies. 
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 It is difficult to vary signals in time because it requires the mixing and/or 
replacement of multiple signal sources to produce the desired signal concentration.  
Temporal variation of signals is useful to enable within-trial controls (between non-
stimulus and stimulus conditions) and to determine the time constants for cellular 
response and adaptation.  Using conventional means, one way to cause a signal change is 
to simply change the medium in the culture plate.  Although straightforward, it requires 
the preparation of multiple solutions and the changing speed is limited by the speed at 
which a person or robot can remove and replace media.   
Microfluidic approaches have led to some improvements.  Fast switching between 
two gradients has been achieved by integrating two Christmas tree architectures.80  This 
arrangement enables fast changes between two conditions, but it is limited in three 
respects:  (i) gradients are limited to two directions, (ii) flows induce shear stress on cells, 
and (iii) inclusion of more than two gradients requires more space on the chip.  To 
provide a continuum of gradients without occupying more chip space, Lin et al.81 used an 
on-chip “mixing module” to mix source streams into arbitrary compositions.  While this 
system allows for more concentration levels, it relies upon changes in flow rate at the 
sources to effect temporal changes.  Given the volume of tubing leading from the syringe 
pump to the chip, changing the flow rate at the source would introduce a significant delay 
upon changing.  Chen et al.82 realized high resolution, time-varying concentration control 
within a single device by developing on-chip serial dilution networks.  The advantage is 
that one could switch among 16 different concentration levels (4-bit) at any moment 
without altering the external flow sources; the limitation is that the fluidic network is 
extremely complex and occupies significant space on the chip. 
Needs Addressed 
This research focuses on the need for new technologies to enable the scale-out of 
microfluidic chamber arrays to realize their potential as high-throughput screening tools.  
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Advances are needed to improve the versatility, microenvironment, and scalability of 
arrays that screen soluble-matrix combinations.  Versatility can be achieved by making 
the chambers individually addressable, and microfluidic perfusion cultures can benefit by 
reducing shear stresses (for cell types not physiologically exposed to shear).  For gradient 
signaling, improvement is needed in scalability, as well as creating a microenvironment 
that combines low shear, low background concentrations, and stable gradients (for better 
experimental control), which has been difficult for researchers to achieve.  A challenge in 
both tasks is to develop a reliable (and reasonably simple) fabrication process to 




FABRICATION OF 3-DIMENSIONAL FLOW NETWORKS 
 
 An important goal of this work is to develop microfluidic assay platforms that are 
conveniently scalable to high-throughput chamber arrays.  This requires flow networks 
that can navigate through the interstices of the array to address rows, columns or 
individual chambers.  To construct such complex flow networks, a fabrication process is 
developed that realizes through-holes between flow layers in a reliable manner. 
3-Dimensional Flow Networks  
 Most PDMS microfluidic devices consist of a single layer, where flows travel 2-
dimensionally.  When there is more than one layer, the device is typically fabricated 
using multilayer soft lithography,83 which results in layers that are fluidically isolated 
from each other.  Each layer serves as either a layer for flow or a layer for integrated 
valves.  It is also possible to realize 3-dimensional (3-D) flow networks, where flows 
travel out-of-plane from layer to layer.  This enables greater design flexibility and more 
efficient use of device real estate. 
 As microfluidic chamber arrays are scaled to higher-throughput formats, 3-D 
flows become increasingly necessary to deliver fluids to and from chambers.  Flow 
streams may need to occasionally navigate over (or under) other flow streams as they 
travel through the array.  The result is a microfluidic channel network with three-
dimensional flows that resemble roadway bridges and underpasses.   
 A number of methods have demonstrated the construction of 3-D flow networks.  
One method utilizes photoresist posts that protrude through a layer of PDMS that is 
coated on the mold.84  The channels of a second layer of PDMS (usually a thick slab) are 
then aligned to the posts and the assembly is cured and detached from the mold.  
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Fabrication attempts based upon the protrusion method are detailed in the following 
section.  Other methods use thin PDMS membranes that are perforated85 or patterned86 
with through-holes and bonded between thick PDMS slabs.  Although reliable at forming 
through-holes, these methods are designed to join thick slabs (order of mm) of PDMS; 
therefore, the use of high-magnification objectives with small working distances to 
observe specimens in the device is not permitted. 
 Kim et al.87 developed a method to realize 3-D flow networks by compressing 
PDMS between multilayer photoresist patterns.  The compression displaces PDMS from 
the tops of photoresist features, realizing through holes.  Folch et al.88 developed a 
similar compression-molding technique.  A distinct advantage of such methods is that 
they do not require the alignment of thin PDMS membranes, which easily fold and 
stretch, making alignment difficult.  In this work, a compression-molding technique is 
developed, which is modified from the works of Kim et al.87 and Folch et al.88  In the 
following sections, the development process is discussed and the final process is detailed. 
Process Development 
 The fabrication of 3-D flow networks requires the creation of through-holes to 
permit inter-layer flows.  In this case, through-holes are created in multi-layer PDMS 
devices.  The development of the fabrication process involves four approaches to arrive at 
the final process.  The four approaches are detailed below, highlighting the learning 
gained from each. 
Protrusion Method:  Attempts and Learning 
 The protrusion method for fabricating through-holes in PDMS involves spin 
coating a layer of PDMS onto a master (Si wafer) with photoresist forming channel 
features and (taller) posts on top of the channel features (see Fig. 5-1).  The PDMS is 
spun to a thickness smaller than the height of the posts but greater than the height of the 
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channel features.  Therefore, the photoresist post protrudes through the top surface of the 
PDMS.  After the PDMS is cured, a second layer of PDMS is aligned and bonded to the 
first layer, and the bonded assembly is peeled off the Si wafer and bonded to a glass slide 
or cover slip.  The protrusion method was developed by Kartalov et al.84 
 
 
Fig. 3-1  Illustration of protrusion fabrication process.  (a) Channel (lower) and post (upper) layers of 
photoresist (SU-8) are patterned on a Si wafer.  (b) PDMS is spin-coated onto the wafer; the photoresist 
post protrudes above the PDMS surface.  (c) A second PDMS layer is bonded to the first layer (usually a 
thick slab for mechanical support).  (d) The two bonded layers of PDMS are peeled off the wafer and 
bonded to a glass substrate.  A through-hole is realized in the location of the photoresist post.  Adapted 
from Kartalov et al.84 
 
 In this work, the protrusion method was first attempted as a means to create 3-D 
flow networks because, in concept, it offers the convenience of not requiring any 
additional equipment or fixturing.  The process could be performed on already available 
spin coaters.  The process was first attempted by spin coating PDMS (20:1 prepolymer-
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to-crosslinking agent) to a thickness of 30 μm onto test wafers with SU-8 (MicroChem 
Corp., Newton, MA, USA) photoresist patterns (57 μm tall); the PDMS was then allowed 
to cure.  The objective was to see if SU-8 features would protrude above the surface of 
the PDMS.  Scanning electron micrographs were imaged to view the test pieces at an 
angle from which it could be determined if protrusions were realized (Fig. 3-2).  The 
images show the SU-8 features outlined against the surface of the PDMS.  More notably, 
the PDMS appears to have a curved surface profile. 
 
 
Fig. 3-2  Images of PDMS spin coated on SU-8 features.  SEM images ((a)-(c)) show SU-8 test features 
outlined against PDMS ((c) is zoom of feature in (b)).  Shadowing indicates curvature in PDMS thickness 
profile.  (d) Stereo-zoom microscope image of PDMS and rectangular SU-8 feature; shadowing also 
indicating curvature in PDMS profile.  Scale bar 200 μm in (a), 50 μm in (c), and 500 μm in (b) and (d).  
SU-8 thickness 57 μm; nominal PDMS thickness 30 μm away from SU-8 features and wafer edge bead. 
 
The curvature in PDMS thickness profile was unexpected, as it was not thoroughly 
addressed in previous work.84  One possible parameter that could affect the PDMS 
curvature is the relaxation time given after the spinning step prior to cure.  A longer 
relaxation time would presumably allow the PDMS film more time to reduce in stress and 
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“flatten-out,” forming a more planar surface.  However, trials with relaxation times 
varying between 25 min and 24 hours showed no visible changes in profile.  Another 
possibility is that the curvature could be due to wetting based on surface tensions.  PDMS 
could exhibit low contact angle spreading on epoxies (like SU-8). 
 Based on the images, the PDMS surface curves nearly to the top of the SU-8 
features (most noticeably in Fig. 3-2(b-d)).  Because the devices in this work are intended 
to have channels as low as 7 μm tall, the protrusion process could produce sloped PDMS 
at each through-hole, which could interfere with proper bonding between layers or 
disrupt the flow fields of fluids traveling through the channels.  These putative failure 
modes are diagramed in Fig. 3-3.  It is also unclear whether a thin layer of PDMS 
remained on top of the SU-8 features, which could complicate through-hole production.  
Based on such reasoning, a different method was pursued with the intention of producing 
a completely flat (planar) surface of PDMS. 
 
Fig. 3-3  Putative failure modes of protrusion method.  (a) Curvature in lower PDMS layer could 
interfere with proper bonding by forming a gap between PDMS layers, resulting in feature warpage 
(residual strain) if bond is realized or leakage due to an unrealized bond.  (b) For low channel heights 
(devices in this work utilize channel heights as low as 7 μm), the peak of the curved PDMS profile could 
disrupt the flow field and change the hydraulic resistance of the channel, as well as interfere with bonding. 
  
 The main learning from protrusion process attempts is the observation of the 
PDMS surface curving upward as it approaches SU-8 features; wetting characteristics 
could affect fabrication, especially for low channel heights (as previously mentioned).  It 
is worth mentioning that one possible way to reduce PDMS curvature/wetting would be 
to chemically modify the surface of the SU-8 (e.g. silanization) to increase the contact 
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angle.  This was not pursued, given initial successes with the compression-molding 
process discussed in the next section. 
Compression-Molding:  Attempts and Learning 
 A compression-molding process to realize through-holes was pursued in-parallel 
with the protrusion method.  The compression-molding process begins by spin coating 
PDMS onto a master mold, which is a Si wafer patterned with photoresist (SU-8) in two 
layers.  The upper layer features define the through-holes (similar to the photoresist posts 
in the protrusion method).  The PDMS is coated thicker than both photoresist layers, and 
a transparency is laminated to the surface of the PDMS.  Pressure is applied by adding 
weight to (or clamping) rigid plates, displacing PDMS from the top surfaces of the upper 
photoresist layer and forming a planar PDMS surface.  Finally, a second PDMS layer is 
aligned and bonded to the first layer, and the bonded assembly is detached from the 
master and bonded to a glass substrate.  This method is similar to the techniques 
described by Folch et al.88 and Kim et al.87 and is diagrammed in Fig. 3-4. 
 The primary rationale for pursuing the compression-molding process was the 
potential to realize a planar surface on the first PDMS layer upon which a second PDMS 
layer could then be intimately bonded.  By realizing a planar surface, bonding problems 
associated with the protrusion method could potentially be avoided and low channel 










Fig. 3-4  Compression-molding process in summary.  (a) PDMS is coated thicker than a two-layer 
photoresist stack.  (b) A transparency is laminated to the PDMS surface, and an assembly of transparencies, 
Si wafers, and rigid plates is stacked; weight is used to apply pressure to displace PDMS from the top 
surfaces of the upper PDMS layer.  PDMS is fully cured by heating.  (c) Stack is disassembled and 
transparency is delaminated from the cured PDMS surface; a planar surface should result.  (d) A second 
PDMS layer (i.e. thick slab pre-molded with channel network) is aligned and bonded to the first layer.  
Bonding is achieved by plasma surface activating both layers; as a result, alignment and bonding must 
occur rapidly (< 1 min).  (e) Bonded layers are detached from master and bonded (by plasma surface 
activation) to a glass substrate.  Subfigure (b) adapted from Kim et al.87 
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 The process was debugged over the course of 20 trials on masters patterned with 
SU-8 layers with thicknesses of 50 μm and 30 μm for the lower and upper layers, 
respectively (total stack height being 80 μm, the sum of both).  All devices in this work 
are based on such thicknesses.  Several processing parameters were debugged throughout 
the trials, including but not limited to the relaxation time after PDMS spin coat, 
transparency lamination method, silanization time for laminated transparencies to assist 
in delamination from PDMS, assembly stacking method (to prevent slippage), and 
intermediate steps.  All processing parameters are listed in the final modified 
compression-molding discussion in a later section of this chapter. 
 The critical learning from compression-molding process development took place 
in three respects:  (i) use of photoresist support posts, (ii) prevention of gas bubble 
formation during compression, and (iii) thermal processing to enable alignment 
reworking.  While a planar surface is in-principle possible with the compression-molding 
process, in practice the compliance and softness of the transparencies causes the 
displacement of PDMS from both upper and lower photoresist surfaces, resulting in a 
PDMS surface that generally conforms to the topography of the photoresist features.  In 
many cases, the PDMS would be completely displaced from the surface of lower 
photoresist features, which caused unintentional fluidic interconnect with upper channels 
when crossing over the lower features.  To prevent such interlayer leakage and assure a 
planar surface, photoresist support posts were integrated into device layouts (Fig. 3-5).  
Support posts are positioned throughout each device, and for critical locations, where a 
lower channel crosses an upper channel, support posts are placed between 150 and 300 
μm from the crossing point to assure unintentional interconnect does not occur (Fig. 3-
5(c)).  The use of support posts makes possible a near-planar PDMS surface, enabling 
intimate bonding between the two PDMS layers without interlayer leakage. 
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Fig. 3-5  Photoresist support posts.  (a) Compliance of transparency causes it to conform to the 
topography of the tops surfaces of lower and upper photoresist layers when compression takes place.  Loss 
of planarity causes unintentional fluidic interconnect between layers when lower and upper channels cross; 
results in device failure.  (b) Support posts prevent transparency from collapsing on lower photoresist layer.  
(c) Support posts (small circular features) in devices developed in this work.  Scale bar in both panels is 
500 μm. 
 
 The prevention of gas bubble formation during the compression step is another 
important learning from this work.  In initial trials, transparencies would be laminated to 
the PDMS surface, taking care not to trap air bubbles; however, numerous gas bubbles 
would nucleate throughout the device during compression (Fig. 3-6).  Such bubbles 
would merge with through-hole features or cause unintentional fluidic interconnect 
between layers.  One aspect of the compression process is that heat is applied to cure the 
PDMS.  Assuming that uncured PDMS behaves as most liquids, the solubility of 
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dissolved air in PDMS would decrease as heat is applied, increasing the likelihood of 
bubble formation.  Therefore, prior to processing, PDMS was placed in a vacuum 
desiccator for 2 hours at ~30 torr to remove dissolved air.  This is roughly 4× longer than 
the typical degassing process to remove large, visible bubbles PDMS prior to casting it in 
non-compression processes.  The extended degassing step effectively ended bubble 
formation during compression. 
 
 
Fig. 3-6  Gas bubbles nucleated in PDMS during compression.  Gas bubble nucleation was a major 
failure mechanism during process development.  Subfigures show gas bubbles merging with a through-hole 
feature (left) and near a through-hole feature (right).  Scale bar is 200 μm for both subfigures. 
 
 
 Another learning is the necessity of permitting reworks during alignment and 
bonding of the two PDMS layers.  The prior mentioned work by Kim et al.87 utilized 
plasma surface activation to bond both layers.  Plasma surface activation enables robust 
covalent bonding between layers; however, the alignment and bond must be completed 
within 1 min prior to surface oxidation, and the alignment is a “one-shot” event.  If the 
alignment is outside of tolerance, no rework could take place.  Alignment time can be 
extended by immersion of PDMS surfaces in solvents (e.g. ethanol) immediately after 
plasma activation to shield the surfaces from oxidation.  However, from a practical 
standpoint, the devices in this work were fabricated in batches (7 die per wafer), and if 
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the wafer was immersed in ethanol after plasma activation, it would likely require the 
stereo-zoom microscope (used for alignment) to be placed in a highly ventilated 
environment (e.g. fume hood) due to ethanol vapors emitting from the dish in which the 
wafer was immersed.  Most importantly, since alignment is manual, the ability to rework 
(peel-off and align again) is important to yield more devices per batch. 
 
 
Fig. 3-7  Partial curing of PDMS during compression-molding.  Typically, compression-molding 
involves heating the stacked assembly in (a) in an oven or on a hot plate until the PDMS is fully cured; 
there is no time limit in the heating process.  The tradeoff is that alignment must be rapid (<1 min) and 
reworks are not possible during alignment.  In this work, the heating schedule is set to partially cure PDMS 
into a solid but tacky surface, providing extra time for alignments and enabling reworks if necessary ((b) 
and (c)).  The layers are then thermally bonded.  Rework is useful to maintain yield in manual alignments, 
and the additional time could be beneficial for automated alignments of large batches of devices per master. 
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 To make reworking possible, the PDMS in both layers was partially cured to the 
point where they were intact, yet tacky to the touch.  To do so, the stacked assembly of 
transparencies and weights on the lower PDMS layer was placed on a hot plate for a 
limited time, which was determined to be 10.5 min at 80 °C after some trials of 
optimization.  Partial curing of PDMS is a nonlinear process in time; thus, heating for 
slightly longer than necessary yields a fully cured PDMS surface that cannot thermally 
bond with the other layer.  On the other hand, heating for too short a time results in still-
liquid (mostly-uncured) PDMS, which does not have the mechanical rigidity for 
successful delamination of the transparency and aligning.  Once removed from the hot 
plate, PDMS cures slowly at room temperature, and the alignment process could proceed 
without time limitation.  If an alignment was out of tolerance, the two sticky PDMS 
surfaces could be carefully peeled apart, and re-aligned.  For manual alignments in this 
work, x- and y-tolerances were set to ± 50 μm.  After aligning all devices, further heating 
(12 hr at 70 °C) would thermally bond both layers into a single monolithic slab.  
Typically, in the final process, 2 devices per batch required rework (re-alignment).  The 
average yield up to the alignment step was 4 to 5 devices (out of 7 attempted).  Thus, 
reworking enabled up to a doubling of yield, when compared to a scenario where no 
rework was possible. 
 Despite the learning from compression-molding process development, batch 
yields were less than 1 device out of 7.  A single un-realized through-hole would render a 
device unusable.  The dominant failure mode for un-realized through-holes appeared to 
be thin PDMS membranes residing over the top surface of upper photoresist features 
(Fig. 3-8).  The hypothesis was that the PDMS was not completely displacing from the 
top surfaces of the photoresist because the pressure was not high enough during 
compression.  Therefore, a system capable of generating higher pressures was sought, 
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since manually stacking more steel weights (40 lbs force at that point) would become 
unwieldy. 
 
Fig. 3-8  Residual PDMS on the surfaces of SU-8 (photoresist) features after compression-molding.  
(a)-(b) A thin PDMS membrane on the surfaces of square SU-8 features is visible by its ripples.  (c) Finger-
like ridges appeared when the PDMS would partially detach off the SU-8 surface when the transparency 
was being delaminated.  (d) PDMS encroaches onto the surface of a square SU-8 feature, leaving only a 
circular area in the interior clear of PDMS.  Residual PDMS was major failure mode while developing the 
modified compression-molding process, leading to the hypothesis that more pressure was required to clear 
PDMS off SU-8 surfaces.  Scale bar for all subfigures is 200 μm. 
Semi-Automated Compression-Molding with NIL: Attempts and Learning 
 A compression-molding machine, the Nano-Imprint Lithography (NIL) tool 
(Obducat AB, Malmo, Sweden), was tested as the compression source for device 
fabrication.  The tool is capable of applying pressures up to 80 bar.  Also, the tool is 
capable of applying heat, which would be useful to partially cure PDMS.  Both pressure 
and heating ramps could be programmed, enabling semi-automated operation.  PDMS 
was spin coated onto the wafer to a thickness greater than both photoresist layers (as per 
other compression-molding trials), and NIL transparencies were laminated to both 
surfaces of the wafer.  The wafer-transparency assembly was loaded into the NIL and 
pressure-heat sequences were run. 
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 Over several attempts, some minor learning emerged.  The NIL was most reliable 
at maintaining pressures if it was gradually ramped (45 s dwells in 10 bar increments).  
Faster ramps would cause the pressure to fluctuate and decay to a basal state of 15-20 
bar.  A pressure of 70 bar was reached on device wafers.  Also, partial curing of PDMS 
was realized using temperature ramps. 
 The main observation is that the NIL did not successfully make any through-
holes.  When each wafer was removed, the transparency appeared to conform very 
precisely to the surface of the photoresist pattern.  The NIL is designed to apply very 
uniform pressure on the stamp and substrate by the use of compressed air as the pressure 
source.  In addition, the two transparencies were sealed together at the edges, preventing 
PDMS from displacing off the wafer (Fig. 3-9). 
 
Fig. 3-9  Schematic of highly conformal transparencies after NIL compression.  The NIL applies very 
uniform pressure by way of compressed air.  It was speculated that pressure uniformity, as well as the 
sealing of the transparencies at their edges, could have prevented PDMS from displacing properly from the 
tops of upper layer photoresist features.  This led to a new hypothesis that focusing the pressure over 
regions with through-holes could completely displace PDMS from the tops of photoresist features. 
 
 These observations led to a new hypothesis that the location of pressure, as 
opposed to pressure in general, could facilitate complete displacement of PDMS from the 
upper photoresist surfaces.  That is, if the pressure was focused over each individual 
device, rather than over the whole wafer, then it was hypothesized that the PDMS could 
better displace off the photoresist surfaces because the regions where pressure was not 
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focused could act as reservoirs where displaced PDMS could collect.  To test the 
hypothesis, small transparency pieces were placed on top of the laminated transparency, 
directly above each device (Fig. 3-10), thereby focusing the pressure above regions with 
through-holes.  This formed the basis of the final process adopted for this work (modified 
compression-molding), which is detailed in the following section. 
 
 
Fig. 3-10  Compression-molding step with pressure localized above device.  Pressure is focused only 
above devices to test the hypothesis that PDMS would better displace off the surface of upper photoresist 
features because it could collect in areas without focused pressure (reservoirs).  Focused pressure formed 
the basis of the process adopted for all devices fabricated in this work.  
 
Adopted Fabrication Method:  Modified Compression-Molding 
 In this work, 3-D flow networks are realized using a compression-molding 
process that is a modification of compression-molding techniques described by Folch et 
al.88 and Kim et al.87  The process developed herein differs in two ways.  First, during the 
compression step, pressure is focused over each device die by the use of small 
transparency sheets.  Focusing the pressure increases yield of through-holes.  Second, the 
alignment step takes place while the two PDMS layers are only partially cured.  This 
allows more time to perform alignments, and it enables reworks if the alignment of 
bonded layers is out of tolerance. 
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 In general, each device in this work is fabricated using a combination of 
techniques, including soft lithography,89 multi-layer PDMS thermal bonding,83 and 
through-hole processing.   
 Fabrication requires two master molds (masters A and B).  Each master is a 
silicon wafer (100 mm diameter) with a photoresist pattern forming device features in 
positive relief.  Photoresist patterns are realized using standard photolithographic 
methods.90  Since the master molds are unique to each of the two types of devices 
developed in this work, details of their fabrication are located in the Methods section of 
Chapters 4 and 5.  For reference, layouts of each type of device are found in Appendix A.  
In general, for both devices, master A contains a two-layer pattern of SU-8 (MicroChem 
Corp., Newton, MA, USA) photoresist.  The first (lower) layer is 50 μm tall, and its 
features define the cell chambers, fluid flow channels, and valve control channels 
(channels that pressurize to close integrated valves; see Appendix C).  The second 
(middle) layer is 30 μm tall and its features define through-holes; it is stacked on top of 
the lower layer, making the combined height of both layers 80 μm.  During the 
compression step, PDMS is displaced from the surfaces at the 80 μm height. 
 For both devices, master B contains patterns made of AZ P4620 (AZ Electronic 
Materials Corp., Branchburg, NJ, USA), a positive-type photoresist.  The AZ features are 
35 or 25 μm tall (for soluble-matrix array in Chapt. 4 or gradient array in Chapt. 5, 
respectively) and predominantly define fluid flow channels.  AZ features have a semi-
circular cross-section, allowing them to be fully closed by integrated valves located 
throughout the device (see Appendix C for valve actuation description).  For the soluble-
matrix array, master B also contains SU-8 features 7 μm tall that define perfusion 
conduits (see Methods in Chapter 4). 
 PDMS devices (with through-holes) are realized via the following process flow, 
which is diagrammed in Fig. 3-11 (a wafer-level view of the compression stack is found 
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in Appendix D and further details are found in Appendix E).  Briefly, PDMS (Sylgard 
184, Dow Corning Corp., Midland, MI, USA) with a base-to-curing agent ratio of 20:1 is 
mixed and degassed under vacuum in a desiccator for 2 hours.  The PDMS is then spin 
coated onto master A to a thickness of 200 µm.  A mylar transparency is laminated on top 
of the PDMS; care is taken not to introduce bubbles between the transparency and 
PDMS.  More transparencies are added, including small device-sized transparencies 
located above device positions.  Additionally, a blank silicon wafer, cloth sheets 
(TechniCloth II, ITW Texwipe, Mahwah, NJ, USA), and steel blocks (total weight ~40 
lbs) are placed on the stack to displace PDMS from the top of the tallest SU-8 features.  
The entire stacked assembly is placed on a flat bake plate (CEE 100CB plate, Brewer 
Science Inc., Rolla, MO, USA) at 80 °C for 10.5 min.  After cooling, the stack is 
disassembled, and the transparency is peeled off the PDMS surface.  Hence, master A is 
left with a layer of partially cured PDMS that is the same height as the tallest SU-8 
features (~80 µm); the tops of such features are devoid of residual PDMS, resulting in 
well-defined through-holes. 
 The PDMS on master A is aligned and bonded to a subsequent PDMS layer, 
which is derived from master B as follows.  PDMS with a base-to-curing agent ratio of 
5:1 is mixed, degassed (2 hours), and poured onto master B to a thickness of 4 mm.  The 
PDMS is cured at 70 °C in a convection oven for 20 minutes.  After cooling, the PDMS 
is peeled off the master and cut into individual device slabs.  Inlet and outlet ports are 
cored through the slabs using 20G luer stubs. 
 Each slab is aligned and attached to corresponding locations on the PDMS layer 
of master A.  The two layers are then cured at 70 °C for at least 4 hours (usually 12+ hr) 
to fully bond into a monolithic device.  After cooling, the devices are peeled off the 
master, and valve control ports are cored through the devices using 21G luer stubs.  
Finally, each device, along with a glass slide, is exposed to air plasma for 30 sec at 18 W 
power (Plasma Cleaner PDC-32G, Harrick Plasma, Ithaca, NY, USA), and the two are 
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brought into contact and irreversibly bonded.  Thus, each microfluidic “chip” is 
comprised of a PDMS device containing all the topographical features (channels, 
chambers, through-holes, etc.) bonded to a glass substrate.  Each device footprint is 24 × 
24 mm (for both types of devices).  Further processing details are found in Appendix E. 
 
Fig. 3-11  PDMS device fabrication process.  Based on modified compression-molding process, including 
focused pressure compression and partial curing of PDMS layers.  All devices in this work are fabricated 




Estimated Yields and Observed Failure Modes 
 Fabrication can be divided into “front-end” and “back-end” processing.  Front-
end processing involves all processing steps performed in the cleanroom (up to and 
including the modified compression-molding process described above), while devices are 
in batches of 7 carried on a single wafer/master.  Back-end processing takes place in a 
non-cleanroom laboratory, and it involves detaching each device from the wafer, coring 
valve control ports, and bonding to a glass substrate.  More detail on these processes is 
found in Appendix E. 
 
Table 3-1  Estimated yields in fabrication of chamber array devices. 
 
  
 For the two types of devices detailed in this work, 175 were attempted.  Front-end 
yields are obtained from yields reported in laboratory notebooks.  Yields for some 
batches were not reported; hence, front-end yields are considered estimates (not actuals).  
As a check of the front-end yields, all reported yields for batches of earlier generations of 
gradient devices were counted, giving a front-end yield of 66%, which is similar to the 
64% estimated for the final generation device.  Back-end yields were calculated by 
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counting the number of experiments attempted, assuming that if an experiment is 
attempted, the device was fabricated successfully.  However, some successfully 
fabricated devices were never used (and therefore never counted), and so the back-end 
yields are estimates as well. 
 The estimated front-end yield for the soluble-matrix (Chapter 4) device is lower 
than that of the gradient (Chapter 5) device.  One possible reason is that there are more 
through-holes in the soluble-matrix array than in the gradient array.  Unrealized through-
holes were a significant failure mode in front-end processing; if there are more holes in 
the array, then there is a greater likelihood of a failed (unrealized) hole somewhere within 
it, stochastically speaking.  An alternative reason for the discrepancy in front-end yields 
is experience.  The soluble-matrix devices were fabricated before the gradient ones were; 
therefore, gradient device fabrication may have benefited from underappreciated (and 
intangible) gains in skill, which would increase its yield.  In addition to front-end yields, 
there is also a discrepancy in back-end yields.  The back-end yield of the gradient device 
is lower than that of the soluble-matrix one.  This could be attributed to a brief period 
when PDMS-to-glass bonding failed for several gradient devices, which dropped the final 
yield count. 
 Failure modes attributed to fabrication are listed in Table 3-2.  Frequencies of 
such failures were not recorded; although, it is recalled that unrealized through-holes 
were by far the most common failure, despite the use of the modified compression-
molding process.  One should note that a single unrealized through-hole in a device 
would render the device unusable (and therefore a failure), and the vast majority of 
device failures were indeed caused by only one or two unrealized through-holes.  The 
soluble-matrix and gradient devices contain 88 and 54 through-holes, respectively.  Thus, 
as the arrays are scaled, more work is required to improve the compression-molding 
process (through-hole to through-hole yield) to prevent the device yields from dropping.  
Further fabrication improvements were not pursued, since the yields were considered 
 41
tolerable (for purposes of this work) and it was decided to shift the focus of the work to 
characterizing and testing the devices with living cells. 
 
Table 3-2  Failure modes observed while fabricating soluble-matrix and gradient devices. 
 
  
 There is another failure mode to note, although it is associated with design rather 
than fabrication:  successful realization of through-holes is dependent upon the spacing 
between through-holes.  If two through-holes are less than 200 μm from each other 
(center-to-center), they typically do not form completely.  This could be due to slight 
height differences between the upper photoresist features of each through-hole.  If one is 
taller than the other, it prevents the transparency from laying flat on the shorter one.  
Thus, the PDMS is not fully displaced.  In addition, through-holes in devices in the center 
of the wafer almost always do not form.  This could be caused by not having a fully 
uniform pressure distribution (among the focused regions) or by slight photoresist height 
differences from the center to the edge of the master wafer. 
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Scaling Efficiency and Scaling Rules 
 Over the past decade, PDMS microfluidic systems have made dramatic progress 
in their features and functionality.  Many systems now incorporate integrated (on-chip) 
pumps and valves that assist in fluid handling through flow channel/chamber networks.  
Despite such progress, challenges still remain, particularly in the area of chamber array 
scalability.  One should note, the term “scaling” in this context does not have the same 
meaning as traditionally interpreted in chemical engineering, where “scaling” typically 
refers to the pursuit of increasing production by scaling “up” the size/volume of reactor 
and processing vessels.  Instead, scaling in this context is the pursuit of scaling “out” to 
larger numbers of chambers. 
 A predominant tenet in microfluidic device design is that flow paths must 
navigate 2-dimensionally, i.e. the flow paths are restricted to the layer they are in.  
Scaling to larger numbers of chambers in an array requires proportionate amounts of 
input/output ports, as well as greater allocations of device real-estate for fluid bussing 
channels to support the chambers.  If flows could navigate vertically (by through-holes) 
between layers, then scaling efficiency could be increased.  An example of this is 
illustrated in Fig. 3-12.  Vertical connectivity between layers enables the creation of 
overpasses and underpasses so that separate channels can cross without mixing; therefore, 
efficiencies are gained by a reduction of (i) input/output ports and (ii) real-estate 
allocation for the same number of chambers.   
 The scaling rule for number of input/output ports for the architecture in Fig. 3-
12(a) would be: 
rowchports NNN += , 
where Nports is the number of input/output ports, Nchamber is the number of chambers, and 
Nrow is the number of rows in the array.  The efficiency of output ports could be improved 
by merging ports for conditions A, B, and C into a single port.  However, this would 
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come with a cost in fluid handling maneuvers; instead of priming each row through a 
single port, the inlet ports would need to be used to load conditions A, B, and C, as well 
as conditions 1-5.  For each outlet port merged (removed), four new attachments (and 




Fig. 3-12  Example of a gain in scaling efficiency using 3-D flows.  (a) and (b) illustrate an array of 
chambers individually addressed with combinatorial conditions.  Conditions A-C are primed by rows; then 
conditions 1-5 are dosed by columns.  (a) For a standard 2-D flow network, each chamber requires an input 
port, as well as more space for bussing channels.  (b) Flow layers with vertical connectivity create 3-D 
flows, reducing input/output ports and space allocations for the same number of chambers and conditions.  
Small black dots denote locations of vertical interconnect (through-holes).  The array detailed in Chapter 4 
addresses a similar problem.  Macro-to-micro (“world-to-chip”) interconnect takes place at input and 
output ports; hence, the larger circular footprints. 
 
 The corresponding scaling rule for the architecture in Fig. 3-12(b), which makes 
use of 3-D flows, is: 
2++= columnsrowsports NNN , 
where Ncolumns is the number of columns and the quantity 2 arises from the two output 
ports.  If arrays were created based on the row-to-column ratios of standard well plate 
formats, the scaling rules would result in the plots in Fig. 3-13. 
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Fig. 3-13  Scaling of inlet/outlet ports for the problem in Fig. 3-12 (combinatorial conditions by rows 
and columns).  For a 2-D flow architecture, the number of ports scales linearly with the number of 
chambers.  A 3-D flow architecture results in the number of ports scaling roughly in the square root of 
chambers.  Numbers of rows and columns for each calculation point based upon standard 6 (2×3), 24 (4×6), 
96 (8×12), 384 (16×24), and 1536 (32×48) well plate formats. 
 
The scaling of input/output ports is important in two respects.  First, because ports are the 
“world-to-chip” (macro-to-micro) interconnect points, each port requires a substantial 
amount of space (footprint) relative to other device features in order to fit the tubes or 
needles for fluid introduction.  For instance, microfluidic systems in this laboratory are 
designed so that center-to-center spacing between ports is at least 1.5 mm, as opposed to 
typical channels in the device that could be 50 to 100 μm wide (and spaced at similar 
distances).  As the array scales to more chambers, a 2-D flow architecture would result in 
an explosion in footprint required for the growth in ports.  Secondly, the likelihood of 
device failure increases with ports.  For PDMS microfluidic devices, each port is punched 
or molded (manually or in a semi-automated way), and plastic tubing or metal needles 
(luer stubs) of a larger gauge are press-fitted into the hole, forming a tight seal.  For this 
work, a port defect could be a punch that misses its target or a crack propagating radially 
from the hole that causes a leaky interconnect (see previous section on Yield).  For 
example, one defective port out of every 100 may result in an acceptable yield for small 
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arrays, but such a rate would drastically decrease yield for arrays approaching 100 
chambers, depending on the defect frequency distribution.  Therefore, minimizing the 
number of ports is important for maintaining device yield.   
 Scaling rules for the additional footprint that must be allocated for fluid bussing 
channels (denoted in Fig. 3-12(a)) (both in length and quantity) could also be derived, 
based on design rules for channel widths and spacings (different for each lab and 
application).  Similar to ports, a 3-D flow architecture would result in greater footprint 
efficiency compared to a 2-D one. 
Microfluidic Arrays and Well Plates 
 The device described in Chapter 4 contends with a variation of the same problem 
in Fig. 3-12, where different matrix signals are coated by rows and media with different 
soluble signals are perfused by columns.  For microfluidic designers, the motivation to 
address individual chambers with different combinations stems from the desire to achieve 
the same level of versatility as conventional well plates.  Well plates are extremely 
versatile, where any combination of conditions can be pipetted into any well.  To reduce 
sample usage and increase throughput, well plates with smaller wells and higher density 
(up to 1536+ wells per plate) are now offered.  Such advances have created challenges, 
such as the growing effect of evaporation and escalating numbers of fluid handling 
maneuvers (pipetting, either manual or robotic).91  Microfluidic systems are well-suited 
to prevent evaporation, since they are closed systems.  In addition, microfluidic systems 
could redefine the notion of fluid handling; instead of robotic (or human) arms 
maneuvering pipettes between wells and reloading/cleaning stations, fluid handling could 
be executed in a microfluidic network by drawing and delivering fluids from desired 
input ports using on-chip valves (and/or pumps).  Automated control of such operations 
could prove to be more rapid and reliable than current handling methods. 
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 However, the abovementioned benefits of microfluidic systems are severely 
negated without 3-D flow networks to facilitate individual addressing of chambers.  In 
addition, integrating an on-chip valve network that isolates chambers from each other is 
critical.  It is inconceivable for an experimentalist to tolerate using a well plate with wells 
that leak among each other (unless such leakage was a deliberately designed as an 
experimental condition).  By the same logic, microfluidic chamber arrays that claim to 
offer similar versatility (individual addressing) as well plates must demonstrate chamber 
isolation.  The use of on-chip valve networks further amplifies the need for 3-D flows, 
since flow channels would also have to navigate over (or under) valve control channels. 
 The pursuit of fabricating 3-D flow networks is not new.  Several groups have 
developed methods to fabricate through-holes and 3-D networks (see beginning of 
chapter, 3-Dimensional Flow Networks); however, such works have only been for 
demonstration, and attempts to implement such architectures for specific applications, 
particularly for cell-based assays, are absent.  It is speculated that attempts at specific 
applications are absent because the creation of 3-D flow networks is challenging even for 
research groups dedicated to microfluidics; instead, groups may judiciously choose to 
pursue applications that can be accomplished with 2-D flows.  Based on the extent of 
process debugging in this work, groups could be deterred from pursuing 3-D flow 
network applications because many “tricks” (the art) of 3-D network fabrication are 
unreported or under-explored.  Moreover, without yield information (actual or estimated), 
researchers have no basis upon which to judge the amount of work required if they 
pursue such applications.   
 This work intends to move microfluidic chamber arrays closer to the goal of one 
day being as well-accepted as well plates to perform cell-based screens.  However, 
regular use of microfluidic chamber arrays in academic and industrial labs is many years 
away for a number of reasons.  First, there is not yet enough scale in microfluidic arrays.  
The arrays constructed in this work (8 and 6 chambers in Chapters 4 and 5, respectively) 
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are small compared to well plates with hundreds or thousands of wells.  The largest 
independently-addressed microfluidic chamber array for cell-based assays contains 96 
chambers, but it could only scale in one dimension, cannot continuously perfuse medium 
to each chamber, and could expose cells to pulses of high shear due to the manner in 
which it performs medium changes.92  The work in Chapter 4 attempts to address such 
issues, but new challenges and technical trade-offs may emerge as researchers continue to 
scale-out microfluidic chamber arrays.   
 Second, there is a lack of automation and standardization in macro-to-micro 
interconnects; fluid sources are connected to ports manually in most settings, and 
although there are some commercially available microfluidic arrays,93 the macro-to-micro 
interconnections for them are proprietary.  Without automation and standardization, 
macro-to-micro interconnections will become a major bottleneck in the usage and 
dissemination of microfluidic chamber array technology.   
 Third, microfluidic devices of the complexity in this work are still too difficult for 
most lay technicians and graduate students to operate.  Procedures like device priming 
and cell loading are labor-intensive and require finesse gained from experience.  Once 
again, lack of technology and standardization in such protocols is a key bottleneck.  
Another difficulty is in controlling microfludic systems; to perform the assays in this 
work, a many instruments need to work in coordination.  Without a “black box” hardware 
and software setup, writing custom-software to coordinate syringe pumps, microscopes, 
x-y stages, on-chip valves, and imaging equipment may prove too difficult for most 
workers.   
 Fourth, microfluidic chamber arrays are still not as generalized and versatile as 
well plates.  For example, any well plate can accept either pure liquids or gels, while 
most microfluidic arrays (including the ones in this work) would require a redesign to 
specifically accommodate different phases.  The concept of generalization, where the 
same device can be used in different ways, is a key concept for large scale 
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commercialization.  If the same device could perform more and different tasks, the result 
would be higher manufacturing volumes and lower costs per unit.  Ultimately, the goal of 
microfluidic chamber arrays should not be to replace well plates, but instead to provide 
an effective alternative, particularly to prevent evaporation, perform complex fluid 
handling, and reduce sample usage. 
General Discussion 
 As previously mentioned, the modified compression-molding technique detailed 
in this chapter differs from other techniques in that it focuses pressure in specific areas 
(device locations) and aligns using partially cured PDMS. 
 Focused pressure results in all through-holes being successfully realized in 
roughly 60% of devices fabricated (front-end yield).  This is an improvement over 
attempts without such modifications (yielding less than 15% of devices), presumably 
because it assists in displacing PDMS from the tops of SU-8 features by providing a 
nearby reservoir between devices into which PDMS can collect.  We also use soft cloths 
(Texwipes) in the stack, further improving the through-hole yield by providing a more 
uniform distribution of pressure across the master and over each device.   
 In addition, the PDMS is partially cured (in lieu of fully cured) so it can be 
thermally bonded to a subsequent PDMS layer (from master B).  The thermal bonding 
technique provides ample time (up to 3 hrs, since PDMS cures slowly at room 
temperature) to properly align the two PDMS layers.  This differs with air plasma 
bonding, which affords far less time (<1 min. after plasma surface activation).  Extra time 
is beneficial, particularly for manual alignments, or for aligning multiple devices on a 
single master, which could take more than a minute to complete (whether manual or 
automated).  Another difference is that plasma bonding is a “one-shot” event.  If the 
layers are aligned outside of tolerance, there is no way to rework.  On the other hand, 
partially cured PDMS layers permit reworking. 
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 An added feature made possible by the 3-D flow network is the seeding and 
attachment of cells onto the surface of the underlying (supporting) substrate of the device 
(in this case, glass).  To elaborate, one consequence of the on-chip push-up valves is that 
cells approach each chamber from the top flow layer.  For cells to make contact with 
glass in the chamber, they must travel by way of through-holes from the top layer (with 
the PDMS surface) to the bottom layer (with the glass surface).  Otherwise, cells would 
seed in the top layer on a surface made of the bulk material of the device (PDMS), as is 
the case for other microfluidic cell culture arrays.92,94 
 The devices in this work are designed with the default option to seed cells on 
glass or other rigid substrate.  This is necessary if high-magnification microscope 
objectives with small working distances are utilized (requiring substrate thicknesses 
comparable to cover slips).  Nevertheless, if one desires for cells to grow on PDMS or 
another soft material, it can be coated to the appropriate thickness on the substrate prior 
to attaching the device. 
 A limitation of the modified compression-molding technique is that it is a batch 
process that currently requires manual alignments.  This problem affects all 3-D flow 
network fabrication processes.  In this case, manual alignment of each device (being 
24×24 mm) requires roughly 5-10 min.  However, it is reasonable to assume that the 
devices could be manufactured in larger volumes in a more automated fashion, given that 
multilayer PDMS devices (also requiring alignments) are commercially available.93   
 Images of fully-fabricated devices showing through-holes are found in Figs. 4-3 
and 5-2.  Close-up views of through-holes are shown below in Fig. 3-14. 
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Fig. 3-14  Through-holes in finished devices.  Top subfigure shows an earlier generation device with a 
500 × 500 μm square through-hole.  Lower subfigure shows through-holes (100 × 80 μm) in soluble 
gradient device (Chapt. 5).  The two types of microfluidic chamber arrays based upon the modified 
compression-molding process contain 88 and 54 through-holes each (for the soluble-matrix and gradient 
designs, respectively).  Both scale bars are 500 μm. 
 
Chapter Summary 
 This chapter reviews the development of a process to produce through-holes for 
vertical connectivity between flow layers (3-D flows) in microfluidic chamber arrays.  
Specifically, this work explores two previously reported fabrication methods (protrusion 
and compression-molding), develops yield-enhancing modifications (for compression-
molding), and estimates the resulting device yields.  Efficiencies provided by 3-D flows 
for array scaling (and associated scaling rules) are discussed.  In addition, ongoing 
challenges that hinder widespread use of microfluidic chamber arrays in academic and 
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industrial laboratories are discussed.  The following chapters (4 and 5) describe attempts 
to apply microfluidic chamber arrays with 3-D flow architectures as actual cell-based 
assays. 
  
Table 3-3  Chapter 3 summary. 
 
* Note:  fabrication process and resulting 3-D flows are featured (and process detailed) in published work.95 
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CHAPTER 4 
A MICROFLUIDIC CHAMBER ARRAY FOR STUDYING 
CELLULAR RESPONSE TO COMBINATIONS OF MATRIX AND 
SOLUBLE SIGNALS 
 
This chapter describes the development of a microfluidic cell culture array with 
unique versatility and parallelization for trials requiring perfusion cultures.  A rectangular 
chamber array in a PDMS device is realized with three attributes:  (i) continuous 
perfusion; (ii) independently-addressable chambers and subarrays; and (iii) flow paths 
that forbid cross-chamber contamination. These attributes are made possible by the 3-D 
flow architecture described in Chapter 3.  Versatility is achieved via subarray, row, 
column, or single chamber addressing for the following:  incubation with adsorbed 
molecules; perfusion of different media; seeding or extraction of cells; and assay staining.  
Moreover, culture surfaces are shielded from direct perfusion to minimize shear-induced 
cell changes.  Device operation is demonstrated by culturing alveolar epithelial type II 
(ATII) cells in different combinations of matrix and soluble signals within the 2×4 
chamber array.  After culture, staining is performed to ascertain responses to each signal 
combination.  By loading and culturing cells to different conditions, in addition to 
performing post-culture assays, it is shown that this prototype array and its 3-D flow 
architecture could facilitate combinatorial screening and form the basis of larger arrays 
for basic and industrial research. 
Specific Motivation and Objectives 
Over the past several years, numerous works have demonstrated the utility of 
microfluidic arrays as screening tools to culture cells in diverse microenvironments.96-102  
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Interest in microfluidic systems arises from the prospect of very low sample usage, 
highly-parallelized experiments, and well-controlled culture conditions, all of which are 
facilitated through miniaturization.  With respect to microenvironments, the screening of 
cellular responses to simultaneous stimulation of soluble and extracellular matrix (ECM) 
cues is a broad line of inquiry that is particularly useful in studying phenotype transitions.  
One example is epithelial-to-mesenchymal transition (EMT), which is implicated in 
numerous developmental and pathological processes.  Greater understanding of 
phenotype transitions could lead to new therapeutic approaches, facilitated by 
microfluidic arrays with new capabilities.  
 Microfluidic chamber arrays have been developed in many forms, and most can 
be categorized into one of three generalized architectures.  First, there are open array 
architectures, where all chambers are fluidically linked, allowing flow and diffusional 
transport among chambers.103-107  The extent of cross-chamber communication 
(convective or diffusional) is determined by the flow rate, flow direction, and device 
geometry.  Second, there are architectures isolated by rows/columns, where flow is 
restricted to individual rows (or columns) by valves or other barriers.108-112  Therefore, 
only communication among chambers within rows (or columns) is possible.  Signals 
secreted from cells in upstream chambers may be a concern, the extent of which depends 
upon the signal and its concentration, which in turn is determined by cell density, 
secretion rate, and flow velocity.  Third, there are architectures where the chambers are 
completely isolated from each other and individually addressed.  This eliminates cross-
chamber communication by extensive use of on-chip valves and delivery channels.92,94  
 In addition to the general array architecture, the chamber design is also an 
important feature, particularly with respect to shear stress.113  Undesired shear-induced 
cell behavior can be minimized by the use of flow barriers104 or by recessing the chamber 
from the main flow path.103,110 
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 In this work, a microfluidic array architecture is introduced that demonstrates a 
novel combination of attributes:  continuous-perfusion through each chamber, no cross-
chamber communication (i.e. contamination), and chamber shielding to reduce shear 
stresses experienced by cells.  At the same time, a high degree of versatility is offered, as 
well as experimental parallelization.  We demonstrate the operation of this device by 
observing the effect of extracellular matrix (ECM) proteins fibronectin (Fn) and laminin 
(Ln), in conjunction with soluble transforming growth factor- β1 (TGF-β1), on alveolar 
epithelial cells.  This requires a combinatorial experimental setup that takes advantage of 
the attributes of our device design. 
Device Design 
 The array device is comprised of three layers.  The bottom layer contains flow 
channels, cell chambers, and control channels (for on-chip valve actuation).  The middle 
layer contains through-holes that connect the top and bottom layers.  The top layer 
contains flow channels, as well as conduits that allow flow into the protected areas of 
chambers (Fig. 4-1). 
 
Fig. 4-1  Schematic of device architecture.  Three-dimensional flow network requires through-holes 
(middle layer) that fluidically connect top and bottom layers.  White arrows indicate selected locations 
where flow travels 3-dimensionally.  (i) Chamber is continuously-perfused by inflowing medium.  (ii) 
Cross-chamber communication is avoided; fresh medium from a delivery channel (not shown) flows 
through the chamber and into an exit channel (also not shown).  (iii) High-resistance conduits on chamber 
ceiling shield the protected area from the majority of flow.  The chamber, along with supporting channel 
network, is repeated to realize a 2×4 prototype array device. 
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Three attributes 
 The first attribute is continuous perfusion.  Continuous perfusion is desirable 
because it offers greater control of the cellular microenvironment when compared to 
traditional static culture.  The concentration profile of any soluble signal of interest could 
be spatially and temporally controlled, whether the signal is pre-loaded into the medium 
or is secreted by cells in the chambers.  Such control has proven useful in eliciting more 
physiological responses from a variety of cells in culture.114-119  
 The second attribute is the implementation of flow paths that forbid cross-
chamber contamination.  Flow paths are arranged such that once a streamline passes 
through a chamber, it does not pass through any other chambers before exiting the device.  
Therefore, there is no cross-talk from chamber to chamber, which eliminates the 
confounding effects of signals from neighboring chambers.  This is especially important 
when cells are known to be highly-sensitive to signals present in other chambers (i.e. 
conditions) of the array or when the sensitivity of the cells to such signals is unknown.  
Additionally, fluid handling systems used with traditional well plate arrays are subjected 
to thorough cleaning procedures to minimize carryover contamination between 
wells.91,120  For microfluidic arrays to yield biologically significant data, they must 
(among other things) meet or exceed the rigor of traditional systems in avoiding 
contamination. 
 The third attribute is a chamber design that reduces the shear stress applied to 
cells by shielding them from direct flow.  One example of a shielded chamber is by Lee 
et al.,104 where the majority of perfusing medium is diverted around a wall-like barrier, 
which surrounds a protected area where cells reside.  Narrow conduits (gaps or mini-
channels) in the barrier allow a small fraction of the overall flow to penetrate through the 
protected area and transport nutrients to the cells.  The fraction of flow is determined by 
the hydraulic resistance of the conduits, which in turn is determined by their geometry.  
The chamber designed in this work is conceptually similar to the one just described.  
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However, there is a notable difference:  the chamber is designed so that flow enters and 
exits the protected area through conduits on the ceiling, a different plane from where the 
cells are attached.  Flow must travel in three dimensions – vertically upward, horizontally 
across a conduit, then vertically downward.  Two conduits serve as inlets at the upstream 
end of the chamber, and two serve as outlets at the downstream end (Fig. 4-1).  The 
purpose is to avoid cell migration or proliferation into the conduits, which could block 
the flow path.  This is especially likely for cells that require seeding at high densities (i.e. 
epithelial cells). 
Modes of operation 
 A key philosophy in designing the array is not only to combine the three attributes 
above, but also to provide considerable versatility to the user.  Such versatility is 
demonstrated through multiple modes of operation and chamber addressing 
configurations.  Figure 4-2 diagrams four basic modes of operation:  (i) incubation of 
chamber surfaces with selected extracellular matrix (ECM) molecules; (ii) loading of 
cells into chambers; (iii) perfusion of selected growth media; and (iv) assay of cellular 
response to culture conditions.  In addition to the addressing configurations illustrated in 
Fig. 4-2, other configurations can be implemented in order to generate more 
combinations of culture conditions or increase replicates.  For instance, different cell 
types could be loaded into separate rows, as opposed to a single cell type. 
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Fig. 4-2  Selected modes of operation shown in a subarray of 4 chambers.  (a) ECM incubation:  matrix 
molecules adsorb to chamber surfaces by rows or individual chambers.  (b) Cell loading:  cell suspension 
flows into rows, and chambers are isolated (individually or together) to confine cells.  Cells attach and 
spread.  (c) Culture:  Perfusion of different media by columns.  Channel architecture directs flows 
over/under other flows to avoid cross-chamber communication.  (d) Assay:  Solutions flow through the 
entry or exit channels to label cells with desired probes.  Illustrations not to scale. 
 
 A compelling feature of the array is the ability to address individual chambers.  
Individual addressing is possible because four on-chip valves regulate flow into each 
chamber (two for column flow and two for row flow).  When all four valves are closed, 
the chamber is fully isolated from the rest of the array.  As a result, the experimentalist is 
given the opportunity to assign conditions or query a response with a high degree of 
chamber specificity.  If desired, different ECM molecules, cell types or assay reagents 
could be addressed to each chamber.  As shown in Fig. 4-2(b), independent addressing is 
particularly useful during cell loading.  As the cell suspension flows across a row, the cell 
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density tends to vary spatially, which is troublesome when the objective is to load each 
chamber with roughly the same number of cells.  If the cell density in a chamber is 
unsuitable, then the valves can be opened momentarily and then closed again to sample a 
new set of cells.  This can be repeated until the appropriate density is achieved.  
Furthermore, once a chamber is isolated, the flow of cells to other chambers continues 
uninterrupted, since cells can travel around isolated chambers via bypass channels.  It is 
important to note that the ability to load cells by individual chambers also implies the 




 Fabrication begins with the creation of two master molds on Si wafers.  Master A 
contains a two-layer pattern of SU-8 (MicroChem Corp., Newton, MA, USA), a 
negative-type photoresist.  The first layer is 50 µm tall, and its features define the 
“bottom” device layer.  The second layer, which is patterned on the first layer, is 30 µm 
tall with features defining the “middle” device layer (i.e. through-holes).  Master B 
contains patterns made of both AZ P4620 (AZ Electronic Materials Corp., Branchburg, 
NJ, USA), a positive-type photoresist, and SU-8, which define the “top” device layer.  
CAD layouts of the bottom, middle, and top layers are shown in Fig. A-1 (Appendix A).  
The AZ P4620 features (35 µm tall) define flow channels.  These channels have a curved, 
almost semi-circular cross-section, allowing them to be fully closed by push-up valves 
located throughout the device (Appendix C).  The SU-8 features on master B (7 µm tall) 
correspond to conduits (four for each chamber) that allow perfusion through the chamber 
ceilings (Fig. 4-1).  Final devices are made of PDMS using the modified compression-
molding process described in Chapter 3 (and in Appendix E). 
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Simulation of chamber flow field 
 The chamber is designed to provide continuous perfusion while protecting cells 
from adverse shear stress.  To achieve these effects, a barrier is used to divert the 
majority of flow around a protected area where cells grow.  Conduits (with high 
hydraulic resistance) on the ceiling of the chamber are intended to allow adequate mass 
transport through the protected area to nourish cells without undesired shear.  To validate 
this rationale, a 3-dimensional finite element model of the chamber is constructed using 
the COMSOL software package (Multiphysics 3.3, COMSOL AB, Stockholm, Sweden). 
 The geometry of the model represents a half chamber, which exploits the two-fold 
symmetry of the design.  All boundary conditions are no-slip, except for the inlet, outlet, 
and symmetry boundaries.  Flow is driven by imposing a pressure drop between the inlet 
and outlet (positive pressure at inlet boundary and zero pressure at outlet boundary).  The 
Navier-Stokes equations are solved at a variety of flow rates, using water as the medium.  
The resulting flow fields are used to generate flow velocity profiles and compare 
residence times through the diverted and protected areas of the chamber (Fig. 4-4 later). 
Cell culture off-device 
 RLE-6TN cells (ATCC, Manassas, VA, USA), a rat-derived ATII cell line, are 
maintained in D-MEM/F-12 medium (Gibco 10565, Invitrogen, Carlsbad, CA, USA) 
with 10% fetal bovine serum and 1% penicillin/streptomyocin.  Cells are incubated at 
37°C and 5% CO2, and medium is changed every 48-72 hours.  
Prior to each trial, cells are detached from their culture flask using trypsin-EDTA 
solution (0.25% w/v trypsin and 0.53 mM EDTA, Gibco 25200, Invitrogen, Carlsbad, 
CA, USA).  Once the cells are detached, excess medium is added, and the suspension is 
centrifuged. The supernatant is aspirated, and the cells are resuspended in medium to a 
density of ~3×106 cells/mL and loaded into the device. 
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Microscope setup and supporting apparatus 
 Device preparation, cell loading, and assays are performed on a DM IRB/E 
inverted microscope (Leica Microsystems GmbH, Wetzlar, Germany) at 10X or 20X 
magnification in phase contrast mode or fluorescence mode.  Hollow stainless steel pins 
(L-shaped, 21G) are press-fitted into device ports and are connected to flexible plastic 
tubing (PE-60) for fluid and pressure delivery.  Perfusion is driven by syringe pump 
(PHD 2000, Harvard Apparatus, Holliston, MA, USA).  Pressurization of on-chip valves 
is regulated by off-chip miniature solenoid valves (Hargraves Technology Corp., 
Mooresville, NC, USA) attached to a pressure source at 30 psig.  Images are captured 
using a digital CCD camera (ORCA C4742-95-12, Hamamatsu Photonics K.K., 
Hamamatsu City, Japan).  Valve actuation and image capture are computer-controlled 
using a custom-designed interface written in the LabVIEW programming environment  
(National Instruments Corp., Austin, TX, USA). 
Device preparation and cell culture in-device 
 Devices are prepared to culture cells under four different signal combinations:  Fn 
only, Ln only, Fn with TGF-β1, and Ln with TGF-β1.  Fn and Ln (33016 and 23017, 
respectively, Invitrogen, Carlsbad, CA, USA) solutions used for incubation are both 50 
nM concentration in phosphate buffered saline (PBS).  When present, TGF-β1 (R&D 
Systems, Minneapolis, MN, USA) concentration is 5 ng/mL.  
 Each device is pre-filled with PBS.  To prevent on-chip valves from introducing 
gas bubbles into the device during experiments, each valve is filled with water.  Solutions 
of ECM protein are introduced through row inlet ports, and each solution is addressed to 
selected chambers by opening the appropriate on-chip valves.  The ECM is incubated at 
37 °C for 1 hr to allow matrix molecules to adsorb to chamber surfaces.  Following ECM 
adsorption, the device is filled with heat-denatured BSA solution (1% w/v in PBS) and 
incubated at room temperature for 30 min to block surfaces from non-specific binding.  
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The device is then flushed with additional PBS, and rows are isolated from each other 
with on-chip valves. 
 Cell suspension is then introduced into the inlet of each row and flows through all 
chambers in the row.  Cells are confined to a chamber by closing its chamber isolation 
valves.  Bypass channels allow cells to travel around closed chambers to other chambers.  
If the density or distribution of cells in a chamber is unsatisfactory, the isolation valves 
can be momentarily re-opened and closed to sample another set of cells. 
 The device is transferred from the microscope to an incubator at 37 °C and 5% 
CO2.  Medium is introduced into medium inlet ports and perfuses through each column at 
0.3 µL/min. 
Cell Assays 
 All assays are performed after 48 hrs in culture in device.  Cell viability is 
determined by staining with two-probe LIVE/DEAD® solution (L-3224, Invitrogen, 
Carlsbad, CA, USA) prepared to manufacturer’s specifications (2 µM calcein AM and 4 
µM ethidium homodimer-1 in PBS).  LIVE/DEAD solution is introduced to the device 
through an assay port (denoted in Fig. A-1), flow is stopped, and the stain is incubated for 
30 min before imaging. 
 To characterize differences in spreading and cell shape in response to culture 
conditions, actin cytoskeletons are labeled with Texas Red®-X phalloidin (T7471, 
Invitrogen, Carlsbad, CA, USA) and imaged.  The following washes are flowed through 
the array:  (i) fix with 4% v/v paraformaldehyde in D-MEM/F-12 medium for 15 min; (ii) 
PBS rinse; (iii) acetone permeabilization for 10 min; (iv) PBS rinse; and (v) phalloidin in 
PBS (160 nM, prepared by manufacturer’s protocol) for 20 min.  Flows are ~1 µL/min.  
Washes are performed by alternating the introduction of the different solutions through 
the assay/exit ports. 
 62
 To characterize differences in the extent of epithelial junction formation, 
immunofluorescent staining for E-cadherin is performed.  The following washes are 
flowed through the array:  (i) fix with 4% v/v paraformaldehyde in D-MEM/F-12 
medium for 10 min; (ii) PBS rinse; (iii) Triton X-100 (0.5% w/v in PBS) 
permeabilization for 10 min; (iv) PBS rinse; (v) goat serum (10% v/v in PBS) blocking 
for 15 min; (vi) primary antibody (36/E-Cadherin, BD Transduction Laboratories, San 
Jose, CA, USA) in PBS+0.2% w/v Tween (PBST) static incubation for 12 hours 
overnight; (vii) PBST rinse; (viii) secondary antibody in PBST (Alexa Fluor® 488-
conjugated goat-anti-mouse, Santa Cruz Biotech Inc., Santa Cruz, CA, USA) static 
incubation for 1 hr; and (ix) PBST rinse.  Optimization of the protocol showed that Triton 
X-100 permeabilization produces higher-quality fluorescent images (more visible 
staining) compared to acetone permeabilization.  All flows are ~1 µL/min, and the 
introduction of different solutions is alternated between assay/exit ports. 
Data analysis 
 To quantify morphological differences, cells are traced by polylines using image 
processing software (Image-Pro 6.1, Media Cybernetics Inc., Bethesda, MD, USA).  
Circularity and area of cells is calculated for each culture condition (30 randomly 
selected cells per condition, 10 from each of 3 trials).  Circularity, C, is defined as C = 
4πA/(P2), where A is cell area and P is cell perimeter.  A circularity of 1 corresponds to a 
perfectly circular shape. 
 For LIVE/DEAD assays, cells emitting on each fluorescent channel (green/red) 
are counted for each condition (6 trials per condition), and percentages live/dead are 
calculated. 
 All statistical analyses are performed by multi-variate ANOVA using Prism 
software (GraphPad Software Inc., La Jolla, CA, USA).  A Tukey’s posthoc test is 
performed. 
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Results and Discussion 
A microfluidic living cell array is introduced, comprised of 8 culture chambers 
that do not cross-communicate, are continuously perfused, and are designed to protect 
cells from undesired shear stresses.  This unique set of capabilities is demonstrated by 
culturing alveolar epithelial cells in pairwise combinations of matrix (Ln or Fn) and 
soluble (TGF-β1 +/-) signal conditions within the array and observing certain cellular 
responses.  Because TGF-β1 induces the expression of numerous soluble factors, 
including more TGF-β1,35,121 cross-contamination among chambers in the array must be 
prevented for proper experimental control.  Otherwise, cross-chamber contamination by 
soluble factors, including TGF-β1, would induce confounding phenotypes.  The features 
introduced herein make it possible for well-controlled interrogation with different 
signaling combinations in a versatile, scalable, and rectangular chamber array format. 
Device characterization 
 An array device loaded with colored dyes (water as carrier fluid) is shown in Fig. 
4-3.  Individual addressing offers the versatility to load different cells or adsorb different 
matrix molecules in each chamber (Fig. 4-3(b-c)).  Also, individual addressing allows the 
experimentalist to fine-tune the cell density in each chamber by momentarily re-opening 
and closing chamber isolation valves to sample different sets of cells as they flow into the 
device; this process is essential to achieve uniform cell densities across chambers for the 
experiments performed in this work.  Figure 4-3(d-f) shows how flow travels through the 
chamber.  Flow enters from a common delivery channel and is expelled into a common 
exit channel that does not feed into other chambers.  Careful inspection of Figs. 4-2 and 
4-3 reveals that a 3-dimensional flow network is vital to prevent cross-chamber 
contamination in an array that is continuously-perfused and has a rectangular 
configuration.  We use the strategies demonstrated in Fig. 4-3 to adsorb different matrix 
molecules by rows, perfuse TGF-β1-containing medium to specific columns, and attain 
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the desired cell densities during cell loading for the experiments summarized in the 
Methods section. 
 
Fig. 4-3  Flow characterization with colored dyes.  (a) Prototype device is a 2×4 chamber array.  Blue 
dye loaded in 3-D flow channel/chamber network; darker square features indicate through-hole locations.  
Purple dye in valve control channels.  (b-c) Chambers can be individually addressed with ECM, cells or 
assay solution.  Yellow dye displaces blue dye in 2 chambers.  (d-f)  Cross-chamber communication 
avoided by routing flow through each chamber from delivery channel to exit channel (curved arrows).  
Upper-right valve is opened and blue dye flows through chamber.  Images at 5, 10, and 20 sec after valve 
opens at experimental flow rate.  Flow into the protected area is markedly slower due to high-resistance 
conduits.  Scale bars:  (a-c) 1000 μm, (d-f) 500 μm. 
 
 Figure 4-4 shows results of the chamber flow field simulation.  Integration of 
velocities at selected boundaries shows that approximately 10% of the total flow through 
the chamber travels through the protected area (1-to-9, protected-to-total flow ratio).  The 
balance of flow travels through the diverted flow channels.  In addition, shear stresses are 
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calculated on the surface of the chamber at experimental flow rates.  Too much flow can 
result in high velocity and high shear, which may induce confounding cellular responses; 
on the other hand, not enough flow will reduce nutrient and gas exchange, which may 
also affect cells adversely.  Having the shielded chamber design allows sufficient 
convective mass transfer and yet avoids direct shear on the cells inside the chamber.  Fig. 
4-4 shows that shear stress on most of the chamber surface is less than 0.005 dyn cm-2.  
As well, in interstitial spaces, shear stresses are expected to be small (compared to other 
in vivo contexts113), although the fibrous 3-dimensional extracellular matrix makes 
precise estimates of shear stress difficult.122  Interstitial fluid velocities of less than 1 μm 
min-1 have been measured, which indicates very low flow (and correspondingly low 
shear).123 
 Because the array was designed as a prototype to demonstrate initial proof-of-
concept, the array is small (2×4) relative to other arrays reported in literature.  Scaling the 
array to larger sizes will require more control channels (and corresponding outlet ports) 
for the additional chambers.  A device of greater scale may increase the complexity of the 
device, as discussed in Chapter 3 (Discussion); however, academic92 and industrial93 




Fig. 4-4  Simulation of chamber flow field.  (a) Oblique view of model geometry with solution shown in 
slice plot.  Volumetric flow rate through diverted channel estimated as 90% of total flow (10% perfuses 
through protected area).  (b) Shear stress field at floor of the chamber, solved using experimental flow rate.  
Shear on diverted surfaces is over an order of magnitude greater than in protected area.  (c) Same solution 
as (b) with heat plot re-scaled to visualize shear stress in protected area; >85% of surface area less than 
0.005 dyn cm-2. 
 
ATII response to soluble-matrix signal combinations 
 The array is used to elicit responses of ATII cells when subjected to four different 
soluble-matrix signal combinations, particularly ones that have been demonstrated to lead 
to three different cellular responses; specifically,  maintenance of epithelial phenotype, 
cellular apoptosis, and epithelial-to-mesenchymal transition (EMT).  EMT is a process 
where fully differentiated epithelial cells undergo a transition to a mesenchymal 
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phenotype, resulting in fibroblast-like and myofibroblast-like characteristics.  EMT can 
be induced by a number of extracellular signals,35 individually or in combination, and 
EMT is known to play a role in development and tumor invasion.32,124,125  In addition, 
EMT is observed in response to epithelial stress or injury in a variety of tissues, where it 
is involved in repair and scar formation.126,127  EMT in the context of epithelial injury and 
fibrosis is not well understood, and recent literature is just beginning to address its 
underlying mechanisms.128  
 With respect to the cell line used in this work, EMT of ATII cells has been 
implicated in idiopathic pulmonary fibrosis (IPF).128  IPF is a condition characterized by 
excessive ECM deposition, resulting in interstitial scar tissue, loss of tissue compliance 
and ultimately decreased gas exchange across the alveolar epithelial barrier.  Under 
normal conditions, ATII cells perform multiple roles in the lung associated with proper 
homeostasis and repair; in response to injury to the alveoli, ATII cells proliferate and 
differentiate into ATI cells.  However, in fibrosis, ATII cells appear to undergo EMT, 
driving the cells toward a fibroblastic (mesenchymal) phenotype.  This increases the 
number of ECM-depositing mesenchymal cells in the interstitial space and further 
perpetuates the fibrotic condition. 
 Elevated levels of active TGF-β1 and deposition of a provisional matrix rich in Fn 
are prominent components of pulmonary fibrosis, whereas a matrix rich in Ln is typical 
of homeostatic physiological conditions.  Previous studies have demonstrated that ATII 
cells undergo markedly different behavioral responses to TGF-β1 depending on their 
underlying substrate.128  In the presence of TGF-β1, ATII cells adhering to Ln-rich 
matrices undergo apoptosis, whereas on Fn-rich matrices they exhibit EMT-like events.  
Given the different possible responses to combinations of matrix (Ln or Fn) and soluble 
(TGF-β1 +/-) signals by ATII cells, such signal combinations were chosen as models for 
the proof-of-concept trials in this work to demonstrate usage of the chamber array.  
Chambers were incubated with Fn or Ln and perfused with medium with and without 
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active TGF-β1.  All signal combinations were present in each array and repeated by 
subarray, and assays are performed to observe and measure responses.  It should be noted 
that experiments are solely intended to elicit different responses for each signal 
combination for purposes of demonstrating array operation, and assays performed are not 
meant to represent the full set of assays required to conclude that specific phenotypes, 
such as EMT, are observed. 
 Cell morphologies in response to each signal combination after 48 hrs in 
culture are shown in Fig. 4-5.  Cells cultured on Ln in the presence of TGF-β1 show 
either contracted morphology or elongated morphology.  Cells cultured on Fn in the 
presence of TGF-β1 show similar elongation, resembling a fibroblast-like phenotype.  
For cells cultured on Fn in the absence of TGF-β1, a similar fibroblast-like morphology 
results.  This is consistent with reports showing that Fn is capable of driving differing 
phenotypes for multiple cell types and inducing EMT in alveolar cells; however, it does 
not conclude a specific phenotype.128-131  Cells cultured on Ln in the absence of TGF-β1 
show a round, semi-cuboidal morphology and are arranged in an orderly monolayer, 
appearing to show an epithelial morphology on-chip, consistent with culture using 
conventional methods in cell culture flasks.  In the Ln with TGF-β1 condition, cells with 
contracted, round morphologies exist with highly-elongated cells (fibroblast-like), 
causing the relatively wide variation in circularities for that condition.  The differences in 
the means of observed circularities among the four signal combinations (pairwise 
comparisons) achieve varying levels of statistical significance, as shown in Fig. 4-5(e).    
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Fig. 4-5  Phase contrast images (representative) of ATII cells after 2 d culture.  Matrix and soluble 
factor signaling combinations of (a) Ln, (b) Ln + TGF-β1, (c) Fn, (d) Fn + TGF-β1.  Monolayer with 
extensive cell-cell contacts suggests epithelial phenotype in Ln condition.  Lower relative density suggests 
decreased proliferation and/or apoptotic events for Ln + TGF-β1 condition.  (e) Box plot of cell circularity 
for each signal combination.  Calculated from traces of 30 randomly selected cells (3 trials, 10 per trial) for 
each signal combination.  Boxes span 25th to 75th quartiles (median line inside) with lower and upper 




Fig. 4-6  LIVE/DEAD fluorescent staining of ATII cells after 2 d culture.  Representative fluorescence 
images (green/red composite overlays) showing entire chamber for each matrix and soluble factor signaling 
combination:  (a) Ln, (b) Ln + TGF-β1, (c) Fn, (d) Fn + TGF-β1.  (e) Percentage of live (green) cells for 
each condition (6 trials each); error bars show SD.  Significant p-values in brackets.  Scale bar 100 µm. 
 
 To quantify cell viability for each combination of soluble and matrix cues, cells 
are stained with LIVE/DEAD fluorescent probes (Fig. 4-6).  Without TGF-β1, cells are 
predominantly viable.  For conditions perfusing TGF-β1, larger fractions of cells are 
stained with the “dead” stain (red stain, Fig. 4-6(b) and 4-6(d)).  The greatest “dead” 
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staining is measured for cells on Ln in the presence of TGF-β1; if the stain is correctly 
indicating cell that are dying, it would be consistent with a previously mentioned 
report.128  However, to definitively ascertain whether cells are dying, a number of other 
assays must be performed (see Limitations subsection). 
 
 
Fig. 4-7  Cytoskeletal staining of ATII cells after 2 d culture.  False color fluorescent images of F-actin 
stained with Texas Red-phalloidin for each matrix and soluble signaling combination:  (a) Ln, (b) Ln + 
TGF-β1, (c) Fn, and (d) Fn + TGF-β1.  Possible stress fiber formation prominent in Fn conditions (with and 
without TGF-β1).  Scale bar 50 µm. 
 
 To further characterize the morphological differences observed for each signal 
combination, cytoskeletal organization and stress fiber formation is visualized in cells by 
staining F-actin with Texas Red phalloidin (Fig. 4-7).  Stress fiber formation is a direct 
indicator of cell contractility and indirect indicator of mesenchymal-like phenotypes.  
There appear to be qualitative differences among some conditions.  Lines of staining are 
observed in the two combinations with Fn (with and without TGF-β1) (Fig. 4-7(c-d)).  In 
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contrast, diffuse and spotty staining is observed in cells on Ln (no TGF-β1) (Fig. 4-7(a)); 
no lines of staining are evident. 
 Cells are also stained for the presence of epithelial cell-cell junctions.  Junctions 
are marked by cell-cell adhesion proteins (e.g. E-cadherin) concentrated at cell edges.  To 
visualize E-cadherin, cells are immunofluorescently-labeled and imaged at each condition 
(Fig. 4-8).  Labeling of E-cadherin in the three combinations with Fn and/or TGF-β1 
(Fig. 4-8(b-d)) appears to show nuclear localization and diffuse staining throughout the 
cells.  ATII cells with epithelial characteristics would not show such staining, but instead 
they would show strong localization of staining at cell-cell junctions.132,133  The Ln (no 
TGF-β1) (Fig. 4-8(a)) condition typically shows slightly less staining throughout the cell 
and occasional localization of E-cadherin at cell-cell contacts and cell edges, suggesting a 
qualitative difference between the Ln only condition and other three conditions. 
 
Fig. 4-8  Cell-cell junction formation of ATII cells after 2 d culture.  False color images of 
immunofluorescently-labeled E-cadherin.  Arrows in (a) indicate localization of E-cadherin at cell-cell 
contacts and cell edges.  Scale same as in Fig. 4-7. 
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Limitations of Data and Confirming Phenotypes 
 Taken together, the data suggest differences among the four conditions as 
measured by circularity and LIVE/DEAD staining, as well as qualitative differences in 
cytoskeletal staining and E-cadhering staining.  However, the data are not adequate to 
conclude that particular phenotypes are observed.  For example, although cells 
undergoing apoptosis may exhibit greater membrane permeability, which LIVE/DEAD 
staining is intended to indicate, apoptosis must be confirmed through assays that 
complement the cell permeability test.  Such additional assays include caspase activation 
assays, DNA fragmentation assays, and annexin V staining.  Similarly, morphological 
readouts (circularity/elongation) and F-actin staining are not adequate to conclude 
whether one observes a mesenchymal phenotype; assays to detect expression of a variety 
of mesenchymal markers, such as α-smooth muscle actin, fibronectin, N-cadherin, and 
vimentin, must be performed.  Furthermore, morphological readouts and the staining of 
E-cadherin are not adequate to confirm the existence of an epithelial phenotype.  The 
expression of other surface marker or internal markers is required, such as epithelial cell 
adhesion molecule (EpCAM) and various cytokeratins. 
 Additional assays required to confirm specific phenotypes (or phenotype 
transitions like EMT) could be facilitated by an array with more chambers.  Because the 
chamber array in this work is efficiently scaled and can address specific chambers 
(individually, by rows, by columns or by subarray), additional assays and required 
replicates could be performed in a single, scaled-out array. 
 Regarding the quality of assays performed, the F-actin and E-cadherin staining 
could be improved.  Visualization of both stains could be improved by using a camera 
with higher resolution and lower background noise.  For F-actin, a brighter, higher-
affinity stain could be utilized, such as an Alexa Fluor®-based stain.  Both stains could 
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be improved by further optimization of the protocol.  For E-cadherin, the 
permeabilization agent and incubation time, as well as the times for primary and 
secondary incubation, most likely require further refinement.  It should be noted that 
optimized protocols from a well plate or flask may not be applied with the same success 
in microfluidic chambers.  The difference in size scale (chamber volumes are 37.5 nL) 
could affect incubation times due to changes in stain/antibody depletion and transport.     
Chapter Summary 
 In this work, a prototype microfluidic chamber array is designed to combine three 
attributes:  (i) continuous perfusion of media through chambers, (ii) a channel and 
chamber network that forbids cross-chamber communication/contamination, and (iii) low 
shear stresses on cells in the chambers.  The array can also be scaled in both the x- and y-
directions and provides considerable versatility regarding individual chamber, row, 
column, and subarray addressing.  The combination of three attributes, scalability, and 
versatility is novel to microfluidic chamber arrays.  The technology that enables such 
characteristics is a 3-D flow network (vertical layer-to-layer interconnectivity) that is 
constructed using the fabrication method developed in Chapter 3.   
 Experiments are performed whereby ATII cells are cultured in four different 
soluble-matrix signaling combinations to demonstrate the operation and application of the 
prototype array.  Quantitative differences in responses to signal combinations are 
observed via morphological readouts (circularity) and LIVE/DEAD staining, while 
qualitative differences are visualized via F-actin and E-cadherin staining.  In addition, 
limitations of the data in confirming phenotypes are discussed. 
 This work tests the array as a unique platform to culture cells under combinations 
of signals, and experiments suggest that the array can provide days-long culture (2-4 
days) conditions and elicit cellular responses comparable to conventional culture and 
imaging.  Furthermore, the array allows for replicates and controls to be perform on the 
 75
same chip at the same time.  The array architecture is particularly well-suited to present 
soluble-matrix signal combinations in order to ascertain differences in cellular response.  
Moreover, the device can be extended to other cell types and transitional phenomena. 
Further Work 
 Currently, the size of the array is small (8 chambers).  Further scaling of the array 
would not require more alignment steps; however, more flow ports and valve control 
channels will be required (see Discussion on scaling in Chapter 3).  To achieve the high 
versatility demonstrated in the prototype device, every 4 new chambers would require 5 
more valve control channels and 2 additional flow ports.  No additional exit ports or 
cell/ECM loading ports would be required, so long as scaling occurs in the x-direction.  
For scaling in the y-direction, every new row of chambers would require 2 additional 
cell/ECM loading ports.  The number of valve control ports could be reduced, depending 
on the level of specificity required in chamber addressing (individual, row, column or 
subarray).    
 A potential challeng of scaling is that alignment of PDMS may become more 
difficult, since it is elastomeric and stretchable.  Thus, small stresses could introduce 
large strains across die that are relatively large.  In this work, the 8 chamber array is 
contained in a PDMS footprint of 24 × 24 mm (roughly an inch squared).  At that 
footprint, stretching did not appear to significantly affect alignment; nonetheless, 
alignment rework due to stretching (slight observed warpage) does occur occasionally.  It 
is conceivable that another 2 rows of chambers could be added to the same footprint 
(making a 16 chamber array).  Further scaling must take into consideration alignment 
tolerances and constraints.  Scaling is not inconceivable, as multilayer (non-3-D flow) 
PDMS microfluidic devices are being made commercially,93 which may speed the 
invention novel “world-to-chip” interconnect technology to ease the scaling process.  
However, as scaling proceeds, new (and unexpected) challenges may emerge. 
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 Also, the array must be further tested with a variety of cell lines and signal 
conditions for which responses are already known from conventional culture systems.  
This work only tested one cell line and four signaling conditions as a proof-of-concept for 
device operation.  More testing and comparison of the responses will uncover previously 
unknown characteristics and limitations of either this microfluidic or conventional culture 
methods.   
 Provided the device is scaled to higher-throughput levels and validated against a 
larger set of signal conditions and cell lines, massively parallel interrogation of soluble-
matrix signaling could be performed to uncover new mechanisms by which cell fates and 
phenotypes are determined in embryonic development, cancer, fibrosis, tissue repair, and 
other soluble-matrix contexts. 
        Table 4-1  Chapter summary. 
 
        * Note:  Design, fabrication, and testing are published work.95 
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CHAPTER 5 
MODULATING SOLUBLE GRADIENTS USING SEQUENTIALLY 
PULSED DELIVERY IN A MICROFLUIDIC CHAMBER ARRAY 
 
 A novel microfluidic chamber array is introduced that generates gradients 
intended for chemotaxis studies.  The two core technologies upon which it is developed 
are sequentially pulsed delivery and a 3-D flow channel architecture.  The two 
technologies combined enable the production of soluble concentration gradients with a 
unique and useful set of characteristics.  Furthermore, the device can be efficiently scaled 
to encompass larger chamber arrays and is fabricated from a single material with a single 
alignment step.  The gradients are characterized by fluorescence measurements, and the 
device is tested as a chemotaxis assay by applying a serum gradient over human breast 
cancer cells and measuring migrational and morphological responses. 
Motivation:  Gradients and Gradient-Generating Devices 
 The directed migration of cells, or chemotaxis, is a critical component of many 
processes in normal physiology and in disease.  Such processes include embryonic 
development,134-137 tissue repair,138-140 immune surveillance,141-143 and cancer 
metastasis.144-146  Chemotaxis is guided by concentration gradients of extracellular 
chemical stimuli, where motile cells travel toward or away from higher concentrations of 
a chemotactic stimulus (chemoattractant or chemorepellant, respectively).  For eukaryotic 
cells, chemotactic gradients are sensed both spatially and temporally through signaling 
networks that internally amplify the external gradient information.147  These signaling 
networks orchestrate cytoskeletal organization, formation of pseudopodia, and 
morphological polarization in a manner that biases the movement of cells in the direction 
of the gradient.147-151  Because chemotaxis is a highly complex and integrative 
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biomolecular-biophysical phenomenon, many of its features and mechanisms remain 
poorly understood, despite a tremendous expansion of knowledge in cell migration over 
the past two decades.  Consequently, chemotaxis continues to be an actively-studied 
field, the results of which could ultimately lead to novel and more effective approaches to 
treat numerous diseases and medical conditions.152 
 To study chemotaxis in vitro, a variety of assays have been developed.  Each type 
of assay utilizes tools and methods that embody a unique approach for establishing the 
assay conditions (i.e. gradient and cellular microenvironment), as well as observing, 
measuring, and characterizing cellular response.  Traditional chemotaxis assays include 
the Boyden chamber (transwell assay),153 Zigmond chamber,154 and Dunn chamber.66  
Also of note are the under-agarose assay155,156 and micropipette-based assays,157-159 which 
permit greater control over gradient positioning and presentation of multi-directional 
combinatorial gradients.  These systems have greatly contributed to our understanding of 
chemotaxis, and their usage continues to be popular today due to ease-of-use, scientific 
acceptance, and commercial availability.160-163 
 However, the capabilities of traditional assays are inherently limited in some key 
respects, one of which is gradient instability.  The gradients of transwell, Dunn, Zigmond, 
and under-agarose assays are unable to stabilize because their sources and sinks force 
toward equilibrium, causing the concentration profile to continually evolve (rising and 
decaying) over time.  As a result, assay times are restricted to a few hours,161,163 and 
correlating cellular responses to specific gradient conditions is largely unfeasible.  
Traditional assays are also vulnerable to gradient instability arising from physical 
perturbations (e.g. mechanical, evaporative, and thermal), which can easily distort or 
destroy the desired concentration profile.  In addition to gradient instability, the 
geometrical configuration and optical properties of popular assays (transwell and under-
agarose) obstruct high-resolution, quantifiable imaging of single cells, limiting such 
assays to end-point or population-based analyses. 
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 The emergence of microfluidic systems has led to considerable progress in 
chemotaxis assays.  Because their fluid flows are laminar, microfluidic systems can 
generate predictable and stable concentration gradients, which can surmount the 
limitations of traditional assays or enable entirely new lines of study.101,164  Furthermore, 
microfluidic systems have demonstrated the potential for massive parallelization and 
greatly reduced sample usage, leading to higher throughput and lower cost 
experimentation.92,165-167  Microfluidic chemotaxis assays and gradient-generating devices 
take a variety of forms and approaches, and many of these are highlighted in 
reviews.161,163,168,169   
Flow-Based and Free-Diffusion-Based Microfluidic Gradient Devices 
 Flow-based and free-diffusion-based systems are the two major categories of 
microfluidic chemotaxis assays,168 and their characteristics play a crucial role in the 
formulation of this work’s design objectives.  Therefore, the driving mechanism, benefits, 
and limitations of both categories are described to provide a framework for our design 
rationale. 
 Flow-based systems rely upon diffusion among multiple parallel flow streams to 
produce gradients.  The flow streams are loaded with media containing different signal 
concentrations, which is typically achieved by the use of an upstream mixing network 
that splits and recombines the flow streams over multiple generations.  When the streams 
meet in a chamber, lateral diffusion between the streams produces a signal gradient 
perpendicular to the direction of flow.  The flow-based concept is an elegant and seminal 
invention in microfluidic chemotaxis assays,170 distinguished by the superb stability and 
predictability of its gradients.  Hence, flow-based systems have been used to study 
cellular response to signal gradients in a broad range of contexts.103,171-174 
 Flow-based systems face a number of limitations, depending on study 
requirements.  First, cells may exhibit undesired responses to shear stresses caused by the 
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flow streams that pass directly over them.  Second, diffusion between flow streams 
causes the slope of the gradient to decrease with each downstream location in the 
chamber.  This limits the number of replicate conditions/locations available per device 
(subject to flow rate and slope tolerance).  Furthermore, it is difficult to create dense 
arrays of chambers with identical gradients in flow-based systems.  The difficulty arises 
from the spatially changing gradient, which limits downstream arraying of chambers, as 
well as the upstream mixing network, which requires considerable on-chip space and can 
only feed into a single chamber at a time.  Consequently, flow-based systems are not 
amenable to the construction of in-line or 2-dimensional chamber arrays that are desirable 
for high-throughput screening applications. 
 In contrast, free-diffusion-based designs produce a signal gradient by way of 
diffusion from a source to a sink across a central chamber, where cells are monitored.  
The source and sink are either flow channels (loaded with high and low signal 
concentrations, respectively) or passive reservoirs.  The defining features of a free-
diffusion-based system are porous barriers with high fluidic resistance, which partition 
the chamber from the source/sink.  The barriers shield the chamber from convection; 
therefore, mass transport becomes diffusion-dominated, and at steady-state, a gradient is 
established.  Free-diffusion-based systems have been developed using barriers that take a 
variety of forms, including microcapillary channels (or gaps),175-177 membranes,178-182 and 
hydrogels.183 
 Free-diffusion-based systems combine the benefits of a low shear 
microenvironment and a stable gradient.  However, such systems can be limiting in two 
respects.  First, the high fluidic resistance of the barriers can restrict the range of 
concentrations the gradient can span.  Ranges that span roughly 0.35 to 0.70 normalized 
concentration (minimum to maximum) have been reported for microcapillary-based177 
and hydrogel-based183 systems, while the balance of concentrations occurs within the 
barriers.  Second, free-diffusion-based systems are often hybrid designs composed of 
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dissimilar components that are required to construct the porous barriers.  Such hybrid 
systems could frustrate attempts to achieve cost-effective, high-volume manufacturing 
that is often necessary for successful commercialization.  The needs of some chemotaxis 
experiments require low shear and the full range of concentrations in the gradient; hence, 
a new design is necessary. 
Device Design 
A prototype microfluidic device is designed with an in-line array of 6 chambers to 
study the migrational response of cells to soluble signal gradients.  Figure 5-1(a) is a 
schematic of 3 chambers in the array, as well as their supporting channel network and 
integrated valves.  The objective is to produce gradients that are fully stable and provide 
exceptionally broad spatial and temporal controllability to experimentalists.  An 
additional and equally important objective is to present the gradients in a chamber array 
that can be efficiently scaled to larger in-line or 2-dimensional arrays while minimizing 
fabrication complexity (Table 5-1).   
 





identical gradients across chambersarray – parallelization 
and throughput
adjustable curvature (linear to concave)
capable of low basal concentrations







 To achieve the objectives, the design makes use of a 3-dimensional channel 
architecture that implements sequentially pulsed delivery.  Sequentially pulsed delivery 
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represents an approach to generating gradients that is markedly different from the 
approaches of flow-based and free-diffusion-based systems.   
Sequentially Pulsed Delivery Concept 
 The concept of sequentially pulsed delivery is depicted in Fig. 5-1.  Two input 
flows with different signal concentrations are positioned on each side of the chambers.  
Four stages of a flow pulsing sequence are shown, illustrating how the flows alternate on 
each side.  Flows are stopped at the specified times by integrated monolithic valves.83  
The valves actuate and de-actuate in manner such that the flows never occur at the same 
time; when flow occurs on one side of the chambers, the other side is completely 
fluidically isolated with a closed valve.  Hence, the trajectory of each flow pulse is 
confined to the channel on its respective side and does not penetrate into the chambers.  
This protects the chambers from cross-convection that would arise from asymmetries in 
pressure or fluidic resistance. 
 The purpose of alternating flows is to periodically replenish each side with its 
input concentration (Fig. 5-1(c)).  Replenishments are frequent enough so that the 
concentration on each side is effectively constant, which in turn provides a steady driving 
force for diffusion across the chamber.  Thus, a stable gradient forms. 
Low Shear Microenvironment 
 The absence of cross-convection through the chambers is not only intended to aid 
in establishing a stable gradient, but also meant to create a microenvironment that is 
effectively shear-free (see Fig. 5-4).  The objective is to better resemble physiological 
conditions for cells in interstitial spaces, stem cells, neurons, and other cell types that do 
not experience significant fluid flows.  For these cell types, shear-induced responses 





Fig. 5-1  Concept of sequentially pulsed delivery along three chambers in the array.  (a) Chambers 
(blue), flow channels (blue), and valves (pink) form a 3-dimensional network.  Media (with or without 
chemotactic stimulus) are input along sides, while cells are loaded via central channels.  Flow travels along 
the sides of the chambers and vertically between layers via through-holes (curved arrows).  Integrated 
valves, exclusive to the bottom layer, regulate flow in the top layer channels.  (b) Four phases of the pulsed 
flow sequence.  Sequence begins with all valves closed, then left side valves open to release flow pulse 
with high concentration (dark blue).  All valves close again; then right side valves open release a flow pulse 
with low concentration (dark yellow).  The sequence repeats throughout the experiment.  (c) Flow pulses 
replenish each side with their respective input concentrations, establishing effectively constant boundary 
conditions.  A gradient forms via diffusion-dominated mass transport. 
 
Temporal and Spatial Control of Gradients 
The objective of providing broad temporal and spatial control over gradients is 
addressed by three specific features.  First, gradients can be turned on and off, which 
makes it possible to perform within-trial controls and enables studies of cellular 
adaptation and response to rising and dissipating gradients.147  Gradients are turned on 
and off by flow selection routers that use integrated, on-chip valves to select which input 
flows are directed into the device (Fig. 5-2(b)). 
Second, gradients are able to approach basal concentrations of zero.  This is 
meant to address the limitation of restricted concentration ranges in free-diffusion-based 
designs, where minimum and maximum scaled concentrations in the chamber can be 
substantially greater than zero and lesser than 1, respectively, when measured in 
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normalized concentration (assuming zero for sink and 1 for source) at steady-state.  
Sequentially pulsed delivery is designed to enable studies to simulate physiologically 
relevant conditions using gradients that straddle low basal concentrations, while at the 
same time presenting a low shear microenvironment.  Such conditions could test cellular 
response to an advancing front of diffusing signals from a distant point source (shallow 
gradient near zero) or a nearby point source (steep gradient near zero).185,186  Gradients 
with low basal concentrations are possible because sequentially pulsed delivery 
eliminates the need for a porous barrier to shield the chamber from convection. 
 Third, the design makes it possible to adjust the curvature of the presented 
concentration profile.  Although cells have shown migrational response to profiles of 
various shapes, eukaryotic cells have shown the greatest response to concave profiles 
with polynomial or exponential fits.174,187  It is hypothesized that by modulating the valve 
actuation times in the pulsing sequence, the curvature of the profile can be adjusted from 
linear to concave.  Valve actuation times are easily adjusted in a custom-written cycling 
program to test the hypothesis. 
Chambers, Array, and Fabrication Approach 
There are three important design objectives that relate to parallelization, 
scalability, and the fabrication approach of the device.  First, all chambers in the array are 
intended to present identical gradient profiles, which enable replicate conditions and the 
potential for large-scale parallelization.  Chambers with identical gradients are designed 
to address the aforementioned limitation of spatially changing gradients in flow-based 
designs, and they come as a result of the sequentially pulsed flows approach and a 3-
dimensional channel architecture that delivers similar flow conditions to each chamber. 
 Second, the chamber array is designed to be conveniently scaled-out to larger in-
line or 2-D arrays.  Efficient scalability is facilitated by the 3-D flows architecture, which 
resembles roadway bridges and underpasses (bridge-and-underpass architecture) 
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(described in Chapter 3).  The architecture enables flow streams to navigate over (or 
under) other streams by traveling vertically between layers, making it possible to 
construct intricate delivery networks that can weave around various obstacles (i.e. valves, 
chambers, other channels) to feed the proper flows to rows and columns of chambers.  
Scalability is designed into the device in anticipation of future design iterations that 
would offer greater experimental throughput. 
 Finally, the device is designed to be made of a single bulk material 
(poly(dimethylsiloxane) (PDMS)) and fabricated by way of a single alignment step.  The 
objective is to minimize fabrication complexity in order to increase the likelihood of 
successfully realizing future versions of the device with massively scaled-out chamber 
arrays.  In particular, we aim to avoid the use of hybrid structures (e.g. separate 
membrane or hydrogel components in PDMS), which is characteristic of many free-
diffusion-based systems.  Use of components made of different materials has led to multi-
layer designs, requiring multiple stacking or alignment steps that interface hard and soft 
materials during fabrication.178,179,181-183,188  Instead, this work employs a modified 
compression-molding technique and an all-PDMS thermal bonding process, requiring one 
alignment step (see Methods below, as well as full description in Chapter 3). 
Methods 
Fabrication 
 Devices are fabricated using soft lithography,89 multi-layer PDMS thermal 
bonding,83 and through-hole processing.  Fabrication requires two master molds (masters 
A and B).  Each master is a silicon wafer (100 mm diameter) with a photoresist pattern 





Fig. 5-2  Fully fabricated device loaded with colored dyes for visualization of chamber array and 3-D 
channel network.  Blue dye is loaded in flow channels; red dye is loaded in valve control channels.  (a) 
Overview of the device.  Flow of inputs is selected by routers – one pair of inputs (inner or outer pair) is 
directed into the chamber network, while the other is diverted.  Pulse control and bypass valves work 
synchronously to pass flow along chamber sides or to effluent (preventing over-pressurization).  Pulse 
control comprises 7 interconnected valves on each side of chamber array.  (b) Magnified view of the right 
flow router, indicating which valves direct inputs into chamber network.  (c) Magnified view of chambers.  
Chamber isolation valves are permanently closed after cell loading.  Scale bar is 1000 μm in (a) and 500 
μm in (b) and (c). 
 
 Master A contains a two-layer pattern of SU-8 (MicroChem Corp., Newton, MA, 
USA), a negative-type photoresist.  The first layer is 50 μm tall, and its features define 
the bottom device layer, containing chambers and parts of the channel network (flow and 
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valve).  The second layer, which is patterned on the first layer, is 30 µm tall with features 
defining the middle device layer (i.e. through-holes).  Master B contains patterns made of 
AZ P4620 (AZ Electronic Materials Corp., Branchburg, NJ, USA), a positive-type 
photoresist, that define flow and valve channels (25 μm tall).  These channels have a 
semi-circular cross-section, allowing them to be fully closed by push-up valves located 
throughout the device. 
 Devices are made by aligning and thermally bonding two molded layers of PDMS 
(Sylgard 184, Dow Corning Corp., Midland, MI, USA) derived from masters A and B.  
Through-holes are realized by the modified compression-molding process described in 
Chapter 3. 
Numerical Simulations 
Flow Field and Shear Stresses 
When flows are sequentially delivered, valves actuate and de-actuate in a manner 
such that flows on either side of the chambers cannot occur at the same time, i.e. when 
pulse control valves open to allow flow on one side, valves on the other side are closed.  
Thus, the chambers are protected from cross-convection, and shear stresses on cells 
attached to the surface of the chambers should be insignificant.  To simulate this 
rationale, a 3-dimensional finite element model of the chamber is constructed using the 
COMSOL software package (Multiphysics 3.5a, COMSOL AB, Stockholm, Sweden). 
 The model geometry consists of a single chamber, along with side flow channels 
and connecting through-holes for layer-to-layer flow.  The geometry is discretized into 
approximately 80,000 elements to ensure sufficient resolution to accurately model the 
curvature of parabolic flow profiles and minimize interpolation in solution plots.  The 
portion of the sequence when flow is allowed along one side of the chamber is simulated 
by specifying all boundary conditions as no-slip, except for inlet and outlet boundaries at 
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the beginning and end of the flow path on a chosen side.  Flow is driven by imposing a 
pressure drop between the inlet and outlet (positive pressure at inlet boundary and zero 
pressure at outlet boundary).  The Navier-Stokes equations are solved to obtain the 
velocity field at steady-state, which is used to calculate shear stresses on the chamber’s 
surface (Fig. 5-4). 
Diffusion-Only Gradient Formation for Comparison with Experimental Data 
A one-dimensional finite element model of the chamber is constructed using the 
COMSOL software package to simulate the formation of a concentration gradient by 
diffusion only.  The boundary conditions are alternated between insulation and 
concentration to mimic a pulsing schedule where pulses are of equal duration (15 s each).  
The model geometry consists of a line, with each end corresponding to the side flow 
through-holes.  A transient model is simulated following the equal pulse flow sequence.  
From time is 0 to 15 seconds, the left side boundary condition is set as concentration 
(arbitrarily set to 1) and right side boundary is insulated.  Both boundaries are set as 
insulated from time 15 to 90 seconds.  Right side boundary is changed to zero 
concentration (0) from time is 90 to 105 seconds, while left side remains insulated.  Both 
boundaries are set as insulated again from time 105 to 180 seconds, which completes a 
single cycle.  Diffusion equations are solved to obtain the concentration profile along the 
line over time.  The 180-second cycle is repeated until steady-state profiles are achieved.  
Each time a boundary condition is changed, the resulting solution is stored and used as 
the initial condition for the following calculation/simulation.  The diffusion coefficient 
used in the model is reported for 70 kDa dextran in PBS.189  
Gradient Characterization Using a Fluorescent Marker 
 Soluble concentration gradients in the chambers are verified by way of 
fluorescence measurements.  Dextran (70,000 MW) labeled with Oregon Green (D-7172, 
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Molecular Probes Inc., Eugene, OR, USA) is dissolved in aqueous buffer and pulsed 
along one side of the chambers.  A sequence of fluorescent images (GFP filter set) is 
acquired to record the formation of the dextran gradient and the time to steady-state.  
Sequences are acquired at different flow rates and flow pulsing schedules to determine 
the effect of those parameters on the gradient (Fig. 5-5). 
Cell Culture Off-Device 
 MDA-MB-231 cells (HTB-26, ATCC, Manassas, VA, USA), a human mammary 
adenocarcinoma cell line, are maintained in Leibovitz's L-15 medium (Gibco 11415, 
Invitrogen, Carlsbad, CA, USA) with 10% fetal bovine serum and 1% 
penicillin/streptomyocin.  Cells are incubated at 37 °C in humidified air, and medium is 
changed every 48-72 hours.  Cells are passaged with trypsin-EDTA solution (0.25% w/v 
trypsin and 0.53 mM EDTA, Gibco 25200, Invitrogen, Carlsbad, CA, USA), and the 
morphology and proliferation rate of cells is monitored over passages to verify consistent 
behaviour. 
 Prior to each trial, cells are serum-deprived by changing medium to L-15 with 
0.1% w/v bovine serum albumin (BSA) (A9418, Sigma, St. Louis, MO, USA) (hereafter 
referred to as base medium) for 12 hours.  Then cells are detached from their culture flask 
using EDTA solution (Versene, Gibco 15040, Invitrogen, Carlsbad, CA, USA).  Once the 
cells are detached, excess base medium is added, and the suspension is centrifuged.  The 
supernatant is aspirated, and the cells are resuspended in base medium to a density of ~1 
× 106 cells/mL and loaded into the device. 
Experimental Setup 
 Device preparation, cell loading, and image acquisition are performed on a DM 
IRB/E inverted microscope (Leica Microsystems GmbH, Wetzlar, Germany) at 10× 
magnification in phase contrast mode (Fig. B-1, Appendix B).  The device is mounted to 
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a motorized x-y stage (Ludl Electronic Products Ltd., Hawthorne, NY, USA) to translate 
it through a 6-position circuit to image each chamber in the array.  Hollow stainless steel 
pins (L-shaped, 21G) are press-fitted into device ports and are connected to flexible 
plastic tubing (PE-60) for fluid and pressure delivery.  Flow is driven by syringe pump 
(PHD 2000, Harvard Apparatus, Holliston, MA, USA).  Pressurization of on-chip valves 
is regulated by off-chip miniature solenoid valves (Series 188, ASCO Valve Inc., 
Florham Park, NJ, USA) attached to a pressure source at 30 psig.  Images are acquired 
using a digital CCD camera (ORCA C4742-95-12, Hamamatsu Photonics K.K., 
Hamamatsu City, Japan).  Valve actuation, stage movement, and image acquisition are 
computer-controlled using a custom-designed interface written in the LabVIEW 
programming environment (National Instruments Corp., Austin, TX, USA). 
Device Preparation, Cell Loading, and Incubation In-Device 
 Each device is pre-filled with phosphate buffered saline (PBS).  To prevent on-
chip valves from introducing gas bubbles into the device during experiments, each valve 
is filled with water.  Fibronectin (Fn) (Gibco 33016, Invitrogen, Carlsbad, CA, USA) at 
concentration 8 μg/mL (in PBS) is introduced through the cell loading port.  The chamber 
array is filled with Fn solution, and it is incubated at 37 °C for 1 hr to allow matrix 
molecules to adsorb to chamber surfaces.  Following adsorption, the device is filled with 
BSA solution (2% w/v in PBS) and incubated at room temperature for 45 min to block 
surfaces from non-specific binding.  Base medium (L-15 with 0.1% w/v BSA) is then 
introduced to the input ports and flushed through the device. 
 Cell suspension is then introduced into the cell loading channel and flowed 
through the chamber array by gentle pressure.  Cells are stopped and confined to their 
chambers by closing the cell loading and pulse control valves.  If the density or 
distribution of cells is unsatisfactory, the valves can be momentarily re-opened and 
closed to sample another set of cells. 
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 The device is transferred from the microscope to an air incubator at 37 °C.  Cells 
are incubated in the device for 12 hours to allow full attachment and spreading on the 
substratum prior to image acquisition. 
Experiment and Image Acquisition 
 After incubation, the device is re-mounted to the microscope stage, and 
experimental media are introduced to the input ports.  The medium entering the ports is 
either base medium or base medium loaded with FBS (16000, Invitrogen, Carlsbad, CA, 
USA), which is intended to be a chemotactic stimulus.  The device is covered by an 
optically transparent enclosure (made of PDMS) into which is fed humidified air to 
prevent gas bubble nucleation in the device.  A heating fan maintains the system at 37 °C. 
 Each experiment is made up of two stages.  The first stage acts as a within-
experiment control wherein the flow pulsing sequence is engaged but there is no FBS.  
Images of each chamber are acquired in 3 min intervals for 6 hrs.  The second stage 
begins immediately after, wherein the flow pulsing sequence continues and a gradient of 
FBS is presented to the cells.  The gradient is turned on by changing the selected input 
flows at the flow routers.  Images are also acquired in 3 min intervals for 6 or more hrs, 
depending on experiment.  Images for each chamber are then compiled into a sequence 
for image processing. 
Image Processing and Cell Tracking 
Cells are segmented in each image from their respective backgrounds for 
morphological and tracking analysis.  We apply a heuristic involving image registration, 
image division, flattening, and cell segmentation through the use of MATLAB (The 
MathWorks Inc., Natick, MA, USA) and Image-Pro 6.1 (Media Cybernetics Inc., 
Bethesda, MD, USA) algorithms.  Fig. 5-3 illustrates the process for a typical image.  The 
image is registered to a background photo (cells absent) and divided by the background to 
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obtain a normalized image.  The resulting image is processed through a flattening 
algorithm to reduce illumination irregularities present throughout the sequence and within 
individual frames (Fig. 5-3(c)).  Programming code for segmentation algorithm is found 
in Appendix I. 
 To segment cells, we take advantage of the characteristics of phase contrast 
microscopy, where cell pixels follow a bimodal intensity distribution.  Protrusions (cell 
membrane extensions) have lower intensities than the median, and therefore are 
segmented by selecting pixels below a predefined intensity threshold (protrusion 
threshold).  The contours of cell bodies (cell bulk containing the nucleus) have higher 
intensities than the median, and therefore are segmented by selecting pixels above a 
separate predefined intensity threshold (body threshold).  Segmented protrusions and cell 
bodies are found in Fig. 5-3(d-e), respectively.  Extraneous debris is identified using an 
area filter and removed.  Fig. 5-3(d) shows the resulting protrusions after morphological 
dilation using an isotropic structuring element to minimize cell fragmentation.  The same 
morphological techniques are applied to the cell bodies in Fig. 5-3(e).  The protrusion and 
body images (Fig. 5-3(d-e)) are superimposed, and the result (Fig. 5-3(f)) is dilated to 
further minimize fragmentation and then flood-filled to close gaps.  Morphological 
erosion is applied to shrink the dilated segments, followed by an additional debris filter 
(Fig. 5-3(f)).  The resulting image is overlaid on the flattened image to verify 




Fig. 5-3  Cell segmentation.  (a) Representative phase contrast image, prior to cell segmentation, with 
applicable region of interest (ROI) (white border).  (b-i) Magnified insets for clarity.  (b) Original phase 
contrast image.  (c) Background divided and flattened image.  (d) Segmented protrusions, followed by 
dilation.  (e) Segmented cell body contours, followed by dilation.  (f) Superimposition of (d) and (e), 
followed by dilation and flood-fill operations.  (g)  Completed segmentations as a result of debris filter and 
erosion operations.  (h) Segmented objects overlaid on flattened image from (c); under-detection denoted 
by arrow.  (i) Hand-correction of under-detection.  (j) Full image of segmented well.  Scale:  ROI rectangle 
is 1000 μm in x-direction. 
 
 After segmentation, cells are selected for analysis, hand-corrected, and tracked.  
Hand correction is applied to under-detected cells by manual placement of 4-10 sided 
polygons (Fig. 5-3(h)).  Corrections apply to undetected protrusions and gaps in 
segmentation, and they are required for approximately 10-20% of all segmentations.  The 
sequence is then tracked using the semi-automatic tracking algorithm in Image-Pro.  The 
algorithm calculates trajectories for cell centroids as well as numerous morphological 
readouts.  Data are then compiled for statistical analysis.  Cells that make contact with 
other cells (or walls), divide, undergo apoptosis, or fail to attach are excluded from 
analysis (roughly 20-40% of cells in each well). 
Data Analysis 
 Data are derived from 3 replicate trials (devices) with 6 identical chambers per 
device.  Migrational and morphological data are collected from a total of 148 cells, which 
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generate 243 cell tracks.  First, the chemotactic index (CI) of cells for the entire region of 
interest (ROI) for each trial is calculated (Fig. 5-8).  Then, the ROI is divided into 4 
spatial sections, and each data point for CI, speed, area, and circularity is calculated from 
non-overlapping subsequences of 7 consecutive photo frames, and each data point is 
binned into one of the 4 sections in the chamber (Fig. 5-9).  Division into 4 sections is 
arbitrary; the chamber could be divided into more or fewer sections depending on 
whether there are enough cells (and corresponding tracks) in each section to produce 
results with meaningful statistical information.  Area and circularity are calculated as the 
average from each set of 7 photos, and speed is calculated by dividing the root-mean-





CI = , 
where dgrad is the net displacement in the direction toward the gradient source (x-
dimension) and daccum is the accumulated distance traveled over the 7 photo set.  




Aycircularit π= , 
where A is cell area and p is cell perimeter.190 
 All statistical analyses are performed by ANOVA using Prism software 
(GraphPad Software Inc., La Jolla, CA, USA).  Tukey’s posthoc tests are performed. 
Results and Discussion 
 In this work, a prototype device for the study of directed cell migration is 
designed, fabricated, characterized, and tested to measure chemotaxis with living cells.  
The device consists of an in-line array of 6 cell observation chambers, integrated on-chip 
valves, input selection routers, and supporting fluid delivery network.  The objective is to 
create a microenvironment presenting soluble concentration gradients to study 
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chemotaxis that exhibits a unique and useful combination of characteristics that has not 
previously been demonstrated.  The characteristics are:  (i) fully stable signal gradients, 
(ii) no flow-induced shear stresses, (iii) concentration profiles that can approach a basal 
concentration of zero, (iv) gradients that can be switched on-off with minimal delay, and 
(v) concentration profiles whose curvature can be adjusted conveniently.  Additional and 
equally important objectives are for the device to demonstrate (i) identical gradients in all 
chambers, (ii) efficient scalability to larger in-line or 2-D arrays, and (iii) a fabrication 
process requiring only a single alignment step.  Two core technologies are developed and 
implemented in the device.  First, sequentially pulsed delivery is used as the physical 
mechanism by which soluble gradients are generated.  Second, a 3-D flow network is 
realized that enables the scale-out of chamber arrays for potentially large-scale 
parallelization. 
Simulation of Chamber Flow Field 
 The purpose of simulating the chamber flow field is to calculate shear stresses on 
the chamber floor during normal device operation.  In concept, the chamber design and 
use of sequentially pulsed delivery should prevent significant flow-induced shear stresses 
on cells during migration experiments.  The motivation for engineering a 
microenvironment with minimal shear stresses is to provide an adequate model for 
physiological contexts where fluid flow is very small; such contexts occur in the 
interstitial spaces throughout connective tissue and in the brain.  
 A 3-D finite element model is used to calculate the velocity field when a flow 
pulse occurs on one side of the chamber.  Since flow cannot occur on both sides 
simultaneously (by definition of sequentially pulsed flows), the model reflects the only 
situation where convection occurs in the chamber region.  The side channels are designed 
so that flow approaches the chamber from an upper layer, travels vertically downward 
into a lower layer channel, and continues downstream in the same channel.  The other 
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side of the chamber is fluidically isolated by integrated on-chip valves to prevent flow 
through the chamber. 
 The velocity plot of Fig. 5-4(a) shows the simulation of flow confined to one side 
of the chamber.  The volumetric flow rate of 2.5 μL min-1 is chosen to model conditions 
in cell migration experiments.  The resulting shear stress field on the chamber floor is 
plotted in Fig. 5-4(b), showing shear stresses less than 0.0005 dyn cm-2 across the entire 
chamber (heat plot) during pulse flow. 
 
 
Fig. 5-4  Simulation of chamber flow field during a flow pulse.  (a) Oblique view of 3-D model 
geometry with solution (velocity field) shown in slice plot.  Heat plot visualizes how flow is confined to the 
path on the side of the chamber.  (b) Shear stress field at the floor of the chamber, solved using a 2.5 μL 
min-1 flow rate (highest experimental flow rate) through the inlet and outlet.  Shear stresses are very low in 
the chamber; less than 0.0005 dyn cm-2. 
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 In comparison, in vivo shear stresses of 10-100 dyn cm-2 have been reported on 
vascular endothelial cells in blood vessels (a high shear context), while less than 2 dyn 
cm-2 has been reported for hepatocytes (mid-shear context).113  In interstitial spaces, shear 
stresses are expected to be smaller, although the fibrous 3-dimensional extracellular 
matrix makes precise estimates of shear stress difficult.122  Interstitial fluid velocities of 
less than 1 μm min-1 have been measured, which indicates extremely low flow (and 
correspondingly low shear).123  As well, human neural stem cells have been successfully 
cultured in microenvironments with shear stresses estimated at 0.0005 dyn cm-2.172  
Therefore, the very low shear stresses shown in Fig. 5-4 suggests an assay platform 
whose most appropriate application would be to model interstitial and other low flow 
contexts (compared to other microfluidic gradient-generating devices). 
Characterization of Gradient Formation 
 Four design objectives relate to concentration gradients generated in the device.  
They must be fully stable, switchable on-off, able to approach zero basal concentration, 
and adjustable in curvature.  The intention is to provide unprecedented control and 
experimental versatility to researchers.  To verify that the gradients meet the design 
objectives, they are characterized by observing the transport of fluorescently-labeled 
dextran dissolved in aqueous medium (PBS) undergoing sequentially pulsed flows.  





Fig. 5-5  Gradient formation and steady-state profiles measured via fluorescence imaging.  Medium 
loaded with fluorescently-labeled dextran (70,000 MW) is pulsed along one side of the chambers.  Results 
of four combinations of flow pulsing sequence and flow rate are shown.  (a)  A pulsing sequence with equal 
pulse times (15 s per pulse) generates a near linear profile at the lesser flow rate (0.25 μL min-1) and 
slightly curved profile at the greater flow rate (2.5 μL min-1).  Fluorescence photographs of chambers at 
steady-state are shown; measurement line (1100 μm) indicates where intensity profiles are measured.  
Time-to-steady-state (rise time) as measured from the center point is shown far right column.  The greater 
flow rate results in a faster rise time (time to 80% of steady-state ~120 min and ~300 min for 2.5 μL min-1 
and 0.25 μL min-1, respectively).  (b) A pulsing sequence with unequal pulse times generates slightly 
curved profiles at the lesser flow rate and noticeably curved (and concave) profiles at the greater flow rate.  
Also, rise times generally decrease (~100 min and ~220 min to 80% of steady-state for greater and lesser 
flow rates, respectively).  Curves for lesser flow rate (two left gradient plots) correspond to 0.5 hr, 1 hr, 2 
hrs, 4 hrs, and steady-state (from bottom curve to top curve).  Curves for greater flow rate with equal 
pulsing (upper right gradient plot):  0.25 hr, 0.5 hr, 1 hr, 2 hrs, and steady-state.  Curves for greater flow 
rate with unequal pulsing (lower right gradient plot):  0.25 hr, 0.5 hr, 1 hr, and steady-state.  Note:  Rise 




 Two parameters are investigated to determine their effect on the formation and 
shape of gradients.  These are the flow rate and the pulsing schedule.  The flow rate is 
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varied to determine if convective penetration into the chamber can assist (or disrupt) 
gradient formation.  The pulsing schedule is varied to simulate unequal periodic 
concentration boundary conditions, particularly if a longer period for the sink side causes 
decay and loss of gradient stability or curvature of the profile at a new steady-state.  
Figure 5-5 summarizes the results; Fig. 5-5(a) (top row) shows results for a flow pulsing 
schedule where the left and right pulses are equal in duration, while Fig. 5-5(b) (bottom 
row) shows results for a pulsing schedule where the pulses on the right side (non-dextran 
side) are significantly longer than the left.  Within each subfigure are concentration plots 
at two flow rates (0.25 μL min-1 vs 2.5 μL min-1), and each plot shows multiple 
concentration profiles at different time points as the gradient forms from a zero 
concentration initial condition.  The time-to-steady-state (rise time) at each condition is 
determined by measuring the fluorescence intensity in the center of the chamber at 
numerous time points as the gradient forms (right column of Fig. 5-5).  
 Near linear steady-state concentration profiles result from the equal pulsing 
schedule (Fig. 5-5(a), although the higher flow rate shows slight curvature at steady-state.  
This could be due to penetration of a convective component into the chamber.  The time-
to-steady-state (rise time) decreases significantly with the higher flow rate.    In Fig. 5-
5(b), the unequal pulsing schedule appears to maintain a near linear (slightly curved) 
steady-state concentration profile at the low flow rate; however, the profile shows 
dramatic curvature at the high flow rate.  Instead of a linear fit, the profile exhibits 
curvature more akin to a polynomial or exponential function.  Again, the higher flow rate 
decreases the rise time significantly.  Comparing the rise time profiles in both pulsing 
schedules shows a slight decrease with the unequal schedule.  Times to 80% of steady-
state with the equal flow pulses are ~120 min and ~300 min for 2.5 μL min-1 and 0.25 μL 
min-1, respectively.  Corresponding values for the unequal pulsing schedule are ~100 min 
and ~220 min.   
 100
 Therefore, the results suggest that the flow rate has a general effect on the rise 
time.  Higher flow rates could enable slight convection to penetrate into the chamber, 
adding to diffusive transport.  Also, there is a switch-like relationship between pulsing 
schedule and flow rate.  That is, the pulsing schedule has little effect on the curvature at a 
low flow rate, but there is a dramatic effect on curvature at a high flow rate.  Once again, 
this effect could be driven by the addition of a slight convective component to transport 
by the greater velocities.  A more exhaustive screen of the parameter space could reveal 
the thresholds where the profile curvature shows greatest sensitivity to pulsing schedule-
flow rate combinations.  Gradient formation can be measured at flow rates spanning at 
least three orders of magnitude (e.g. 0.1 to 10 μL min-1) at higher resolution with pulsing 
schedules scanning different left-right flow ratios.  Changes to the duration of full periods 
should be investigated also. 
Discussion 
 The ability to change the curvature of the concentration profile from linear to 
exponential is an important feature, as it enables the creation of a microenvironment that 
mimics diffusion from a point source (signal release) into an infinite reservoir (interstitial 
space).  Although curved concentration profiles have been engineered using flow-based 
gradient devices,174,187 the resulting microenvironment produces shear stresses due to the 
convection required for gradient generation.  Furthermore, to switch between an 
exponential and linear gradient, flow-based systems require that the upstream mixing 
network be redesigned.  At the same time, free-diffusion-based systems producing a 
stable concentration gradient are limited only to linear profiles.  This work introduces a 
gradient-generating technology that exhibits both low shear and curved profiles, which 
could enable new types of studies that can model additional physiological conditions.  In 
addition, changing between a linear and exponential gradient requires only a change in 
flow rate, rather than a different device design. 
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 The results also demonstrate that the gradients can be switched on and off.  In 
order to perform the characterization, a flow selection router upstream of the chamber 
array first chooses a flow stream without fluorescent dextran, and upon initiation of the 
photo sequence, the router selects the input streams with the probe.  The ability to switch 
gradients on and off could enable studies of cellular response to rising and dissipating 
gradients or repeated bursts of gradients, which could shed light on adaptive cellular 
decision-making processes.191,192  Also, gradient switching provides a within-trial 
(within-population) control condition, enabling the experimentalist to collect response 
data before and after initiation of the gradient.  This could increase the total amount of 
data for the same trial, saving time or enabling more experimentation with a given 
number of cells.  However, the utility of gradient switching is limited by the rise time, 
which in turn is determined by the diffusion coefficient of the signal.  Rise times should 
be appropriate to the cell system and response being studied, as each cell type and 
response could operate at differing time scales. 
 The rise times are measured using 70 kDa dextran, which is chosen as a 
representative molecular weight.  However, external signaling proteins vary significantly 
in their molecular weights; for example, epidermal growth factor (EGF) is ~6 kDa, while 
platelet-derived growth factor (PDGF) is ~25 kDa, and fibronectin is ~440 kDa.  
According to the Stokes-Einstein relationship and assuming that proteins are spherical 
(simplifying assumption), the diffusion coefficient is inversely proportional to the cubed 
root of molecular weight.  Taking EGF as an example, its rise time would be less than 
half (0.44) that of the dextran, assuming transport is purely diffusive.  Therefore, the rise 
times reported in these data are solely demonstrative, as it will vary depending on the size 
of the signal of interest. 
 The results show the attainment of two other objectives that are critical to the 
suite of capabilities offered by the device.  First, the rise time plots in Fig. 5-5 show that 
intensities approach a steady-state, which demonstrates gradient stability.  Second, basal 
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concentrations can approach zero, which is most evident from the high flow rate or 
unequal pulsing conditions.  This is significant because it has been shown that some cells 
respond best to shallow gradients with low basal concentrations,185,192 and producing 
microenvironments that mimic such gradients, while at the same time presenting low 
shear, may position the technology in this work as a key tool to query cellular response 
under such conditions.  Other microfluidic platforms generating stable gradients must 
trade-off the conditions; free-diffusion-based systems are low shear, but cannot reach 
zero concentration, while flow-based systems can achieve zero concentration, but 
introduce shear. 
Comparison of Concentration Profiles to Diffusion-Only Model   
 Fluorescence profiles are compared to a diffusion-only model (see Methods 
section for model details) to ascertain whether gradient formation is purely diffusion 
driven.  Figure 5-6 shows comparisons at two different flow rates (0.25 and 2.5 μL min-
1).  The measured plots are copies of the plots in Fig. 5-5(a) (top row with the equal flow 
pulsing schedule).  Figure 5-6(a) shows that the model and experimental plots match well 
as the gradient forms at the 1 and 2 hr time points.  At later time points (4 hr and steady-
state), the model plots approach a linear shape, which is expected for a diffusion-only 
model.  However, the measured plots deviate slightly from linearity (exhibiting some 
concavity).  In Fig. 5-6(b), measured plots rise significantly faster than those of the 
model.  This can be attributed to the greater flow rate (2.5 μL min-1, 10× greater than in 
Fig. 5-6(a)).  However, at steady-state, the measured plot falls below the model, showing 
more concavity than in Fig. 5-6(a). 
 The rough agreement between measured and modeled plots during gradient 
formation in Fig. 5-6(a) suggests that at low flow rates (0.25 μL min-1), the transport of 
soluble species is mostly diffusion-driven.  At higher flow rates, the dramatic differences 
in measured and modeled plots suggest that transport is driven not only by diffusion, but 
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also by convective effects.  Such effects also appear to increase the concavity of the 
measured plots as flow rate is increased.  Although convection could be a component in 
the transport, simulation of the flow field at the high flow rate (2.5 μL min-1) shows that 
shear stresses remain low on the chamber cell culture surface (Fig. 5-4).  Error in the 
measured plots could come from fluorescence measurement variation, as well as general 
chamber-to-chamber or device-to-device variation, which is discussed in the following 
section.  Error could also be caused by use of an inaccurate diffusivity in the model. 
 
Fig. 5-6  Comparison of concentration profiles for numerical modeling and measured data.  Measured 
results (noisy curves) of flow pulsing schedule in Fig. 5(a) and two flow rates (0.25 µL min-1 and 2.5 µL 
min-1) are shown in comparison with a one dimensional numerical model of diffusion only (smooth curves).  
(a) The measured pulsed data corresponds with the model at the lower flow rate during the initial start up.  
As the plots approach steady state (s.s.) the diffusion model approaches a linear plot and the measured data 
still exhibits a slight concave shape.  (b) Measurements at the higher flow rate produce curved profiles that 
deviate noticeably from the diffusion model after the first hour.  Note:  Corresponding time points for 
measured and modeled plots share the same gray level.  Plots in (a) correspond to 1 hr (bottom), 2 hrs, 4 hrs 
and steady-state.  Plots in (b) correspond to .5 hr (bottom), 1 hr, 2 hrs and steady-state.  Model uses 
diffusion coefficient of 70 kDa dextran as measured in literature (2.3 × 10-7 cm2 s-1).189 
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Concentration Profile Variation 
 Designing chamber arrays with identical gradients is an important objective, as it 
can address the limitation in flow-based systems where the concentration profile changes 
from location to location in the downstream direction.  Identical gradients in all chambers 
enhances the replication (and hence parallelization) potential of the array.  In practice, 
variation in concentration profiles exists, and it can be treated in two ways:  (i) chamber-
to-chamber variation (within a device) and (ii) device-to-device variation.  Observations 
of both types of variation are summarized in Fig. 5-7.  Concentration profiles of all 6 
chambers across 6 devices are measured at the experimental pulsing schedule and flow 
rate condition (see Fig. 5-5(b), unequal pulsing at 2.5 μL min-1). 
 A possible cause of chamber-to-chamber and device-to-device variation are 
obstructions in the upstream or downstream flow channels feeding the chambers, which 
could be caused by small fabrication defects or particles that flow into the devices and get 
lodged in the flow path.  Such events could cause the flow rate to deviate from the 
intended target, making the flow rates on each side of chambers different, leading to 
shifting or bending profiles.  In addition, fluorescence measurement error may be 
contributing to the variation, such as fluorescent light source fluctuations and camera 
noise.  In addition, inexact alignment of normalizing images (full bright and full dark) to 
measured images could cause registration/shift errors. 
 Comparison of the measured variation with other methods or devices is difficult.  
The gradient in transwell (Boyden chamber) assays typically spans only 10 μm, the 
profile is not stable, and (because of its vertical orientation and small pore sizes) it is 
difficult to measure its concentration profile.  Other standard gradient-generating tools, 
like the Zigmond or Dunn chambers also cannot produce stable profiles; thus, deciding 
which profile (time point) is used for comparison may be subjective.  Moreover, literature 
does not report the variation in profiles in microfluidic gradient devices.  From an 
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engineering standpoint, it is reasonable and ultimately necessary to understand device 
variation; however, in microfluidics, such analysis has not yet become a standard 
procedure.  One could attempt to construct devices reported in literature and perform 
experiments to determine the variation, but such activities could prove time-consuming 
and difficult to replicate, owing to the experience and specific expertise required for such 
work. 
 For the chambers and devices in this work, knowing the upper and lower bounds 
of concentration (based on SD or other % confidence intervals) could be helpful to 
develop rules for the size of spatial sections (resolution); based upon the variation in 
concentration at a specific x-location, x-tolerances (+ and -) could be established to 
define what the experimentalist deems as an equivalent concentration condition.  Thus, 
sections could not be made smaller than the span of such tolerances; if so, adjacent 
sections could be considered redundant conditions. 
 Another way to look at profile variation is from the cell standpoint.  It has been 
reported that eukaryotic cells can sense spatial differences in concentrations as low as 2-
10% from one side of the cell to the other (down to cell widths of 10-20 μm).147  The 
noise in the fluorescence measurements makes it difficult to ascertain gradients on the 
length scales of cell widths, but the use of low noise cameras could lead to new and more 
precise understanding of migrational responses to slight differences in gradient and 
concentration.  Also, little is known about the affect of background concentration on 
migrational responses, although some have begun to investigate it.187 
 One possible way to approximate the gradients and estimate errors (similar to Fig. 
5-7) is to fit the concentration plots with polynomials, and then find the gradient at each 
location.  The standard deviation in gradient could be estimate in that manner, and it 
could be compared to the magnitude of the gradient at the location.  If the standard 
deviation large enough to cast uncertainty about whether there would be a cellular 
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response, it should be noted.  Although, the sensitivities of different types of cells should 
not be assumed to be the same. 
 
 
Fig. 5-7  Variation in concentration profiles, chamber-to-chamber and device-to-device.  Full plots are 
shown in the top row.  Bottom row shows mean and SD at selected locations.  Profiles are measured at 
steady-state using experimental conditions:  flow rate of 2.5 μL min-1 and unequal pulsing schedule (see 
Fig. 5-5(b), lower row).  Normalized concentration does not reach 1 because the plots (and experimental 
region of interest) do not span the full length the chamber in the x-direction. 
 
Testing of Device via Cell Migration Experiments  
 To test whether the device can be used as a chemotaxis platform, cells are loaded 
into the device and their response to FBS gradients is measured.  Specifically, human 
 107
breast cancer cells (MDA-MB-231, epithelial origin) are plated in the array of 6 
chambers, and the migrational and morphological responses of single cells in each 
chamber are quantified before and after a FBS gradient is applied.  To quantify the 
responses, time-lapse phase contrast photos are acquired, and the cells in each frame are 
segmented.  The segment locations and morphological information are used to calculate 
responses.  The particular responses include chemotactic index (CI), speed, area, and 
circularity.   
 Cellular response is first considered with respect to CI across the entire region of 
interest (ROI).  The CI of each cell is calculated based upon its first and last x-locations, 
as well as its accumulated distance, for controls and experimental trials.  Additionally, 
spatially specific information is obtained by dividing the chamber into 4 sections along 
the x-dimension, and responses are binned based upon the location in the chamber they 
are observed.  The reason for binning the chamber into sections is to acknowledge that 
the concentration profile within the chamber (when the gradient is applied) is not truly a 
single condition.  Instead, the concentration profile is a collection of different conditions 
based upon the gradient and background concentration at each location within the 
chamber.  In this case of an exponentially-shaped profile, each incremental movement 
toward the source increases both the background concentration and the gradient.  Ideally, 
an experimentalist would divide the chamber into an infinite number of sections so as to 
obtain data for cell behavior at every infinitesimally different condition.  However, this is 
not practical, since there will not be enough cells (and corresponding tracks) at each 
condition to produce results with meaningful statistical information.  Therefore, the 
number of sections is limited by the number of cells (data).  Dividing the chamber into 
sections and binning the data accordingly is a way to effectively increase the number of 
experiments/conditions in a single trial, which could increase research productivity and 
shed light on differential responses among sections.  Further details are found in the 
Methods and Materials section of this chapter. 
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 MDA-MB-231 cells are chosen as the model cell line because they are shown to 
migrate in response to various signals, including growth factors, cytokines, and general 
sera.193,194  Being of epithelial origin, a suspected mechanism for metastasis for the cells 
is to undergo epithelial-to-mesenchymal transition (EMT), migrate through low flow 
interstitial spaces of the stroma, and ultimately intravasate into blood vessels.29  
Therefore, from the shear perspective, the device of this work is likely more appropriate 
as an interstitial (low flow) model when compared with flow-based gradient devices that 
produce significant shear stresses.   
 The chemoattractant used in these test experiments is fetal bovine serum (FBS).  
FBS is commonly used as a chemoattractant, either as a control against which to compare 
the responses to a defined medium or to model a biological context in its own right.  
Therefore, testing to see if a serum gradient elicits a chemotactic response from cells is 
critical to validate that the device works as designed. 
 The test experiments create a curved, exponentially-shaped concentration profile 
of serum.  The profile presents two general contexts:  (i) shallower gradients with low 
basal concentration on the right side of the chamber and (ii) a steeper gradients with high 
basal concentration on the left side (serum side) (Fig 5-9(a)).  In doing so, the ability of 
the device to produce curved concentration profiles with near zero basal concentrations is 
utilized. 
Observations 
 Figure 5-8 shows CI considering the entire region of interest (ROI) for controls 
and experimental trials.  Stages 1 and 2 differ depending on the trial.  For the positive 
control, stage 1 is without FBS and stage 2 is with a uniform profile of FBS.  For the 
negative controls, both stages 1 and 2 are without FBS.  For the experimental trials, stage 
1 is without FBS, while stage 2 is with a FBS gradient (as shown in Fig. 5-9(a)) with 
peak concentration on the left.   
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 The positive control trial shows a slight increase in CI from stage 1 to 2, although 
there are no statistics (based on independent trials) to estimate its error.  Two independent 
trials are performed for the negative controls, and three trials are performed as 
experiments.  Further trials could determine whether test comparisons achieve 




Fig. 5-8  Chemotactic index (CI) for positive controls, negative controls, and experimental trials.  
Stage 1 for all three categories is with no FBS.  Stage 2 for the positive control is a uniform FBS 
concentration profile (10% v/v).  Stage 2 for negative controls is with no FBS.  Stage 2 for the experimental 




Fig. 5-9  CI from cell migration experiments by section.  (a) The chamber region of interest (ROI) is 
divided into 4 equal sections to spatially bin data.  Representative segmented images show cells colored 
white and migration tracks in gray.  Concentration profile of FBS is plotted as a polynomial fit (for clarity) 
of the steady-state profile generated by 2.5 μL min-1 flow rate and unequal flow pulsing schedule (see Fig. 
5-5(b), right gradient plot).  (b) CI measurements by section at both experimental conditions; change 
between conditions is plotted below.  (c) CI measurements by trial (3 trials performed) to show inter-trial 
variability.  Data gathered from 148 cells across the 3 trials.  Error bars are SEM.  Stars indicate statistical 
significance between conditions (p < 0.05).  Scale:  Image in (a) spans 1000 μm in x-direction.   
 
 Figure 5-9(a) shows a representative ROI and the 4 spatial sections into which 
data are binned; cell are segmented in white and migrational tracks are in gray.  The 
concentration profile of serum (shown with sections delineated) reaches a maximum of 
5% FBS.  CI by spatial section is aggregated and plotted, showing statistically significant 
changes in CI in sections 3 and 4 after the gradient is applied.  To gauge experiment-to-
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experiment variability, data are graphed by trial for comparison.  Variation among trials 
is noticeable; however, the results for each trial are consistent in trend. 
 Data are also plotted in time.  These data are contained in Appendix H.   
 
 
Fig. 5-10  Speed, area, and circularity from cell migration experiments by section.  Results are shown 
by spatial section (1-4) for both experimental conditions.  Change of means is shown in percent.  
Experimental conditions the same as described in Fig. 5-8.  Error bars are SEM. 
 
 Speed, area, and circularity for both non-gradient and gradient conditions are 
reported by spatial section in Fig. 5-10.  In general, speed and circularity increase upon 
gradient stimulation, while area decreases.  In the gradient condition, both area and 
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circularity show a slight trend in spatial section, where the area increases from left to 
right, while circularity decreases in the same direction.  As area decreases, circularity 
appears to increase. 
 
Discussion 
 A critical response in chemotaxis experiments is the chemotactic index (CI), since 
it captures both the direction and magnitude of a cells migrational trajectory relative to 
the gradient.  Positive CI indicates net movement toward the chemoattractant source, 
while a negative CI indicates movement away.   
 The results of these experiments are very preliminary, as seen in Fig. 5-8 (entire 
ROI).  Only two independent trials were performed for the negative controls, and one of 
them showed substantially higher CI in stage 2 than any other trial (first and second 
negative control stage 2 CIs are -0.010 and 0.105), which brings about the wide SEM.  
The second negative control CI is also greater than all the experimental trial stage 2 CIs 
(0.040, 0.093, and 0.058).  By performing more negative controls, it could be determined 
if the second control is an outlier and therefore whether the stage 2 CI for negative 
controls is anomalously high in these results.  The experimental trials also require more 
trials to determine whether there is a statistically significant difference between stage 1 
and stage 2 of the experimental trials, as well as between stage 2 of the negative/positive 
controls and stage 2 of the experimental trials.  Overall, Fig. 5-8 indicates that trial 
numbers should be increased to ascertain any meaningful statistics. 
One way to detect possible drivers of the overall results and to detect possible 
anomalous behavior is to divide the ROI into sections.  For instance, after dividing the 
ROI into four equal sections, results in Fig. 5-9(b) show a statistically significant (in-
trial) positive CI change in sections 3 and 4 when the serum gradient is applied.  In 
particular, it appears that cells in section 3 change direction the gradient is applied and 
migrate, on average, up the gradient toward the FBS source.  In addition, cells in section 
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4 appear to change from a net rightward migration (negative CI) to a CI of zero.  One 
should bear in mind, these are preliminary results and the analysis is shown as an 
example.  For a full analysis, more trials would have to be performed, especially since 
there are fewer cells to consider (compared to the full ROI), and test comparisons must be 
performed not only with the in-trial controls, but also with the positive and negative 
controls. 
 Regarding the controls, negative control trials (no FBS gradient throughout the 
whole trial) are performed in order to determine whether stage 1 of gradient trials (first 6 
hrs without gradient) are appropriate as intra-trial negative controls, as well as to 
determine whether measured cell behavior in stage 2 of gradient trials (12 hrs with the 
gradient applied) could be different from stage 1 simply due to the passage of time (not 
due to the FBS gradient).  Results of negative controls are shown in Fig. G-1 (Appendix 
G), and both stages of the negative controls are compared to stage 1 of gradient trials and 
to each other.  No statistically significant differences are observed; however, further 
negative controls should be performed to build statistics, given the low N.  A positive 
control (uniform FBS profile) is also performed.  Certain measurements of the positive 
control appear to be different from those of stage 2 of gradient trials (with gradient), 
which is what one would expect; however, nothing can be inferred, since there are no 
statistics associated with the control measurements (N=1 for positive control). 
 As an aside, there appears to be a directional bias in the migration of cells before 
the gradient is applied.  CI values indicate that cells in sections 1 and 2 tend to migrate to 
the left (positive CI), while cells in sections 3 and 4 tend to migrate to the right (negative 
CI) (see Fig. 5-9(b), no gradient conditions).  Such behavior may stem from the cells’ 
random-walk-like movement without a directional stimulus (i.e. gradient).  Without 
directional stimulus, cells move and disperse in a manner similar to molecular diffusion, 
characterized by a random motility coefficient, μ, which is analogous to a molecular 
diffusion coefficient.195  Cells are loaded through the middle of the chamber, and 
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therefore, the cell population is concentrated in sections 2 and 3 (middle two sections) 
when experiments begin.  Tracking data suggest that cells disperse away from the middle 
of the chamber to the left and right during the non-gradient condition, which is consistent 
with the hypothesis of random-walk-like dispersion.  When the gradient is applied, the 
responses from sections 3 and 4 suggest that the directional bias away from the serum 
source may be reduced (and even shifted toward the serum source for cells in section 3).  
 The CI response from sections 1 and 2 is difficult to interpret; however, possible 
phenomena can be put forth.  When no gradient is applied, the results suggest a positive 
CI due to random dispersion from the middle of the chamber.  When the gradient is 
applied, cells continue to show positive CI, but the mechanism is not clear.  The cells 
could be continuing in their dispersive movement.  Another possibility is that cells sense 
the gradient, but the level of background concentration causes the cells’ morphology 
(area and circularity) to change, as shown in Fig. 5-10, in a manner that affects 
chemotaxis.  The reduction in area and rise in circularity suggest a contractile 
morphology indicative of cells that have partially detached from the substratum, which 
would suggest that cell-substratum adhesion is reduced or intracellular tension is 
increased.  Cell speed is greatest at intermediate levels of cell-substratum 
adhesiveness;195 therefore, a reduction of adhesion could interfere with efficient 
chemotaxis, resulting in the slightly lower CI for sections 1 and 2 during gradient 
stimulation.  One possible way to test for this is to perform the same experiment, but coat 
the substrate with a much higher concentration of fibronectin than that which is used in 
the experiments shown (8 μm mL-1).  The presumption is that the increased Fn 
concentration increases the adhesion for cells nearest to the source, enabling them to 
chemotax more efficiently.  Another, more simple experiment is to reduce the source 
concentration so that the gradient is inherently shallower on the left side of the chamber.   
 Time course plots demonstrate the utility of monitoring of cellular response 
during transient conditions.  Most notably, area and circularity measurements suggest that 
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cellular response is most dramatic after 3 hours.  The rise time shown in Fig. 5-5 at the 
experimental condition is roughly 100 min for 70 kDa dextran, which is slightly less than 
the cellular response time.  However, FBS is a complex medium containing smaller and 
faster diffusing growth factors that could be contributing to cellular response (e.g. EGF 6 
kDa).  In this case, the rise times could be less than half that of the dextran.  Experiments 
with a defined medium could more precisely shed light on the timing of cellular 
responses with respect to rise time.  If a faster rise time is ultimately required, the 
characterization shown in Fig. 5-5 suggests that increasing the flow rate could reduce the 
rise time significantly.  Of course, this comes with the trade-off that more reagent/sample 
would be used at a higher flow rate, and some reagents are very rare and/or expensive, 
which would limit the number of experiments or prohibit them completely. 
Chapter Summary 
 This chapter details the development of a prototype microfluidic chamber array 
that generates soluble concentration gradients.  The device is designed to generate 
gradients with a novel combination of features:  fully stable, low shear, switchable on-off, 
capable of low basal concentrations, and adjustable profile curvatures.  In addition, the 
chamber array is scalable, and it is fabricated in a single material (PDMS) and a single 
alignment step, which increases the potential for future high-throughput screening and 
manufacturability.  This diverse combination of features is made possible by sequentially 
pulsed delivery and 3-D flow networks.  
 Device design includes numerical simulations of both the velocity field (to 
ascertain shear stresses) and diffusion-only mass transport.  Gradient characterization via 
fluorescence measurements yields information regarding gradient formation 
(concentration profiles at numerous time points after the gradient is turned on), rise times, 
and steady-state profiles.  Characterization data are also used to compare with the 
diffusion-only model, showing that mass transport is likely driven by both diffusive and 
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convective components at a high flow rate (2.5 μL min-1), while it is diffusion-dominated 
at a lower flow rate (0.25 μL min-1).  In addition, fluorescence data are used to measure 
chamber-to-chamber and device-to-device variation among concentration profiles.   
 Finally, human breast cancer cells are introduced into the array, and certain 
morphological and migrational responses to a FBS gradient are observed.  Cell 
experiments are performed to test whether the array and the gradients it produces could 
elicit responses from cells so as to prove the concept of its use as a migration screening 
tool.  Preliminary experiments show high variability chemotactic index (CI) in 
experimental trials and controls that precludes any conclusion with respect to chemotactic 
response.  A major source of uncertainty stems from the low number of trials.  If more 
trials are performed, statistical significance may emerge.  Although statistical 
significance is not achieved when considering the full chamber, the p-value for in-trial 
non-gradient controls compared to the gradient condition is somewhat low (~0.1).  By 
partitioning chamber into sections, one can begin to understand what spatial regions may 
be driving such a result.  For example, certain sections of the chamber (3 and 4) show 
statistically significant differences in CI when comparing non-gradient controls with the 
gradient condition; however, it must be emphasized that further trials are required to 
increase the power of statistical measures and to confirm whether the responses are due to 
the gradient or other phenomena.  For instance, cell migration could be affected by 
competing autocrine and paracrine signal gradients, as well as matrix remodeling in the 
tracks through which cells translocate.  Additionally, if it is hypothesized that the cells 
respond best to the shallow gradients and low basal concentrations (sections 3 and 4), 
trials could be performed where the input concentration of FBS is lowered, producing a 
shallow gradient (and low basal concentration) condition in different sections (1 and 2).  
Also, other cell types could be tested against gradients of known chemoattractants, as 
their responses may be more obvious than those from the trials already performed; the 
breast cancer line (MDA-MB-231) used in this work may only respond with small 
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changes to its net directional bias, making analysis more difficult than required for proof-
of-concept purposes.  Moreover, the hypothesis that cells disperse via random-walk due 
to a concentrated loading distribution (in the middle of the chambers) should be tested by 
modifying the design of the array so as to load cells uniformly and observing their 
movement in the absence of a gradient.  The above proposed experiments are a few of 
many that should be performed to further optimize the device and provide clearer 
explanations of how the array performs as a cell migration screening tool. 
 It should be noted that all gradient-generating microfluidic devices face similar 
challenges with respect to their ability to be translated into mainstream biological 
research.  With respect to microenvironment, flow-based devices have become the most 
commonly-used gradient-generating microfluidic platform.103,170-174,187  This has 
happened despite evidence that shear induced responses could confound results, both in 
terms of migrational bias184 and metabolism.196  Also, flow-based gradient devices 
inherently remove any autocrine or paracrine signals that are secreted by the cells being 
studied (due to the direct flow over the cells), which could further confound results 
(although, such a characteristic could also act as an experimental condition118).  
Furthermore, as previously mentioned, the device-to-device variation in gradients is 
unstudied (or unreported) in microfluidics literature.  In all such literature, the 
concentration profile from only a single device is reported.  This work attempts to 
address the lack of variation information by measuring variation across a batch of 6 
devices, and it is shown that notable variation exists.  If variation in such a well-
controlled system (i.e. computer-timed valve actuation sequences) with a well-accepted 
and repeatable fabrication process (i.e. photolithographically manufactured molds) exists, 
then it is reasonable to expect that similar or greater variation could exist in other 
microfluidic systems.  If so, then experimental results based upon such systems could be 
called into question without the support of proper controls and assisting agents, such as a 
fluorescent marker to monitor the gradient (so long as the marker does not interfere with 
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experiment itself).  However, these challenges should not deter researchers from further 
developing microfluidic gradient-generating systems.  The potential for stable and 
highly-controllable gradients, array scalability, and low sample usage offered by 
microfluidics is likely to exceed the performance of conventional methods, such as 
transwell, Dunn, and under-agarose assays.  Such conventional methods are inherently 
unable to maintain stable gradients, and perturbations (mechanical or thermal) could 
disrupt or destroy gradients that are generated.  Fertile ground exists for advancement in 
microfluidic gradient-generators, so long as it is approached with a systematic, 





















      Table 5-2  Chapter summary. 
 





This work is intended to advance the state-of-the-art in microfluidic cell-based 
assays.  An underlying theme of the research is the creation of 3-D flow networks in 
order to realize chamber arrays that can ultimately be scaled to larger, higher-throughput 
arrays.  The main objectives of this research are to develop a fabrication method for 3-D 
flows, and also to test two particular microfluidic assay platforms that generate 
microenvironments with unique characteristics to address complex biological 
phenomena. 
Fabrication of 3-D Flow Networks 
 A fabrication method is developed to realize 3-D flow networks (vertical 
connectivity between flow layers) based upon focused compression and alignment with 
partial curing.  It is referred to as a modified compression-molding process.  Progress in 
device technology is often made possible by improvements in fabrication, and in this 
case, the modified compression-molding process improves final device yield to almost 
50%.  Such a yield, while low by most industrial standards, enables the design and testing 
of chamber arrays for specific cell-based assays in an academic setting. 
 With respect to the microfluidics field in general, the learning in this work 
underscores the need for more systematic attention to fabrication process development in 
future publications/literature.  It appears that most microfluidics fabrication knowledge is 
either significantly under-explored or under-reported.  A prime example of under-
reporting is the treatment of the original compression-molding process upon which this 
work’s fabrication process (modified compression-molding) is based.  A diagram of the 
compression stack is found in the original publication; however, there are no detailed 
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comments regarding the process flow, yields, and failure modes.87  It is possible that the 
idea of using focused pressure during compression, which is described in this work and 
published,95 is fabrication knowledge that is already known to the original inventors of 
the compression process, but simply not made public (either deliberately or by lack of 
appreciation of its worth).  Another example is the protrusion method of fabricating 
through-holes.  Although the possible effect of PDMS surface tension (wetting and 
profile curvature) is mentioned in a single sentence in the original publication,84 there are 
no specific parameters (e.g. feature widths or PDMS thickness ranges) mentioned that 
could cause device failure, nor is there a description of the frequency or severity of such 
failures.  The lack of fabrication details in microfluidics literature comes with a heavy 
price to advance the field, where significant time and effort are spent by research groups 
(like this one) debugging and “re-inventing” processes that could already be well-
understood by others. 
 When it comes to fabrication, much of the focus in microfluidics, particularly for 
PDMS-based devices, is the simplicity of rapid prototyping granted by soft lithographic 
methods.  Perhaps the idea of simplicity is over-emphasized because microfluidics is still 
a young field of study, between 10 and 20 years old, and those who work in the field are 
prone to emphasize its benefits (and minimize its challenges) in order to build interest in 
the work.  This work is no exception.  However, this work acknowledges that in order to 
create more capable devices (including those with 3-D flows and very unique sets of 
features), fabrication complexity will grow accordingly.  Therefore, certain learning is 
detailed, such as the method to reduce gas bubble nucleation during compression, use of 
support posts to maintain PDMS surface planarity, yield benefits of thermal bonding, and 
overall estimates of device yields for the developed fabrication process.  In doing so, the 
fabrication process is elevated to the same level of importance as design, and it is hoped 
that similar emphasis will be adopted in future works in the field. 
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 A key benefit of 3-D flow networks is the ability to scale to large arrays 
efficiently (with respect to required device footprint and input/output ports).  In addition, 
3-D flow networks could facilitate more convenient addressing of individual chambers.  
The motivation to address individual chambers with different combinations stems from 
the desire to achieve the same level of versatility as conventional well plates.  However, 
microfluidic chamber array technologies face many hurdles in that goal.  Ultimately, the 
goal of microfluidic chamber arrays should not be to replace well plates, but instead to 
provide an effective alternative, particularly to prevent evaporation, perform complex 
fluid handling, reduce sample usage, and provide unique capabilities (e.g. fully stable 
concentration gradients). 
 Simple, reliable, and reproducible means of fabricating through-holes and 3-D 
flow networks will bring about greater efficiency in microfluidic device layout and 
operation, and perhaps more importantly, it could open the design space so as to bring 
about creative technological advances and applications yet to be conceived.  The key 
advances, learning, and limitations regarding 3-D flow networks in this work are 
reviewed in the Chapter Summary in Chapter 3 (Table 3-3). 
Microfluidic Chamber Array for Soluble-Matrix Signaling Studies 
A microfluidic chamber array is designed, built, and tested that can present cells 
with different signaling combinations of both soluble and matrix factors.  To provide a 
unique set of capabilities desirable to life scientists, the array operates with continuous 
perfusion, prevents cross-chamber contamination, protects cells from excessive shear, 
and offers considerable experimental versatility.  These attributes are made possible by 
implementing a 3-D flow network, which is fabricated using the modified compression-
molding technique described in Chapter 3. 
 The array is tested as a screening tool for studying phenotype transitions and 
cellular behavior by observing the responses of alveolar epithelial cells under 
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combinatorial soluble and matrix conditions.  Given that cellular response mechanisms 
are complex, this array technology is ideal to perform studies where cellular response is 
sensitive to microenvironmental conditions within a parallelized, well-controlled, 
scalable microfluidic format.  Furthermore, the array could be used to perform studies 
under different perfusion rates (in combination with soluble and matrix signals) or 
adapted to stimulate cells with time-varying signal patterns. 
 The array must be further tested with different cell-signal models, scaled-up, and 
automated to a greater extent.  Such a setup will lead to higher control and throughput, 
making the array capable of larger-scale studies.  These studies could lead to insights into 
the mechanisms for the onset and progression of pathological phenotypes and the 
identification of novel therapeutic targets to treat diseases.  A challenge to successfully 
deploying such systems is likely to be at the interface between the device and the macro-
scale world.  While manually inserting pins and tubes into devices is acceptable in 
academic settings, industrial applications will require automation in this respect.  Major 
advances and limitations of this work are reviewed in Table 4-1 (Chapter 4 summary). 
Soluble Gradients via Sequentially-Pulsed Delivery in a Chamber Array 
 A novel microfluidic chamber array that generates soluble signal gradients is 
introduced based upon a technology referred to as sequentially pulsed delivery.  Similar 
to the soluble-matrix chamber array, the sequentially pulsed delivery array is enabled by 
a 3-D flow network.  As a result, a rich set of microenvironmental features is integrated 
into the array, which includes:  (i) fully stable signal gradients, (ii) very low shear 
stresses, (iii) gradient profiles able to approach zero concentration, (iv) gradients that can 
be switched on-off, and (v) gradient profiles whose curvature are changeable (without 
changing inlet concentrations or upstream flow architecture).  These microenvironmental 
features offer wide-ranging flexibility in the spatial and temporal control of gradients.  In 
addition, the following system-wide features are exhibited:  (i) similar gradients in all 
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chambers, (ii) a network architecture enabling scale-out of in-line or 2-dimensional 
chamber arrays, and (iii) a fabrication process requiring only a single alignment step.  
The system-wide features are intended to facilitate greater throughput and 
manufacturability. 
 The system is tested as a chemotaxis assay by measuring the response of human 
breast cancer cells to gradients of FBS.  Migrational and morphological readouts are 
rapidly quantified on frame-by-frame and single cell bases.  Cellular responses are 
stratified along spatial and temporal dimensions.  Some statistically significant responses 
are measured, but more experimentation is required to confirm that the gradient caused 
directed migration. 
 The abovementioned studies serve to highlight numerous features of the system 
and begin testing it as a versatile, high-throughput, and high-content assay platform, 
which could bring about significant contributions to our understanding of cellular 
behaviors and their underlying biomolecular mechanisms in response to spatially and 
temporally changing gradients.  Before such work can be performed, more validation of 
the array with different cell types and microenvironmental contexts is necessary (using 
different chemoattractants and matrix substrata).  This way, incompatibilities with the 
design can be identified and addressed.  Improved and expanded versions of this array 
technology could be directly applied to studies in cancer, development, tissue 
regeneration/repair, and immunology, as well as serve as a tool to screen potential 
therapeutic compounds to treat related diseases in a massively parallel fashion.  Major 
advances and limitations of this work are reviewed in the Chapter Summary of Chapter 5. 
Future Potential for Technology in This Work – Possible Applications in Cancer 
 The experiments performed in this work for both arrays are intended as initial 
proof-of-concept trials to test for proper device operation.  Once designs and protocols 
are optimized, future work could focus on adapting and scaling-out the devices for rapid 
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screening of cancer cell response to various growth factor-matrix stimuli to determine 
what conditions maintain, exacerbate or reverse their phenotypes, as well as screening 
potential drugs against the cells to identify and understand differential efficacy based 
upon the signaling conditions.  This could provide clinicians with insights as to when and 
where an anti-cancer drug will have the greatest effect on cancer cells.   
 Similar applications exist to rapidly screen potential drugs against cells within 
gradient microenvironments.  There is great need for rapid, high-content screening in the 
context of cell migration, since few platforms provide stable, reproducible gradients in a 
high-throughput array format.  The great need stems from the knowledge that migrating 
cancer cells are known to be resistant to apoptosis, and they are also the most lethal 
(being prone to metastasize).  Screening migratory cancer cells against various 
combinations of drug-chemoattractant-matrix combinations could yield new insights in 
how to specifically tailor drugs to arrest the migration of metastasizing cells, perhaps 
making them more vulnerable to standard anti-cancer drugs.  Such findings could lead to 
new and highly effective combination therapy approaches to treat metastatic cancer. 
Challenges and Future Directions for Microfluidic Systems 
 This work focuses on microfluidic chamber arrays that are enhanced by 3-D flow 
networks.  However, much of the learning from this work is applicable to the 
microfluidics field in general.  In the author’s opinion, the greatest challenge to the 
advancement of microfluidics (for life science use) continues to be its degree of 
acceptance by biologists.  It is likely that biologists are afraid to attempt microfluidic 
experimentation because they fear that (i) the results would not be comparable to those of 
flasks and well plates, therefore raising more questions than answers, and (ii) it is not 
simple, easy, or cost-effective enough to try.  Such concerns are raised in this research.  
With respect to lack of comparability, experiments in Chapter 4 showed that new assay 
protocols may be required to properly stain cells in a microfluidic system (as opposed to 
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in a standard well plate).  In addition, the random-walk dispersion observed in the 
gradient device (Chapter 5) may indicate a device specific response that makes its results 
difficult to compare with other literature.  That being said, researchers must be careful not 
to assume that flask/well plate behavior is always the “normal” mode; the results in a 
microfluidic device could be highlighting behavior that differs from flasks but is closer to 
true physiological or pathological behavior. 
 From the standpoint of simplicity and cost, the greatest challenge for a lay 
biologist, aside from building the devices themselves, is the lack of standardized and 
easy-to-use world-to-chip interconnect technologies.  The vast majority of intangible and 
experience-based knowledge is contained in the act of setting-up a microfluidic 
experiment, which is predominantly an exercise in attaching and detaching world-to-chip 
interconnects (tubes and needles) as the device is primed, incubated, and loaded with 
cells.  The learning process and initial failure rates for new users are daunting.  
Unfortunately, most research in microfluidic systems is devoted to the internal fluidic 
circuitry of the device (in the search for a “killer application”), not the world-to-chip 
connections.  The use of 3-D flow networks and concomitant efficiencies in scaling could 
minimize the number of world-to-chip ports; nevertheless, new world-to-chip 
interconnecting approaches will be required regardless of device circuitry, ideally where 
a device is inserted into an interconnect fixture or box and the connections are established 
without manual manipulation. 
 Moving forward, there are two directions the author would pursue, building upon 
the learning from this work.  First, there is a great opportunity, as just mentioned, to 
develop new world-to-chip interconnect technologies.  Such technologies could focus on 
new approaches for interfacing devices to connecting fixtures (sealing and 
pressurizing/priming devices), innovative entry ports (on the connecting fixture) where 
fluids could be easily introduced, and standardized equipment and programs to automate 
the process of preparing a microfluidic device for experiments.  A challenge in such 
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interconnects is minimizing dead volumes so that microfluidic systems best realize their 
potential for low sample usage.  Although such a research topic may not be as 
“fashionable” as working on internal device circuitry, there are opportunities to make an 
impact, given that the world-to-chip interconnect field is still nascent.  It would be wise 
to advocate for the establishment of an academic-industrial consortium to host workshops 
and conferences on the topic, thereby building interest in the field and emphasizing the 
necessity for interconnect standards.  In addition, given the practical nature of the work, 
opportunities for industrial collaborations should be aggressively cultivated for 
knowledge sharing and funding. 
 A second research thrust, based directly upon the 3-D flows research of this work, 
would be to integrate diverse unit operations onto a single device.  This is an ongoing aim 
in microfluidics research because it would reduce the amount of manual operations a 
worker is required to do.  From the world-to-chip interconnect standpoint, functional 
integration bypasses the need for cells (or other samples) to be introduced and/or 
extracted from a device via world-to-chip ports.  The advancement of 3-D flow networks 
is crucial for functional integration, as it enables samples to be shuttled from one 
functional area on the chip to another in an efficient manner.  It is recommended that the 
research start by integrating commonly performed life science functions, such as cell 
culture, cell selection, lysis, and separations.  Although some of such functions have 
already been integrated in earlier microfludic devices, none have done so using the 
efficiency, scalability (many of the same unit operations), and packing-density that 3-D 
flows could offer. 
No matter what research is pursued, it is extremely important for microfluidics 
projects to be pursued in the context of strong collaborations.  These collaborations 
should be both on the fabrication side and the biology side in order to maintain focus and 
share ideas.  It is the hope of the author that this work will move the field of microfluidics 
closer to widespread adoption and to the establishment of a new and productive industry.
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APPENDIX A 
LAYOUTS OF MICROFLUIDIC DEVICES 
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Fig. A-1  CAD layout of chamber array for soluble-matrix signaling.  Green (top) layer includes flow 
channels.  Red (lower) layer includes chambers and pressure (control) lines for integrated valves.  Purple 
(top) layer denotes conduits leading into chambers.  Light blue features are through-holes (middle layer).  






Fig. A-2  CAD layout of chamber array for soluble gradient signaling.  Blue (top) layer includes flow 
channels.  Black (lower) layer includes chambers and pressure (control) lines for integrated valves.  Light 








Fig. B-1  Setup for chemotaxis experiments.  Device is mounted to motorized x-y stage on inverted 
microscope.  Flow and pressure tubes enter device through stainless steel L-shaped pins.  Humidified air is 
flowed into transparent PDMS enclosure around the device to prevent bubble nucleation in the array.  




INTEGRATED, ON-CHIP VALVES 
 
 
Fig. C-1  Integrated “push-up” PDMS valves.  In this work, on-chip valves are actuated by pressurizing 
valves located in a lower layer.  The pressure deflects a flexible PDMS membrane upward so that it stops 
fluid flow in a channel in the upper layer (subfigure (b)).  This type of valve is based on the work of Unger 
et al.83  Membrane thickness is 30 μm for devices in this work, and pressures required for full closure are 
27-30 psig.  (c) Valves around a chamber in a soluble gradient-generating device.  Cross-section A-A 
corresponds to the illustrations in (a) and (b).  Scale bar is 500 μm. 
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APPENDIX D 
WAFER LEVEL VIEW OF MODIFIED COMPRESSION-MOLDING 
 
weight (40 lbs, flat steel blocks)
cloths
large (main)  transparency
stack
blank Si wafer






Fig. D-1  Wafer-level view of stack for modified compression-molding fabrication process.  Small 
transparency sheets cut to the size of each device are placed on the main transparency stack.  Small sheets 
are aligned to device locations.  The main stack and small sheets are Scotch®-taped together to maintain 
correct relative positioning.  When weight is applied, pressure is focused above each device, and PDMS is 
laterally displaced from the tops of photoresist features. 
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APPENDIX E 
DETAILED FABRICATION PROCESS 
 





1 Master A prep. Master A is a 100 mm polished Si wafer (0.5 mm thick) patterned with 2 layers of 
SU-8 photoresist.  First and second layers correspond to lower and middle 
layers, respectively, in CAD layouts shown in Appendix A. 
1. SU-8 features are 50 μm and 30 μm tall in first and second layers, 
respectively.  Second layer is patterned on first layer, making total 
thickness 80 μm.  Fabrication is performed using standard 
photolithography processes90 and recipes from MicroChem Corp. 
2. Partially silanize by vapor deposition. 
a. Place 0.2 mL silane (T2492, United Chemical Technologies, 
Bristol, PA, USA) in a glass vial. 
b. Vial and master are placed in a vacuum desiccator, evacuated 
to ~30 torr. 
c. Silane deposits (by vapor) on master A for 15 min in 
desiccator.  Do not silanize longer (a master with a full silane 
layer causes the PDMS to detach from the master (stick to the 
transparency) during compression-molding process). 
d. Excess adsorbed silane removed by casting PDMS (10:1 
prepolymer:crosslinker ratio) on wafer, curing at 70 °C for 1 hr, 
and peeling off the master. 
Note:  Silanization performed in fume hood.  This process is performed on the 
master once. 
2 Master B prep. Master B is a 100 mm polished Si wafer patterned with AZ P4620 photoresist.  
AZ features correspond to top layer in CAD layouts in Appendix A. 
1. AZ features are 35 or 25 μm tall (for soluble-matrix or gradient device, 
resp.) and fabricated using standard photolithography processes90 and 
recipes from AZ Electronic Materials. 
a. Note:  Prior to AZ patterning, to improve adhesion of AZ 
photoresist, hexamethyldisilazane (MicroPrime HP Primer, 
Shin-Etsu Chemical Co., Tokyo, Japan) is spin coated onto 
the wafer at 3000 rpm for 30 s, then placed on a hotplate at 
110 °C for 45 s to evaporate residuals. 
2. Reflow AZ features so that cross-sections change from rectangular to 
semi-circular cross-sections (assists with complete closing of on-chip 
valves (Appendix C)). 
a. Place master on hot plate at room temperature. 
b. Ramp temperature to 125 °C, then turn off (let ramp down to 
room temperature) 
c. Remove master from hot plate when temperature reaches 40 
°C. 
3. Fully silanize by vapor deposition 
a. Place 0.2 mL silane in a glass vial. 
b. Vial and master are placed in a vacuum desiccator; evacuated 
to ~30 torr. 
d. Silane deposits (by vapor) on master B for 6+ hr in desiccator.  
e. Excess adsorbed silane removed by casting PDMS (10:1 
prepolymer:crosslinker ratio) on wafer, curing at 70 °C for 1 hr, 
and peeling off the master within 5 min after removing from 
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oven (waiting longer will result in AZ features detaching from 
master). 




A silane layer is vapor-deposited on the transparency that is laminated to 
uncured PDMS on master A.  This prevents the PDMS from peeling off the wafer 
(adhering to the transparency) when the transparency is de-laminated after 
compression/partial curing. 
1. Place 0.2 mL silane in a glass vial. 
2. Vial and transparency are placed in a vacuum desiccator, which is 
evacuated to ~30 torr. 
3. Silane deposits (by vapor) on transparency for 30 min. 
4. Excess adsorbed silane removed by wiping transparency gently with 
IPA-soaked cleanroom cloth (Texwipe).  Transparency ready for 
lamination. 
Notes:  These procedures are performed in a fume hood.  Transparency can be 
re-used by wiping away residual PDMS with an IPA-soaked Texwipe (the 
silanization should then be repeated). 
4 PDMS prep. 1. PDMS mix 1:  30 g PDMS prepolymer and 1.5 g crosslinking agent are 
mixed in a cup. 
2. PDMS mix 2:  55 g PDMS prepolymer and 11 g crosslinking agent are 
mixed in a cup. 
3. Both mixtures are degassed under vacuum in a desiccator (~30 torr) for 
2 hr. 
5 Spin coat PDMS 
on Master A 
1. Master A is placed on a spin coater chuck, and PDMS mix 1 is poured 
onto the master until it is ¾ the radius of the wafer.  PDMS should be 
poured slowly to avoid bubble trapping. 
2. Spread:  Spin at 500 rpm (100 rpm/s acceleration) for 15 s. 
3. Spin:  Spin at 1000 rpm (500 rpm/s accel.) for 31 s. 
4. Relax:  Let PDMS relax on the master for at least 15 min 
5. Remove master A from spin coater and place on a large transparency 
(acts as a backing for the master and the subsequent stack) on a flat 
lab table; cover the master with a 150 mm Petri dish cover to prevent 
dust from settling on the uncured PDMS. 
6 Partial cure 
PDMS slab on 
Master B 
1. Place master B in a 150 mm Petri dish. 
2. Pour all PDMS mix 2 onto master B.  PDMS should be poured slowly to 
avoid bubble trapping.  PDMS should be ~4 mm thick.   
3. Gently press on the master using a razor blade to force any air bubbles 
out from underneath the master (avoid device features).  
4. Place Petri dish with master into an oven at 70 °C; make sure that the 
dish is level by using a leveler.  Petri dish should not be covered.  Start 
timer. 
5. Check progress of cure occasionally by touching the PDMS with a 
plastic pipette.  If oven temperature is not uniform, rotate dish to make 
sure PDMS cures evenly. 
6. Once PDMS cures into a solid slab, remove from oven.  Should take 
roughly 15-20 min.  PDMS is partially cured. 
7. Within 2-5 min of removing from oven, cut around the master and 
slowly peel PDMS slab off of master.  (Delaying over 5 min may cause 
AZ photoresist to detach from master when peeling the PDMS off.) 
8. Store PDMS slab in a Petri dish.  PDMS slab contains top layer 




Laminate the transparency from step 1 onto master A. 
1. Fix one side of the transparency with tape.  (Tape should contact the 
larger transparency that acts as a backing for the master.) 
2. Carefully (and slowly) laminate transparency from one side to the other 
side of the master.  Do not trap bubbles underneath.  Bubbles can be 
released by pulling-up transparency and re-laminating.  A glass or 
plastic rod with a rounded end can be used to assist in lamination. 
3. Tape-down the other end of the transparency. 
8 Stack onto 
Master A 
1. Place a 2nd transparency onto the first one.   
2. Use a 50 mL serological pipette (or similar cylindrical object) to roll over 
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the two transparencies to displace excess PDMS (use gentle hand 
pressure).  Wipe the top of the 2nd transparency with an IPA soaked 
Texwipe to remove any particles. 
3. Stack 5 more transparencies on top of the first 2.  The top (7th) 
transparency is the small sheet cut to the size of the device footprint 
(see Appendix D for stack illustration). 
4. Place a blank Si wafer (polished side down) on the stack. 
5. Place 2 Texwipes on the stack.  The cloths assist in providing uniform 
pressure distribution across the devices and soft contact with the steel 
plates. 
6. Place steel plates on the stack amounting 40 lbs force. 
7. Stack must sit on the lab table for 10 min (at room temperature) to 
allow initial displacement of PDMS. 
Note:  Transparencies must be kept clean throughout stacking process to 
prevent particles from lodging between sheets.  Tape should be used to secure 
transparencies to the large backing transparency. 
9 Partial cure 
master A 
1. Remove steel weights from stack. 
2. Carry master A (with stack of transparencies, blank wafer, and 
Texwipes) to a hot plate and place on center of hot plate.  Hot plate 
must be flat with uniform heat (for semiconductor processing; this work 
used the CEE 100CB plate, Brewer Science Inc., Rolla, MO, USA.  Hot 
plate must be 80 °C. 
3. Quickly re-stack steel plates on hot plate and allow stack to heat for 
10.5 min. 
4. Remove steel weights, carry master/transparencies/wafer stack to a lab 
table, and allow to cool for 5 min. 
5. Remove the blank wafer and transparencies. 
6. Carefully (and slowly) peel the first transparency off of the partially 
cured PDMS on master A.  The partially cured PDMS should be tacky. 
10 Cut slabs, 
punch, align, 
and bond 
1. Cut devices out of the PDMS slab from master B. 
2. Punch input/output ports into slab devices using 20G luer stubs. 
3. Blow compressed gas through each port to remove residual particles of 
PDMS and use Scotch tape to clean off both sides of the slab devices. 
4. Use stereo-zoom microscope to align each slab device to a device 
location on master A.  Rework if alignment is out of tolerance. 
5. Place master A (with aligned slab devices) into an oven at 70 °C for 






1 Cut and 
punch 
devices 
1. Remove master A (with device slabs) from oven. 
2. Use blade to cut the thin layer of PDMS (from master A) along the edges of 
each device slab. 
3. Gently peel each device (2 bonded layers of PDMS) off of master A and 
store in a dust-free container (like a new Petri dish). 
4. Punch input/output ports for valve control channels into devices using 21G 
luer stubs. 
5. Blow compressed gas through each port to remove residual particles of 




1. Place a device and a glass slide (or cover slip) into air plasma bonding 
chamber (Plasma Cleaner PDC-32G, Harrick Plasma, Ithaca, NY, USA).  
Make sure the device and glass are clean and free of particles. 
2. Expose device and glass to air plasma for 30 s at 18 W power.  Remove 
both from chamber. 
3. Place device on the glass within 1 min.  Gently tap the device (using 
tweezers or similar object) to make contact between the device and glass.  





















Fig. F-1  Transwell assays, testing responses of cells (MDA-MB-231) to signals (FBS and EGF).  
Membranes were pre-coated with fibronectin (8 µg/ml) for adhesion.  Cells were seeded at equal densities 
per well (80,000 cells/well) and were incubated for 6 hours.  After incubation, cells on the lower surface of 
the membrane were stained with hematoxylin and counted in the field of view under a light microscope in 3 
different locations per well.  Each assay condition is performed in triplicate.  FBS concentration is 10% v/v 





CONTROLS TRIALS FOR FBS GRADIENT EXPERIMENTS 
 
 
Fig. G-1  Negative (left) and positive (right) controls compared to gradient trials.  Negative controls 
(N=2 trials) are compared to stage 1 (the non-gradient stage) of gradient trials (N=3); no significant 
differences are measured between conditions in any of the 4 sections (all pairwise tests yield p>0.05).  
Positive control (N=1) is compared to stage 2 (gradient stage) of gradient trials.   
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APPENDIX H 
TIME-DEPENDENT RESULTS FROM FBS GRADIENT 
EXPERIMENTS 
 
 The CI for each section is shown over the 18 hour trial course (Fig. H-1).  The 
first 6 hours are without a gradient, while the 12 following hours are with the gradient 
switched on.  Sections 1 and 2 show no significant changes in CI between conditions, 
while sections 3 and 4 suggest an upward shift in CI upon gradient stimulation.  These 
trends are consistent with the spatial plots in Fig. 5-9. 
 The first 3 hours with gradient is followed by possible adaptation over the 
following hours (Fig. H-2, especially area and circularity columns).  Such trends suggest 
that cells may be returning to non-gradient behavior, which could be caused by cellular 
adaptation (as previously stated), desensitization, and/or receptor saturation or 
endocytosis in response to the new microenvironment.  The trend is detectable to varying 
degrees in sections 1, 2 and 3; in contrast, section 4 (furthest from the gradient source) 
shows a less severe response.   
 Time dependent results could be helpful too further understand the transient 
progression of cellular response; however, further trials are required to make conclusions. 
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Fig. H-1  Chemotactic index (CI) by time, stratified by spatial section of chamber.  Cells are monitored 
for 6 hrs with no FBS stimuli.  At 6 hrs, a FBS gradient is applied and cells are monitored for 12 hrs 






Fig. H-2  Speed, area, and circularity by time, stratified by spatial section of chamber.  Cells are 
monitored for 6 hrs with no FBS stimuli.  At 6 hrs, a FBS gradient is applied and cells are monitored for 12 




CELL SEGMENTATION CODE 
 
Cell segmentation code was written in MATLAB script, and is shown below.  The code 
executes the segmentation heuristic described in Chapter 5 (Methods). 
 
function image_segmentation(Trial, Well, Part, Thresh) 
%IMAGE_SEGMENTATION Perform cell segmentation on a single sequence. 
%   Please make sure that the flattened sequence file is in the folder 
of 
%   the current trial.  Then, enter the Trial#, Well#, Part#, and 
%   thresholding factor (separated by commas) when calling this 
function. 
%    
%   Remarks 
%   ------- 
%   Use the run_segmentation function to perform a cell segmentation on 
six 
%   (6) different wells each in two (2) parts at a constant 
thresholding 
%   factor. 
%    
%   Example 
%   ------- 
%   If the current sequence you want to segment is from Trial 
%   5, Well 2, Part 1, with a thresholding factor of 0.7: 
% 
%   The T05_Well2_Part1 folder should include the file: - 
%   T05_Well2_Part1_Flat.tif 
% 
%   And to perform the segmentation on this sequence you would type: 
% 
%   image_segmentation(05,2,1,0.7) 
% 
%   See also RUN_SEGMENTATION, IMAGE_DIVISION, RUN_DIVISION 
  
% Begin the timer to determine the time required for this function 
tic 
  
% Convert numerical inputs to strings for creating filenames 
Trial = num2str(Trial); 
Well = num2str(Well); 
Part = num2str(Part); 
  
% Determine folder names and locations based on the current location of 
the 
% Cell Segmentation folder (using the pwd function) or the locations of 
% folders created using the im_division function 
trial_folder = strcat(pwd, '\', 'T', Trial, '_', 'Well', Well, '_',... 
    'Part', Part, '\'); 
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other_folder = strcat(trial_folder, '\', 'Other Sequences', '\'); 
final_folder = strcat(trial_folder, '\', 'Final Sequences', '\'); 
  
% Create the Final Sequences folder (the other folders should have 
already 
% been created in the im_division function).  Since we will be writing 
to 
% this folder only (no reading), it does not need to be added to the 
% current directory. 
% mkdir(final_folder); 
  





% Determine the names and locations of the divided images sequence, the 
% flattened images sequence, the ROI images sequence, and the yet to be 
% created segmented and overlay image sequences from the user inputs of 
% trial #, well #, and part # 
im_divided_name = strcat(pwd, '\', 'T', Trial, '_', 'Well', Well,... 
    '_', 'Part', Part, '_', 'Divided', '.', 'tif'); 
im_ROI_name = strcat(other_folder, 'T', Trial, '_', 'Well', Well, 
'_',... 
    'Part', Part, '_', 'ROI', '.', 'tif'); 
im_flat_name = strcat(pwd, '\', 'T', Trial, '_', 'Well', Well, '_',... 
    'Part', Part, '_', 'Flat', '.', 'tif'); 
im_segmented_name = strcat(pwd, '\', 'T', Trial, '_', 'Well', Well,... 
    '_', 'Part', Part, '_', 'Segmented', '.', 'tif'); 
im_overlay_name = strcat(pwd, '\', 'T', Trial, '_', 'Well', Well,... 
    '_', 'Part', Part, '_', 'Overlay', '.', 'tif'); 
  
% Determine number of images in the sequence using the imfinfo 
function, 
% and then store this number into sequence size 
file_info = imfinfo(im_flat_name); 
sequence_size = max(size(file_info)); 
  
% Begin iterating through the entire sequence to produce black and 
white 
% photos of cells only 
for i = 1:sequence_size 
     
    i % Display the current iteration 
     
    % Read in the flattened image of the current iteration to begin 
    % performing segmentation 
    im_flat = imread(im_flat_name,i); 
     
    
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
    %%%%%%%%%%%%%%%%%%%%%%%% CELL PROCESS DETECTION 
%%%%%%%%%%%%%%%%%%%%%%% 
    
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
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    % Create a new image for manipulation to isolate the processes of 
the 
    % cells (while maintaining the quality of the original) 
    im_processes = im_flat; 
     
    % Define the threshold based on the median and standard 
    % deviation of all pixel intensities within the ROI.  The user-
input 
    % thresholding factor determines what fraction of the standard 
    % deviation to subtract from the median pixel intensity.  Thus, the 
    % threshold pixel intensity becomes the median pixel intensity 
value of 
    % the image less the standard deviation of all pixel intensities 
    % multiplied by the user-input value.  Only the standard deviation 
is 
    % multiplied by the user-input value. 
    stdev = std2(im_flat); 
    range_factor_processes = median(im_flat(:))-Thresh*stdev; 
     
    % Set all pixel intensities above the range factor for processes 
    % (multiplied by the median pixel intensity spanning a 16-bit 
image) 
    % equal to zero (black).  This should eliminate most of the 
background 
    % and halos in the image since the processes are darker than both 
of 
    % these features.  This creates a logical, black and white image 
where 
    % processes should appear white on a black background. 
    im_processes(im_processes > range_factor_processes) = 0; 
     
    % Determine the areas of the resulting white pixel regions (i.e., 
the 
    % area of the processes and small particles that may have been 
picked 
    % up during the process segmentation).  Label each of these areas 
with 
    % a region number using the bwlabel function. 
    props_processes = regionprops(logical(im_processes), 'Area'); 
    im_label_processes = bwlabel(im_processes); 
     
    % Find the regions of the black and white image that have a pixel 
area 
    % less than 30. 
    index_processes = find([props_processes.Area] < 30); 
     
    % Iterate through the regions with pixel areas less than 30 and set 
the 
    % pixel intensity values to zero.  This should eliminate small 
debris 
    % picked up during the process segmentation. 
    for j = 1:length(index_processes) 
        im_processes(im_label_processes == index_processes(j)) = 0; 
    end 
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    % Create a structuring element to dilate (fatten) the processes, 
and 
    % then perform the dilation 
    strel_processes = ones(5,5); 
    im_processes = imdilate(im_processes, strel_processes); 
     
    
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
    %%%%%%%%%%%%%%%%%%%%%% CELL HALO (BODY) DETECTION 
%%%%%%%%%%%%%%%%%%%%% 
    
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
     
    % Create a new image for manipulation to isolate the halos (bodies) 
of 
    % the cells (while maintaining the quality of the original) 
    im_halos = im_flat; 
     
    % Define the thresholding fudge factor to capture the greatest 
number 
    % of halos during segmentation.  This value was found to be 
relatively 
    % constant for our images at 1.02, and it did not appear to require 
any 
    % incremental increase or decrease throughout the trials. 
    range_factor_halos = 1.02; 
     
    % Set all pixel intensities below the range factor for halos 
    % (multiplied by the median pixel intensity spanning a 16-bit 
image) 
    % equal to zero (black).  This should eliminate most of the 
background 
    % and processes in the image since the halos are brighter than both 
of 
    % these features.  This creates a logical, black and white image 
where 
    % the halos should appear white on a black background. 
    im_halos(im_halos < range_factor_halos*32768) = 0; 
     
    % Determine the areas of the resulting white pixel regions (i.e., 
the 
    % area of the halos and small particles that may have been picked 
up 
    % during the halo segmentation).  Then, label each of these areas 
with 
    % a region number using the bwlabel function. 
    props_halos = regionprops(logical(im_halos), 'Area'); 
    im_label_halos = bwlabel(im_halos); 
     
         
    % Find the regions of the black and white image that have a pixel 
area 
    % less than 30. 
    index_halos = find([props_halos.Area] < 30); 
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    % Iterate through the regions with pixel areas less than 30 and set 
the 
    % pixel intensity values to zero.  This should eliminate small 
bright 
    % spots (debris or other fluctuations) picked up during the halo 
    % segmentation. 
    for j = 1:length(index_halos) 
        im_halos(im_label_halos == index_halos(j)) = 0; 
    end 
     
    % Create a structuring element to dilate (fatten) the halos, and 
then 
    % perform the dilation.  This structuring element is smaller than 
that 
    % for processes because the halos represent a slightly fatter 
region 
    % than the actual cell bodies; however, it improves the likelihood 
that 
    % process and halo regions will meet in the combination step. 
    strel_halos = ones(3,3); 
    im_halos = imdilate(im_halos, strel_halos); 
     
    
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
    %%%%%%%%%%%%%%%%%%% CELL PROCESS & HALO COMBINATION 
%%%%%%%%%%%%%%%%%%% 
    
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%% 
     
    % Create an image that includes "positive" (white) pixels from the 
    % logical process and halo images 
    im_combined = im_halos | im_processes; 
  
    % Create a structuring element to dilate the image of the combined 
    % features (halos and processes) to increase the likelihood that 
these 
    % features will touch 
    strel_dilate_combined = ones(4,4); 
     
    % Perform the dilation and fill and holes between features with 
    % positive (white) pixel values 
    im_combined = imdilate(im_combined, strel_dilate_combined); 
    im_combined = imfill(im_combined,'holes'); 
     
    % Now that the two features have been combined, create a 
structuring 
    % element to erode the resulting cells to improve their fit to the 
    % actual size of the cells in the image 
    strel_erode_combined = ones(7,7); 
     
    % Perform the erosion 
    im_combined = imerode(im_combined, strel_erode_combined); 
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    % Determine the areas of the resulting white pixel regions (i.e., 
the 
    % area of the combined cell features and potential regions that do 
not 
    % correspond to a cell).  Then, label each of these areas with a 
region 
    % number using the bwlabel function. 
    props_combined = regionprops(logical(im_combined), 'Area'); 
    im_label_combined = bwlabel(im_combined); 
     
    % Find the regions of the black and white image that have a pixel 
area 
    % less than 300.  These regions should correspond to large non-cell 
    % particles that were picked up during segmentation. 
    index = find([props_combined.Area] < 300); 
     
    % Iterate through the regions with pixel areas less than 300 and 
set 
    % the pixel intensity values to zero. 
    for j = 1:length(index) 
        im_combined(im_label_combined == index(j)) = 0; 
    end 
     
    % Convert the combined image from a logical to an 8-bit image 
    im_combined = mat2gray(im_combined); 
     
    % Write the final image of combined processes and halos as a black 
and 
    % white image 
    imwrite(im_combined, im_segmented_name, 'tif', 'WriteMode', 
'append'); 




% Begin iterating through the segmented image sequence to produce a 
% sequence of photos in which the segmentation is "overlayed" on the 
% original photos.  This provides a good way to determine how much of 
the 
% cell was segmented in the previous step, and it also allows for hand 
% corrections if necessary. 
for i = 1:sequence_size 
     
    % Read in the black and white segmented image corresponding to the 
    % current iteration 
    im_segmented = imread(im_segmented_name, i); 
     
    % Read in the corresponding ROI image (original phase photo) for 
the 
    % current iteration.  Convert to a grayscale image with pixel 
    % intensities between 0 and 1 (this simplifies the overlay).  Since 
we 
    % later want to threshold these images so that cell regions are the 
    % only pixels with maximum intensity, multiply the image by 0.98. 
    im_overlay = mat2gray(imread(im_ROI_name, i)); 
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    im_overlay = 0.98*im_overlay; 
     
    % Find any non-black pixels from the segmented image and set the 
    % corresponding pixels of the ROI image to the maximum pixel 
intensity. 
    im_overlay(im_segmented > 0) = 1; 
     
    % Write the final overlay image to a file in the "Final Sequences" 
    % folder.  Note that the image is saved as an 8-bit image. 
    imwrite(im_overlay, im_overlay_name, 'tif', 'WriteMode', 'append'); 
end 
  
% Move the divided image to the "Other Sequences" folder (to reduce 
clutter 
% within the current trial's folder). 
%movefile(im_divided_name, other_folder); 
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